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Summary 
 
First isolated from the myxobacterium Sorangium cellulosm So Ce12 in 1994, the chivosazoles have 
been reported to possess antiproliferative activity against human cancer cell lines, as well as 
antifungal activity. This thesis focuses on studies towards the total synthesis of chivosazole F. Some 
developments towards the total synthesis of chivosazole A are also discussed. 
 
 
 
Chapter 1 discusses the isolation, characterisation and biological activity of the chivosazoles, as well 
as the first total synthesis of chivosazole F reported by the Kalesse group and the previous work 
towards synthesising chivosazole F in our group. 
 
Chapter 2 describes the synthesis of the three key fragments A, B and C, their coupling reactions and 
subsequent modifications for assembling the backbone of chivosazole F. Paterson boron aldol 
methodology and Evans-Tishchenko reduction were utilised to construct the 1,4-syn and 1,3-anti 
stereochemical relationships within both fragment A and fragment B. Di-tert-butyl silyl group was 
used for the efficient and precise protection of the terminal diol of B. The key stereochemistry of 
fragment C was defined with a vinylogous Mukaiyama aldol reaction. Site-selective Stille 
cross-coupling reactions of the three fragments, via a one-pot process, rapidly installed the requisite 
stereodefined polyene motifs within chivosazole F. Optimised Still-Gennari-type HWE olefination 
conditions were applied to install the (2Z,4E)-dienoate in D. MnO2-mediated double oxidation of D 
turned the terminal alcohol into an aldehyde and the oxazoline into an oxazole, followed by a 
Stork-Zhao olefination transforming the aldehyde to a Z-vinyl iodide for a macro-Stille coupling 
reaction, which achieved the ring closure to afford macrocycle E.  
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Chapter 3 discusses the developments towards the synthesis of the southern fragment F of 
chivosazole A. Sugar I was prepared first and conditions were screened for the glycosylation of H 
and I to afford G.  
 
 
 
Chapter 4 outlines the achievements of this research and points out some future issues that need to be 
tackled. 
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Nomenclature 
 
Compound numbering 
 
The numbering system used for any structurally related compounds will be with reference to the 
numbering of the carbon chain of chivosazole A (18). This numbering is given on the structure and is 
used in 1H NMR assignments. When atoms on the macrocycle and the sugar are both referred to, the 
sugar numbering will be primed e.g. C1’, C2’ etc. 
 
 
 
Syn and Anti diastereomers 
 
The syn and anti convention for assigning the stereochemistry of acyclic compounds is used in this 
dissertation.  
 
 
 ! and " anomers 
 
The α  and β  converntion in carbohydrate nomenclature is used to describe the relative 
configurational relationship between the anomeric centre (C1) and the anomeric reference centre 
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(C5). 
 
 
 
The naming of compounds follows the IUPAC convention. 
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DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
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DMAP 4-N,N-dimethyaminopyridine 
DMB    3,4-dimethoxybenzyl 
DMBTCA 3,4-dimethoxybenzyl trichloroacetimidate 
DMF    dimethylformamide 
DMP Dess-Martin periodinane 
DMSO dimethylsulphoxide 
  
 
ix 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ee enantiomeric excess 
eq.    equivalent(s) 
Et   ethyl 
g gram(s) 
h hour(s) 
HMPA hexamethylphosphoramide 
HOBt hydroxybenzotriazole 
HPLC high-performance liquid chromatography 
HRMS high resolution mass spectroscopy 
HWE Horner-Wadsworth-Emmons 
Hz Hertz 
IC50 median inhibition constant that reduces the effect 
by 50% 
Ipc iso-pinocampheyl 
IUPAC International Union of Pure and Applied Chemistry 
IR infrared spectroscopy 
J 1H-1H coupling constant 
LLS longest linear sequence 
m multiplet 
M   moles per litre 
MS molecular sieves 
Me   methyl 
mg   milligram(s) 
MHz Mega-Hertz 
min minute(s) 
mL millilitre(s) 
mmol millimole(s) 
MTPA α-methoxy-α-(trifluoromethyl)phenylacetic acid 
  
 
x 
NBS N-bromosuccinimide 
nm nanometre(s) 
NMR nuclear magnetic resonance 
nOe nuclear Overhauser effect 
PE petroleum ether 
Ph phenyl 
pin pinacol 
PMB 4-methoxybenzyl 
PMBTCA 4-methoxybenzyl trichloroacetimidate 
PPTS pyridinium p-toluenesulfonate 
iPr isopropyl 
ppm parts per million 
py. pyridine 
q quartet 
qn quintet 
R   unspecified substituent 
Rf   TLC retention factor 
rt   room temperature 
s singlet 
So ce Sorangium cellulosum 
t triplet 
TBAF tetra-n-butylammonium fluoride 
TBME methyl tert-butyl ether 
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TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
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Tf trifluoromethane sulfonyl 
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xi 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TMS trimethylsilyl 
TLC    thin layer chromatography 
UV ultra violet 
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Chapter 1 Introduction 
 
1.1 Natural products in drug discovery 
 
Natural products have been a research focus for drug discovery since the early 1800s. The 
development of the first commercialised natural product, morphine (1), by E. Merck in 1826 and the 
promotion of the first semi-synthetic, natural product-derived drug, aspirin (2), by Bayer in 1899 
started a new age in which medicines could be isolated from plants and then utilised independently 
from the original sources.1,2 
 
The landmark discovery of penicillin (3, 4) by Fleming in 1929 extended the research focus from 
plants to microbes as sources of novel compounds possessing antibacterial, antifungal or antiparasitic 
activities.1,3 Other important properties of microbial natural products include antitumour and 
anticholesterolemic activities. The latter were exploited in the development of atorvastatin (Lipitor, 5) 
and simvastatin (Mevacor, 6) from the fungal metabolites mevastatin and lovastatin, inhibitors of 
HMG-CoA reductase. These drugs are among the best-selling class of all time. 3 , 4  During 
investigation of microbes for the production of antibiotics, research on plants has mainly focused on 
anticancer drug discovery as in the case of Taxol and the vinca alkaloids.5,6 
 
In this context, marine organisms did not receive much attention until the latter part of the 20th 
century. Considering that over 90% of macro-organism phyla originate from the seafloor and that 
marine micro-organisms are much more diverse compared to macro-organisms, marine organisms 
can be regarded as an invaluable source of secondary metabolites, often having novel structures and 
biochemical modes of action.7 Particular attention has been paid to the anticancer properties of many 
marine natural products. To date, several marine-derived drugs have been approved for commercial 
use, including Ecteinascidin-743 (ET-743/trabectedin/Yondelis, 7), eribulin mesylate 
(E7389/Halaven, 8) and monomethylauristatin E (Vedotin, 9). Some marine-derived agents in 
  
 
2 
clinical trials include aplidine (plitidepsin/dehydrodidemnin B, 10), kahalalide F (11), PM10450 
(zalypsis, 12) and PM1183 (lurbinectedin, 13).8 
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1.2 Myxobacteria 
 
After an intensive study on actinomycetes over the last century, the potential of this class of bacteria 
for providing new bioactive structures has been shrinking. As a promising alternative, myxobacteria 
have become a novel research focus. Among Gram-negative bacteria, myxobacteria are special 
because of their ability to move by gliding and creeping on surfaces and to form fruiting bodies, a 
property similar to eukaryotic organisms or fungi, which distinguishes them from other prokaryotic 
bacteria.9 Of great interest to natural product chemists are their bioactive secondary metabolites 
based on novel molecular scaffolds.10 Among the genuses of myxobacteria, Sorangium is of special 
interest, having provided nearly half of the known secondary metabolites of myxobacterial origin.11 
For example, five compound families have been characterised from S. cellulosum So ce12: tubulin 
destabilizers disorazoles (14), eubacterial RNA polymerase inhibitors sorangicins (15), bactericidal 
sorangiolides (16), the sulfangolides (17), and the antifungal and anticancer chivosazoles 
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(18).12,13,14,15,16 
 
 
 
1.3 Chivosazoles 
 
The chivosazoles were first isolated from the myxobacterium So ce12 in 1994 during research on the 
disorazoles.13 Subsequently, several other strains of S. cellulosum were also reported to be sources of 
chivosazoles. Strain So ce192 was chosen for the purpose of isolation of the chivosazoles as it only 
contains soraphens as co-metabolites. Separation of chivosazoles A-E was achieved by a sequence of 
purification steps: elution from adsorber resin, partition between methanol and n-heptane, silica-gel 
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flash chromatography, and a combination of normal-phase and reversed-phase HPLC.16  
 
Chivosazoles are potent and selective modulators of actin, which is the most abundant protein in 
eukaryotic cells and accounts for about 10% of the total protein mass.17 F-actin is the constituent of 
microfilaments, which provide structural support for cells and mediate many essential processes such 
as cell motility, cell division and many more.18 The binding of chivosazoles to actin causes 
inhibition of actin polymerisation and depolymerisation of F-actin, resulting in a cytostatic effect on 
cells. Chivosazole A was reported to possess potent antiproliferative activity against human cancer 
cell lines (IC50 = 2.9 nM for K-562; IC50 = 3.5 nM for KB-3-1; IC50 = 8.1 nM for A-549).19 
Chivosazole F is similar to latrunculin A20 as they both interact with actin by direct binding, and the 
binding sites for chivosazole F and latrunculin A partially overlap. Latrunculin A has proven its 
usefulness in interrogating actin-related processes. As a microbial metabolite, chivosazole F is 
potentially more useful, because collection of chivosazole F is more convenient compared to the 
tedious isolation or complicated synthesis of latrunculin A.21 
 
The planar structure of chivosazole A was elucidated based on mass spectrometry and NMR methods 
that confirmed the oxazole-containing 31-membered macrocycle, three conjugated polyene regions, 
ten stereocentres and a 6-deoxyglucose derivative. The structures of chivosazoles B-E were 
identified by comparing their MS and NMR data with that of chivosazole A. Chivosazole F was 
isolated from So ce885 as the only chivosazole without the glycosyl side-chain at C11.16 The relative 
and absolute configuration of chivosazole A was elucidated in 2007 through a combination of 
chemical degradation, partial synthesis, NMR spectroscopy and genetic analysis.22 
 
Table 1.1: Structures of chivosazole A-F 
Chivosazoles R1 R2 R3 R4 
18 A Me R2a Me Me 
19 B H R2a Me Me 
20 C Me R2a H H 
21 D H R2a H Me 
22 E H R2a H H 
23 F Me R2b     
R2a =
R2b = H
O OH
R3O OR4
1
11
26
27
30
35
O
O
N
O
OR2
OH OH
OH
R1O
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The double bond geometries in chivosazole A were deduced from their vicinal coupling constants (3J 
= 14-15 Hz for E-alkenes; 10-12 Hz for Z-alkenes). The 1,3-anti relationship between the alcohols at 
C32 and C34 was established by formation of the acetonide derivative 24 (Scheme 1.1) and use of 
the 13C NMR method described by Rychnovsky and Evans.23 To identify the configuration at the 
C29, C30 and C31 stereocentres, TBS-protected chivosazole A was degraded into fragment 25 
(Figure 1.3). NOESY analysis of fragment 25, together with the established 1,3-anti relationship of 
the C32-C34 diol allowed the relative stereochemistry of the whole fragment to be deduced. 
Subsequently, fragment 25 was synthesised independently to confirm the proposed relative 
stereochemistry and to determine the absolute configuration by comparison of NMR data and [α]D 
values. 
 
 
 
 
 
Due to the limited availability of chivosazole A, assignment of the remaining five stereocentres was 
achieved by a combination of computational modelling and genetic analysis.22 Molecular modelling 
of the chivosazole skeleton without all substituents provided a set of energy-minimised conformers 
first. The substituents were then superimposed onto the conformers, the configuration of which was 
manipulated to best fit the NMR coupling data, leading to an assignment of the absolute 
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Scheme 1.1: Formation of acetonide derivative 24 and chemical degradation of chivosazole A
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configuration of chivosazole A. This assignment was subsequently supported by analysing 
chivosazole biosynthesis.24   
 
Confirmation of the proposed structure and the significant biological profile inspired efforts to 
investigate a total synthesis that led to the completion of chivosazole F by Kalesse in 2010,25 which 
is discussed in detail in the next section. 
 
1.4 Kalesse’s synthesis of chivosazole F 
 
Considering the potential chemical instability of the polyenes, the triene region and tetraene region 
were installed last as part of the macrolactone formation. After retrosynthetic analysis, fragments 
28-31 were proposed for the carbon backbone assembly (Scheme 1.2). 
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In the forward synthesis, preparation of fragment 27 was based on the synthetic route used to access 
fragment 25 for stereochemical verification (Scheme 1.3). Diastereoselective aldol methodology 
developed by Evans was first applied to install the 1,2-syn relationship in adduct 34. 
Acyloxazolidinone 34 was transformed into aldehyde 35 in a sequence of three steps, followed by 
addition of silyl enol ether 36 via an 1,3-anti-selective Mukaiyama aldol reaction based on the Evans 
polar model26 to give β-hydroxy ketone 37. Reduction of ketone 37 under Evans-Saksena conditions 
(Me4NBH(OAc)3, MeCN/AcOH)27 constructed the 1,3-anti diol in 38. Subsequent elaboration, 
including diol protection, PMP-acetal opening and alcohol oxidation, provided aldehyde 39. The 
(Z)-double bond of enoate 40 was installed by Ando olefination28 and the product was transformed 
into fragment 30 over four further steps. The coupling of phosphonate 30 and aldehyde 31 afforded 
the required olefin as a 1:1 mixture of geometrical isomers, which is a significant flaw in this route. 
Silyl deprotection and MnO2 promoted oxidation provided eastern hemisphere 27. 
 
 
 
To commence the synthesis of the northeastern fragment 28, a Nagao titanium-meditated acetate 
aldol reaction29 was employed to afford adduct 46. The newly formed hydroxyl group was protected 
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9 
as a TBS ether and aldehyde 47 was provided by reduction with DIBAL-H. A boron-mediated aldol 
reaction30 between aldehyde 47 and ester 48 under Masamune conditions gave anti adduct 49. 
Aldehyde 28 was synthesised from 49 through a sequence of methylation, deprotection, oxidation, 
esterification, oxazole formation under Wipf conditions31 and DIBAL-H reduction. 
 
 
 
The anti relationship within fragment 29 was established by a Marshall-Tamura reaction with 
aldehyde 50 bearing a triethylsilyl ether in the α-position to increase the modest diastereoselectivity 
of the unsubstituted aldehyde (Scheme 1.5). 32  Subsequent protecting group elaborations and 
bromination provided allyl bromide 29 in 53% yield over four steps. 
 
 
 
Wittig olefination33 of aldehyde 28 with the phosphonium ylid derived from allyl bromide 29 was 
used to couple the fragments with good (Z)-selectivity. Intermediate 53 was then transformed into 
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10 
western hemisphere 26 via a sequence of PMB deprotection, palladium-catalysed hydrostannylation, 
tin-iodine exchange and bromination. 
 
 
 
With both hemispheres in hand, fragment union was achieved by conversion of bromide 26 into the 
phophonium salt and subsequent Wittig reaction with 27 to construct the (E,E,Z)-triene configuration. 
Intramolecular Stille coupling was employed to achieve macrocyclisation to give the fully protected 
chivosazole. Finally, after global silyl deprotection, the total synthesis of chivosazole F was 
completed. The spectroscopic data were in accordance with the data originally reported for natural 
chivosazole F and confirmed the previously proposed configurational assignment. 
 
 
Although the total synthesis was an impressive achievement in itself, the route suffers from several 
Br
OTBS
OPMB
OTBS
MeO
28
O
N
H
O
OPMB
OTBS
MeO
O
N
OTBS
Br
OTBS
MeO
O
N
OTBS
I
1. PBu3, MeCN
2. 28, KOtBu
(91%, E:Z > 10:1)
1. DDQ
2. Bu3SnH, PdCl2(PPh3)2
3. I2
4. MsCl, Et3N
5. LiBr
(35%)29
53 26
Scheme 1.6: Synthesis of western hemisphere 26 (Kalesse)
O O O
TBS TBS
O
OBu3Sn
H
27
PBu3Br
OTBS
MeO
O
N
OTBS
I
OTBS
MeO
O
N
O
O O O
TBS TBSOBu3Sn
I
TBS
23 chivosazole F
KOtBu, PhMe
(48%, over 2 steps)
1. PdCl2(PhCN)2, DMF/THF
2. HF•py, py, THF
(18%, over 2 steps)
54
55
Scheme 1.7: Completion of the first synthesis of chivosazole F by Kalesse et al.
26
PBu3, MeCN
  
 
11 
deficiencies, such as poor selectivity in defining the olefinic geometry of the southern tetraenoate 
and low overall yield (<0.5%). Also, the protecting group strategy does not allow access to 
chivosazole A as the protecting group on C11 alcohol is not differentiated. 
 
Studies towards the total synthesis of the chivosazoles in the Paterson group were intended to 
develop a more efficient synthetic strategy with better stereochemical control and higher overall 
yield. Furthermore, by differential protection of the C11 alcohol, selective glycosylation could be 
incorporated into the route, making chivosazole A accessible. 
 
1.5 Synthetic strategy evolution 
 
The chivosazoles have proved to be highly challenging synthetic targets, and considerable efforts 
have previously been pursued in our group, leading to a complex story as summarised here. 
 
1.5.1 The first-generation endgame strategy 
 
Through the exploration of the syntheses of initially selected chivosazole fragments and their 
proposed couplings, the endgame strategy has been through three iterations. These strategies are 
discussed in turn. In the first-generation endgame strategy proposed by Lisa Gibson and Jennifer 
Kan,34,59 the parent chivosazole structure was disconnected to reveal four fragments 57, 58, 59 and 
60 of similar size and complexity, making the route highly convergent (Scheme 1.8). Sonogashira 
coupling of 59 and 60 would afford the southern hemisphere of chivosazole F. Due to the sensitivity 
of the tetraene, the (2Z)-alkene and the (6Z)-alkene were masked as alkynes in 60 so that the tetraene 
motif could be unveiled at a late stage. Stille coupling of 57 and 58 would generate the northern 
hemisphere, which could then be coupled with the southern hemisphere by Suzuki coupling. Ester 
hydrolysis followed by macrolactonisation was envisaged to close the ring. Alkyne reduction would 
then unveil the tetraene and afford macrolactone 56.  
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Investigation of the synthesis of the C14-C26 northwestern fragment 57 was carried out by Gibson.34 
It was found that installation of the pinacol boronate moiety onto a precursor oxazole aldehyde 61 
via Takai olefination35 was unsuccessful (Scheme 1.9). 
 
 
 
The reason for the failure was deduced to be the incompatibility of the oxazole aldehyde moiety with 
the Takai olefination conditions used for this transformation. A test of this hypothesis was carried out 
by submitting oxazole aldehyde 63 and isobutyraldehyde to Takai olefination using reagent 62 
(Scheme 1.10). Takai olefination of oxazole aldehyde 63 did not provide the expected product 64. 
However, Takai olefination of isobutyraldehyde afforded the desired (E)-olefinic product 65 in 71% 
yield. Based on the test result, it appeared that installing pinacol boronate onto oxazole aldehyde 61 
would prove challenging. A different coupling strategy was required to replace the Suzuki coupling.  
Bpin
MeO
O
N
OTES
O
O
OTBS
OO
1
30 35
11
2619
IMeO
O
N
OTBS 26
14
Me3Sn
HO OO
35
Stille coupling
Macrolactonisation
27E E
E
Z
C27-C35 North-eastern FragmentC14-C26 North-western Fragment
Suzuki coupling
56
57
I
OTES
Br
13
Z
E
Scheme 1.8: First-generation endgame strategy
58
CO2Me
1
8
7
Sonogashira coupling
59 60
C8-C13 South-western Fragment C1-C7 South-eastern Fragment
IMeO
OTBSO
N
O
H
IMeO
OTBSO
N
Bpin
CrCl2, LiI, THF, Cl2HCB O
O
61
62
57
Scheme 1.9: Attempt to install pinacol boronate
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With experience in our group of transforming aldehyde 66 into vinyl iodide 67 under more 
conventional Takai conditions using CHI3 (Scheme 1.11),36 it was proposed that the vinyl iodide 
might be an easier alternative functionality to install. This could then participate in a Stille 
cross-coupling to form the C14-C15 bond in our endgame strategy.  
 
 
 
Following this modification, an initial trial of the Takai olefination with the model oxazole aldehyde 
63 afforded vinyl iodide 68 in 51% yield (Scheme 1.12). 
 
H15C7
N
O
H
O
H15C7
N
O
B
O
O
63 64
CrCl2, LiI, THF
Cl2HCB
O
O
62
H
O CrCl2, LiI, THF
Cl2HCB
O
O
62
B O
O
71%)
65
Scheme 1.10: Model systems for Takai olefination
OTBS
MeO
O
N
OTESStille 
Cross-Coupling
OTBS
MeO
O
N
OTES
I R3Sn
Scheme 1.11: Modified endgame strategy
O
H
TBSO
PMBO
TBSO
OPMB
I
CrCl2, CHI3, dioxane/THF
(74%)
66 67
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When the same Takai reaction conditions were applied to the real system 69, however, the desired 
vinyl iodide 70 was formed in a meagre 7% yield (Scheme 1.13).  
 
 
 
Given that neither of these two homologation approaches produced a synthetically useful result, 
pre-installing the vinyl iodide prior to formation of the oxazole was considered, as this could 
introduce the desired coupling handle with the additional benefit of greater convergency. Amide 
coupling of amino alcohol 72 with acid 71 followed by cyclisation was expected to yield the oxazole 
species 74 with the desired (E)-vinyl iodide moiety (Scheme 1.14).  
 
 
 
Having a vinyl iodide at both ends of the linchpin fragment 74 might cause a site-selectivity problem 
for the fragment coupling. To overcome this, construction of the northern hemisphere 78 was 
completed before installation of the oxazole vinyl iodide (Scheme 1.15). Iododiene 75 was 
transformed by Wulff-Stille stannylation37 to stannane 76, which was coupled with vinyl iodide 77 
H15C7
N
O I
68
H15C7
N
O
H
O
63
(51%)
CrCl2, CHI3, dioxane/THF
Scheme 1.12: Model system for testing the Takai olefination
MeO
OTBSO
N
O
H 69
(7%)
CrCl2, CHI3, dioxane/THF
OH O O
MeO
OTBSO
N OH O O
I
70
Scheme 1.13: Takai olefination of 69
OTBS
MeO
O
OH
HO NH2
I
amide coupling
OTBS
MeO
O
NH
OH I
cyclisation
OTBS
MeO
O
N
I
Scheme 1.14: Envisioned pre-installation of the vinyl iodide and subsequent oxazole formation
I
I I
71
72
73 74
  
 
15 
to construct the northern hemisphere 78. Alcohol 78 was then oxidised to aldehyde 79. However, 
Pinnick oxidation of aldehyde 79 caused the triene to isomerise, yielding no desired product 80. This 
result indicated that the vinyl iodide should be installed before the critical Stille fragment coupling. 
 
 
 
To tackle the site-selectivity issue for the fragment coupling, Mungyuen Li38 prepared bis-halide 81 
(Scheme 1.16), with a bromide at C26 in place of an iodide, as shown in Scheme 1.16. This approach 
was based on the premise that the reactivity of the vinyl iodide and the vinyl bromide should be 
sufficiently differentiated for the subsequent site-selective Stille cross-coupling at C14. The oxazole 
was masked as an oxazoline as de-iodination was observed during oxidation of the oxazoline to the 
required oxazole. It was concluded that this oxidation would best be carried out after cross-coupling 
to avoid this de-iodination side reaction. 
 
TESO OO
I
OTBS
MeO
OH
I
(Me3Sn)2, Pd(PPh3)4, (5 mol%),
iPr2NEt, PhH, 80 ºC
(59%)
OTBS
MeO
OH
SnMe3
Pd(PPh3)4 (20 mol%),
CuTc, Ph2PO2NBu4,
DMF, 0 ºC
(77%)
OTBS
MeO
OH TESO OO
DMP, NaHCO3,
CH2Cl2
(94%)
OTBS
MeO
O TESO OO
OTBS
MeO
OH TESO OO
O
NaClO2, NaH2PO4•H2O,
tBuOH, H2O, 2-methyl-2-butene
H
Scheme 1.15: Synthesis and modification of the northern hemisphere 78
75 76
77
78
79
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The focus was then turned to the Sonogashira coupling between the south-western fragment 59 and 
the south-eastern fragment 60, which was studied by Jennifer Kan.59 Two model compounds 82 and 
83 were designed to test the Sonogashira coupling (Scheme 1.17).   
 
 
 
Preparation of iodide 82 started with Swern oxidation39 and Corey-Fuchs olefination40 of (S)-Roche 
ester-derived alcohol 85. The resulting dibromide 86 was treated with nBuLi and quenched with 
methyl iodide, which gave alkyne 87. Generating iodide 82 from alkyne 87 by Schwartz 
reagent-mediated hydrozirconation41  was undermined by isomerisation and PMB-deprotection. 
Stannylcupration and halogen-tin exchange proved more successful and provided vinyl iodide 82 as 
a single stereoisomer (Scheme 1.18).  
 
I
OTBS
MeO
O
N
I
North-western 
fragment
evolution
Br
OTBS
MeO
O
N
I
Scheme 1.16: Envisaged revision to fragment 74
8114
26
14
26
74
TIPSSonogashira
coupling
Br
TIPS
OTES
I
+
Scheme 1.17: The planned Sonogashira coupling
I
PMBO
83
59
82 84
CO2Me
60
PMBO
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Though vinyl iodide 82 could be synthesised, it required an excess of nBuLi, Bu3SnH and I2. An 
alternative option would be to employ the intermediate dibromoolefin 86 for the coupling instead 
with control over the stereochemistry based on the steric effect of the vicinal (Z)-substituent,42 
which could lead to a shorter, more economical and practical route (Scheme 1.19).  
 
 
 
However, after a screen of Sonogashira coupling conditions by Kan,59 Uenishi conditions43 were 
applied for the coupling between 86 and 83, which yielded 90 as the sole product (Scheme 1.20).  
 
I
PMBO
PMBO
OH
1. (COCl)2, DMSO, Et3N, CH2Cl2
    !78 to 0 ºC, 1 h
2. PPh3, CBr4, CH2Cl2, 0 ºC
(89% over 2 steps)
PMBO
Br
Br
nBuLi, THF, !78 ºC;
MeI, 0 ºC
(82%)
PMBO
PMBO
1. Bu3Sn(Bu)Cu(CN)Li2
    THF, !78 ºC, 2 h; MeOH
2. I2, CH2Cl2, 0 ºC
Cp2ZrHCl, PhH or THF, 40 ºC, 30 min;
I2, rt, 1h
Scheme 1.18: Synthesis of (E)-vinyl iodide 82
82
85 86 87
87
PMBO
Br
Br
TIPS
TIPS
Br
+
PMBO
Sonogashira
coupling
TIPS
PMBO
Negishi
coupling
ZnMe2
Scheme 1.19: An alternative way of constructing dienediyne 89
86
83
88 89
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With the unsatisfying result of these trials and considering that the installation of conjugated 
(Z,E)-polyenes by late stage alkyne reduction seemed ambitious, a second endgame strategy was 
proposed. 
 
1.5.2 The second-generation endgame strategies 
 
The second-generation endgame strategy features the modified linchpin fragment 81 and a different 
disconnection of the southern hemisphere, based on what had been learnt previously (Scheme 1.21). 
A Stille coupling utilising the stannane of 92 and the iodide terminus of 91 was proposed to construct 
the southern hemisphere. The C13 bromide would subsequently be transformed to a stannane. 
Fragment 81 incorporates an iodide and a bromide for the planned sequential Stille couplings with 
the new southern hemisphere and the north-eastern fragment 58. Ester hydrolysis and 
macrolactonisation would then accomplish the ring closure and afford macrocycle 56. 
 
PMBO
Br
Br
TIPS
TIPS
+
PMBO
TIPS
Pd(dppf)Cl2, CuI
iPr2NH, PhH, 2 h
(22%, 86% brsm)
Scheme 1.20: Sonogashira coupling of dibromoolefin 86 with enediyne 83
86
83 90
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Vinyl iodide 91 and stannane 92 were synthesised and conditions were found by Jennifer Kan59 to 
effect the Stille coupling between 91 and 92 with no olefin isomerisation (Scheme 1.22).  
 
 
 
One key premise of this endgame strategy is that the tetraenoate motif within the southern fragment 
93 could undergo hydrolysis and esterification without compromising the sensitive olefin geometry. 
To test this hypothesis, hydrolysis of tetraenoate 93 to the corresponding carboxylic acid was first 
investigated. After a screen of conditions, Ba(OH)2 in MeOH was chosen to facilitate the 
saponification, which afforded acid 94 as a single isomer in a satisfactory 70% yield. The TES ether 
was also cleaved under the reaction conditions (Scheme 1.23).  
 
I
MeO
O
N
OTES
O
O
OTBS
OO
1
30 35
11
2619
BrMeO
O
N
OTBS 26
14
Me3Sn
HO OO
35
Stille coupling
Macrolactonisation
27E E
E
Z
C27-C35 North-eastern FragmentC14-C26 North-western Fragment
Stille coupling
56
Scheme 1.21: Second-generation endgame strategy
58
Stille coupling
C6-C13 South-western Fragment C1-C5 South-eastern Fragment
Br
OTES
I
7 91
CO2Me
Bu3Sn
5
92
13
1
81
CO2Me
Bu3SnBr
OTES
I
91 92
Pd(PPh3)4, CuTC,
Bu4NO2PPh2, DMF
0 ºC
+ (85%)
Br
OTES
CO2Me
93
Scheme 1.22: Construction of the southern hemisphere 93
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Due to the tendency for alkene isomerisation of the activated tetraenoic acid 94, a structurally 
simpler acid 96, which is also a precursor to the southern fragment, was used to study the 
esterification with model alcohol 95 (Scheme 1.24). Nevertheless, after testing a series of conditions, 
either no desired product 97 was generated or the isomerised product 98 was obtained.  
 
 
 
 
Another key premise of the endgame strategy is the successful transformation of the C13 bromide to 
the stannane after the formation of 93. Halogen-lithium exchange followed by stannylation with 
Bu3SnCl was chosen for the transformation. Unfortunately, neither ester 93 nor acid 94 could be 
converted to the desired organostannanes under such conditions (Scheme 1.25). Instead, 
decomposition of the starting materials was observed.  
 
 
 
However, vinyl bromide 101, a precursor to the southern fragment, was successfully transformed to 
the corresponding vinyl stannane 102 under the same conditions (Scheme 1.26).  This indicated that 
the sensitive tetraenoate is incompatible with the halogen-tin exchange. 
Br
OTES
CO2Me Ba(OH)2, MeOH, 18h
(70%)
Br
OH
CO2H
Scheme 1.23: Hydrolysis of tetraenoate 93
93 94
CO2H
Z
E
Bu3Sn
HO OO
PMBO
O OO
PMBO
Z
E
Bu3Sn
O
O OO
PMBO
Bu3Sn
O
E
E
conditions
Scheme 1.24: Model system for testing esterification
97 9895 96
Br
OR1
COOR2
tBuLi, Et2O, !78 ºC, 5 min;
Bu3SnCl Bu3Sn
OR1
COOR2
R1 = TES  R2 = Me  93
R1 = H      R2 = H     94
R1 = TES  R2 = Me   99
R1 = H      R2 = H     100
Scheme 1.25: Attempted vinyl stannane synthesis through halogen-lithium-tin exchange
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With the failure of the esterification and the stannylation, a third-generation endgame strategy was 
proposed. 
 
1.5.3 The third-generation endgame strategies 
 
Due to the lability of the open-chain tetraenoate to alkene isomerisation, the crucial 
(2Z,4E,6Z,8E)-tetraenoate motif would be built up in conjunction with the macrocyclisation and two 
strategies were proposed to achieve this (Scheme 1.27). The north-eastern fragment 103 incorporates 
an Ando-type phosphonate at the hindered C30 alcohol, which would facilitate an HWE olefination 
to construct the (2Z)-alkene. The bond disconnections in both approaches are the same, but the 
ordering in the forward synthetic sense varies.  
 
Br
OTES
OH
Bu3Sn
OTES
OH
tBuLi, Et2O, !78 ºC;
Bu3SnCl
(68%)
Scheme 1.26: halogen-lithium-tin exchange of vinyl bromide 101
101 102
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Strategy I was studied by Jennifer Kan.59 Stille coupling44 between 104 and 105 was achieved to 
yield triene 109 with good configurational stability (Scheme 1.28). No homo-coupling product of 
iodostannane 104 was observed. The excellent site-selectivity could arise from a rate difference of 
Sn-Cu transmetalation between stannane 104 and stannane 105. (Z)-vinyl stannane 104 is sterically 
more hindered compared to (E)-vinyl stannane 105 and so undergoes a slower transmetalation. 
Aldehyde 106, alcohol 107 and Weinreb amide 108 were also tested in the Stille coupling with 104. 
However, the corresponding triene products proved to be configurationally unstable.  
I
MeO
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N
OTES
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O
OTBS
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Scheme 1.27: Third-generation endgame strategy
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The same conditions were applied to the Stille coupling reaction between the north-western fragment 
81 and the southern hemisphere 109, and the Stille coupling reaction between the newly formed 
advanced fragment 113 and the north-eastern fragment 103. Good yields and complete control over 
the desired alkene geometry were achieved in both Stille coupling reactions and the backbone of 
chivosazole F was constructed (Scheme 1.29). 
 
Bu3Sn
OTES
I
104
Bu3Sn
105
O
OMe
+
Pd2dba3, tBu3P, CuTC
Ph2PO2NBu4, DMF, 0 ºC
(72%)
Bu3Sn
OTES
CO2Me
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Scheme 1.28: Stille coupling to construct the triene motif
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The universal Stille-coupling conditions led to an attempt to achieve the three sequential couplings in 
a one-pot process (Scheme 1.30). The reaction was carefully monitored to ensure the fragments were 
fully consumed before the addition of the next building block. The desired coupling product 114 was 
afforded in 56% yield with excellent site-selectivity and stereoselectivity. The efficient one-pot 
process both maximised step economy and minimised waste generation. However, transformation of 
the ester in 114 to aldehyde for the intramolecular HWE olefination was unsuccessful due to triene 
isomerisation, which diverted the focus onto the more conservative strategy II (Scheme 1.27). 
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CO2Me
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I
BrMeO
O
N
OTBS
Me3Sn
O OO
81
O
P
OPh
O
OPh
Pd2dba3, tBu3P, CuTC
Ph2PO2NBu4, DMF, 0 ºC+
OTES
CO2Me
113
BrMeO
O
N
OTBS
OTES
CO2Me
113
BrMeO
O
N
OTBS
+
103
Pd2dba3, tBu3P, CuTC
Ph2PO2NBu4, DMF, 0 ºC
(83%)
O OOO
P
OPh
O
PhOOTES
CO2Me
MeO
O
N
OTBS
114
Scheme 1.29: Synthesis of 114 via two Stille coupling reactions
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Strategy II was studied by Li.38 Stille coupling between 81 and 102 was firstly effected under 
Fürstner-type conditions83 to afford 115 in 80% yield. The same conditions were then applied to the 
Stille coupling between 115 and 103 to construct 116 in 92% yield (Scheme 1.31).  
 
I
BrMeO
O
N
OTBS
Me3Sn
O OO
81
O
P
OPh
O
OPh
+
103
Pd2dba3, tBu3P, CuTC
Ph2PO2NBu4, DMF, 0 ºC(56%)
O OOO
P
OPh
O
PhOOTES
CO2Me
MeO
O
N
OTBS
114
Scheme 1.30: Synthesis of 114 via a one-pot process
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With the same reaction conditions, these two Stille couplings could also be carried out in a one-pot 
process, leading to 116 in an overall 86% yield with complete control over the desired alkene 
geometry (Scheme 1.32). 
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Scheme 1.31: Construction of 116 via two Stille couplings
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With the advanced fragment 116 in hand, an Ando-type HWE olefination of 116 was effected to 
afford a mixture of (2Z,4E)-dienoate 117 and (2E,4E)-dienoate 118 (Scheme 1.33). The best 
selectivity (117:118 = 1.3:1) was achieved using KOtBu as the base at –78 °C.  
 
 
 
MnO2 was used to oxidise both the C7 alcohol and the oxazoline of the desired (2Z,4E)-dienoate 117 
to afford 119 (Scheme 1.34). Stork-Zhao olefination71 of aldehyde 119 transformed the C7 aldehyde 
Bu3Sn
OTES
OH
Br
OTBS
MeO
O
N
I
Me3Sn
O OO
Pd(PPh3)4, CuTC,
Bu4NO2PPh2, DMF
0 ºC
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Scheme 1.32: Site-selective Stille coupling reactions to form 116
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into the (Z)-vinyl iodide. Due to its vulnerability to isomerisation, the resulting vinyl iodide was 
immediately submitted to intramolecular Stille reaction to construct macrocycle 56. It is worth noting, 
however, that Li38 reported problems with the global deprotection step with the acetonide on C32 and 
C34 appearing more stable than anticipated. 
 
 
 
As the southern (4E,6Z,8E)-triene motif of 114 was reported to be highly susceptible to alkene 
isomerisation, Strategy II was selected as the more promising strategy and is investigated in detail in 
this thesis. The more adventurous Strategy I may still be feasible with further refinement. The key 
issues that needed to be tackled in Strategy II were as follows:   
(i) The poor selectivity of the late stage Ando-type olefination (Scheme 1.33), which provided 
(2Z,4E)-dienoate 117 and (2E,4E)-dienoate 118 as a 1.3 : 1.0 mixture; 
(ii) The protecting group strategy to make the final global deprotection step as straightforward as 
possible.  
(iii) Several steps would benefit from improvement in the yield by further reaction optimisation. 
 
To begin to overcome these shortcomings, the first objective was to replicate the synthesis of the key 
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Scheme 1.34: Modifications towards the total synthesis of chivosazole F
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chivosazole fragments and optimise the reaction conditions. These studies are discussed in the 
following chapter. 
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Chapter 2 Results and discussion on Chivosazole F 
 
The retrosynthetic analysis of 120 (Scheme 2.1) is based on the third-generation endgame strategy 
with some modifications. North-western fragment 81 incorporates a C14 iodide and a C26 bromide 
for the planned sequential Stille cross-couplings with stannane 102 and stannane 121. Aldehyde 106 
is supposed to react with phosphonate 121 via an Ando-type/Still-Gennari-type HWE olefination to 
construct the (2Z)-alkene. The C7 alcohol of 102 would be transformed to a (Z)-vinyl iodide for a 
macro-Stille coupling with the stannane of 106 to afford the macrocycle 120. The synthesis of 
fragment 81, 121 and 102, fragment couplings and subsequent modifications will be discussed in 
turn in this chapter. 
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Scheme 2.1: Retrosynthetic analysis
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2.1 Synthesis of the C14-C26 north-western fragment  
 
The north-western fragment 81 possesses a 1,3-anti, 1,4-syn stereochemical motif (Scheme 2.2). The 
1,4-syn relationship could be constructed by an asymmetric aldol reaction between the Roche ester 
derived methyl ketone 124 and the corresponding aldehyde 125. The 1,3-anti stereochemical 
relationship would be installed via a diastereoselective 1,3-anti reduction. As discussed before, 
owing to the low yield obtained in forming the vinyl iodide at C15 from precursor aldehyde 69 
(Scheme 1.13), the vinyl iodide moiety was to be attached before the formation of the oxazoline.  
 
 
 
In the forward synthetic sense, the (S)-Roche ester derived methyl ketone 124 was prepared via a 
three-step reaction sequence. Firstly, the alcohol group of (S)-Roche ester 126 was protected as the 
3,4-dimethoxybenzyl ether 127 with DMBTCA and PPTS in 91% yield (Scheme 2.3). Ester 127 was 
transformed into Weinreb amide 128 with N,O-dimethylhydroxylamine and iso-propyl magnesium 
chloride in 95% yield.45 Mono-addition of MeMgBr via chelated intermediate 12946 gave the 
methyl ketone 124 in 87% yield.  
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Scheme 2.2: Retrosynthetic analysis of the northwestern fragment 81
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Bromodienal 125 was synthesised in two steps from sulphur trioxide pyridine complex 130 (Scheme 
2.4).47 Hydrolysis of pyridinium complex 130 with KOH gave potassium glutaconaldehyde salt 132 
via the formation of the intermediate iminesulfonate dianion 131. 
 
 
 
Bromination of the hydrolysis product 132 yielded the required bromodienyl aldehyde 125 and the 
Z-isomer 133 (Scheme 2.5). The bromination conditions with PPh3 and Br248 (Table 2.1, Entry 1) 
gave a disappointingly low yield of 3%. At the same time, numerous unidentified side products were 
observed when monitoring the reaction process. A screen of reaction conditions was then carried out 
to try and improve the yield. 
 
 
 
 
 
HO
OMe
O
DMBO O
DMBTCA, PPTS
CH2Cl2
(91%)
DMBO
OMe
O
Me(MeO)NH•HCl, 
iPrMgCl, THF, —20 °C
(95%)
 MeMgBr, THF, 0 °C
20 20
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N
O
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(87%)
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Scheme 2.3: Preparation of DMB-protected methyl ketone 124
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Table 2.1: Optimization of conditions for the bromination reaction 
 
Entry Scale Reagent Solvent Temperature Time Yield 
1 500 mg Br2 (1.2 eq.), PPh3 (1.2 eq.) CH2Cl2 0 oC 3 h 3% 
2 1 g Br2 (1.2 eq.), PPh3 (1.2 eq.) CH2Cl2 0 oC to rt 16 h 9% 
3 500 mg Br2 (1.5 eq.), PPh3 (1.5 eq.) CH2Cl2 0 oC to rt 16 h 10% 
4 500 mg NBS (2.0 eq.), PPh3 (2.0 eq.) CH2Cl2 0 oC to rt 7 h 11% 
5 500 mg NBS (2.0 eq.), PPh3 (2.0 eq.) CH2Cl2 0 oC to rt 16 h 20% 
6 100 mg CBr4 (1.5 eq.), PPh3 (1.5 eq.) CH2Cl2 0 oC to rt 16 h 0 
7 100 mg PBr3 (1.5 eq.) Et2O 0 oC to rt 16 h 9% 
8 100 mg PBr3 (1.5 eq.) THF 50 oC 5 h 3% 
9 500 mg NBS (2.0 eq.), PPh3 (2.0 eq.) CH2Cl2 40 oC 16 h 20% 
10 6 g NBS (2.0 eq.), PPh3 (2.0 eq.) CH2Cl2 0 oC to rt 16 h 20% 
11 5 g NBS (2.0 eq.), PPh3 (2.0 eq.) CH2Cl2 0 oC to rt 40 h 30% 
 
 
No significant improvement in yield was observed when the temperature was raised and the reaction 
time was prolonged (Entry 2). Raising the number of equivalents of the reagents from 1.2 to 1.5 did 
not affect the yield significantly (Entry 3). Several common conditions for bromination were also 
tried. Potassium glutaconaldehyde stirred in dichloromethane with N-bromosuccinimide and 
triphenylphosphine49 for 7 h (Entry 4) formed a black solution, and after workup and purification, an 
11% yield of product 125 was obtained. As the starting material was not very soluble, it was difficult 
to monitor the reaction conversion. Therefore, an extended reaction time (16 h) was employed to 
maximise the conversion, which improved the yield from 11% to 20% (Entry 5). Carbon 
tetrabromide with triphenylphosphine50 (Entry 6) was also tested but unfortunately no reaction was 
observed. Phosphorus tribromide51 gave an initial 9% yield at room temperature (Entry 7). However, 
warming up the reaction to 50 °C reduced the yield to 3% (Entry 8). 
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Having surveyed a number of different bromination conditions, the most promising result was 
produced by N-bromosuccinimide and triphenylphosphine, and so these conditions were selected for 
further optimisation experiments. Neither gentle warming of the reaction (Entry 9) nor increasing the 
reaction scale (Entry 10) improved the yield, but extending the reaction time to 40 h raised the yield 
from 20% to 30% (Entry 11) for the desired E,E-diene 85. 
 
With methyl ketone 124 and aldehyde 125 in hand, the asymmetric boron-mediated aldol reaction 
developed in the Paterson group,52 was employed to install the required stereochemistry (Scheme 
2.6). Methyl ketone 124 was enolised with (–)-Ipc2BCl and triethylamine in Et2O at 0 ˚C to form 
boron enolate 134, which reacted with aldehyde 125 to give the 1,4-syn aldol product 136 with 
excellent diastereoselectivity but in a disappointing yield (24%, >95:5 dr).  
 
 
 
Two possible transition states are compared in Figure 2.1. Aldol reactions of such unsubstituted 
enolborinates are proposed to proceed via a boat transition state,53 stabilised by a formyl hydrogen 
bond between the aldehyde proton and the β-alkoxy group on the enolate.54 For transition state TS 
138, there is an unfavourable eclipsing interaction between the alkene and the methyl group on the 
enolate, which is absent in TS 137, the favoured transition state. This leads to the desired 
stereochemistry in the product 136.  
 
ODMBO
H
O
Br
(—)-Ipc2BCl, Et3N
Et2O, 0 °C, 30 min
ODMBO
B(Ipc)2
—78 °C, 30 min;
—20 °C, 16 h
Br
ODMB
O
B(Ipc)2
Br
ODMB
OH
OO pH 7 buffer
SiO2, 30 min, rt
a (24%, >95:5 dr)
b (85%, >95:5 dr)
124
Scheme 2.6: Diastereoselective boron-meditated 1,4-syn aldol reaction
a commercial (—)-Ipc2BCl reagent; b Freshly prepared (—)-Ipc2BCl reagent
134
135136
125
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The oxidative workup with hydrogen peroxide usually employed for such reactions was not used for 
the cleavage of the resulting boron species 135 (Scheme 2.6) as the bromodiene was susceptible to 
isomerisation and oxidation. An alternative workup using pH 7 buffer and silica gel was applied. 
Despite the mild work up, the yield was unsatisfactory as the reaction did not go to completion, and 
this was attributed to the low quality of commercial (–)-Ipc2BCl. Methods were therefore 
investigated for the preparation of fresh (–)-Ipc2BCl.  
 
The most convenient preparation of (–)-Ipc2BCl 140 was by double hydroboration of pinene 139 
with monochloroborane which produced the reagent as a 1M solution in Et2O (Scheme 2.7).55 Using 
the freshly prepared reagent in the aldol reaction between methyl ketone 124 and aldehyde 125 
improved the yield to 85% with excellent diastereoselectivity (>95:5 dr) for formation of the desired 
adduct 136 (Scheme 2.6). 
 
 
 
With the aldol adduct 136 in hand, reduction under Evans-Tishchenko conditions56 was employed to 
install the 1,3-anti relationship between the hydroxyl stereocentres at C20 and C22 (Scheme 2.8). 
Samarium(III) acts as a Lewis acid catalyst to promote the formation of a hemiacetal from β-hydroxy 
ketone 136 and propionaldehyde. This intermediate can undergo intramolecular hydride transfer via 
the chelated, bicyclic transition state TS 141 to afford the propionate modified 1,3-diol 142. The 
O
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O H
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O
R
H
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Figure 2.1: Comparison of the possible transition states
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product 142 was obtained in excellent yield (95%) and diastereoselectivity (>95:5 dr) through this 
transformation. At this stage, all the required stereochemistry had been installed for the 
north-western fragment and attention was focused towards the installation of the oxazole. 
 
 
 
The newly-formed hydroxyl group was transformed into the corresponding methyl ether 143 by 
reaction of alcohol 142 with Meerwein’s salt and Proton Sponge® in CH2Cl2 at room temperature 
(Scheme 2.9). Unfortunately, complete conversion could not be achieved even with a large excess of 
reagents. The starting material 142 could, however, be recovered and resubmitted to provide methyl 
ether 143 in 80% yield after one recycle. 
 
 
 
Methanolysis of the propionate ester 143 using K2CO3 in methanol generated alcohol 144 (Scheme 
2.10), and the free hydroxyl group at C22 was protected as the TBS ether 145 (TBSCl, imidazole, 
CH2Cl2) in 89% yield over two steps. 
 
SmI2, EtCHO, THF, —20 °C
(95%, >95:5 dr)
DMBO
OH O
BrDMBO
O OH
Br
1,4-syn
18 26
H O
O
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Scheme 2.8: Evans-Tishchenko selective 1,3-anti reduction of 136
136 142
O
Me3OBF4, Proton Sponge®
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Scheme 2.9: Methylation of alcohol 142
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The remaining steps to access the oxazole precursor involved DDQ-meditated oxidative cleavage of 
the DMB group to form alcohol 146 in 95% yield (Scheme 2.11). Due to the lower oxidation 
potential of the DMB ether, it was considered a superior choice to the PMB protecting group in order 
to avoid potential allylic oxidation at C22.57,58 Alcohol 146 was oxidised to carboxylic acid 123 in 
90% yield by treatment with TEMPO and BAIB in MeCN and H2O (1:1)59 in readiness for the 
subsequent amide coupling. 
 
 
 
Having prepared acid 123, amino alcohol 122 containing the vinyl iodide terminus was needed as the 
fragment coupling partner (Scheme 2.12).  
 
 
DMBO
OMe OTBS
Br
TBSCl, imidazole
CH2Cl2
K2CO3, MeOHDMBO
OMe O
Br DMBO
OMe OH
Br
2618
(98%)
(91%)
143 144
145
Scheme 2.10: Protecting group exchange at C22
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O
DMBO Br
OTBSOMe
HO Br
OTBSOMe
DDQ, pH 7 buffer, DCM, 0 °C
(95 %)
TEMPO, BAIB, MeCN-H2O (1:1), rtHO Br
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Scheme 2.11: DDQ-mediated oxidative cleavage and oxidation
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Scheme 2.12: Proposed method for oxazoline formation
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The synthesis of vinyl iodide 122 commenced by transforming serine 147 into the corresponding 
methyl ester using thionyl chloride and methanol (Scheme 2.13). The amine group was selectively 
protected as the Boc carbamate with Boc2O and Et3N in CH2Cl2. After protection of the amine and 
the alcohol as the aminal by treatment with 2,2-dimethoxypropane and BF3•OEt2, ester 148 was 
obtained in 99% yield over 3 steps.60 Methods were then explored to reduce the ester of 148 to an 
aldehyde for a subsequent Takai olefination to install the (E)-vinyl iodide. 
 
 
 
An attempt was made to reduce ester 148 directly to aldehyde 149 with DIBAL-H at –78 ˚C61 
(Scheme 2.14). However, this reaction failed to provide any product and the starting material 148 
was recovered. 
 
 
 
Ester 148 was reduced to alcohol 150 with lithium borohydride in 60% yield (Scheme 2.15). The 
newly formed alcohol would then be oxidised to the aldehyde.  
 
 
 
Alcohol 150 was oxidised under Swern conditions62 to give aldehyde 149. Aldehyde 149 was 
NH2
HO OH
O
1. SOCl2, MeOH, —10 oC to rt
2. Boc2O, Et3N, CH2Cl2, 0 oC
3. 2,2-dimethoxypropane, BF3•OEt2, acetone, rt
(99% over 3 steps)
NBocO
OMe
O
147 148
Scheme 2.13: Preparation of ester 148
NBocO
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O
148 149
Scheme 2.14: Proposed DIBAL-H reduction of ester 148
H
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O
NBocO
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Scheme 2.15: Proposed method for reduction of ester 148 into alcohol 150
LiBH4, EtOH, THF, 0 ºC to rt
(60%)
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immediately subjected to a Takai olefination to afford vinyl iodide 151 with the desired E-geometry 
cleanly in 85% yield over two steps. Finally, deprotection of the acetonide and Boc group under 
acidic conditions supplied amino alcohol 122 as the HCl salt in 99% yield. No decomposition of 
amino alcohol 122 was observed when the product was stored in the dark at –20 ˚C (Scheme 2.16). 
 
 
 
It now remained to couple the amino alcohol 122 to carboxylic acid 123 and subsequently cyclise to 
form an oxazoline ring. EDC-mediated amide coupling (EDC, HOBt, iPr2NEt, CH2Cl2) was 
employed in the coupling of the two components to form amide 152 in 90% yield (Scheme 2.17). 
Careful monitoring of this reaction by TLC avoided formation of the bis-coupled product 153. 
Cyclisation of amide 152 to oxazoline 81 using DAST proceeded smoothly in 99% yield. Kan59 
demonstrated that oxidation of the oxazoline to the oxazole was possible using MnO2; however, this 
reaction did not tolerate the vinyl iodide. Oxidation was thus delayed until after fragment coupling 
and oxazoline 81 was used as the northwestern fragment for the fragment coupling.  
 
NH2.HCl
I
HO
NBocO
OH
NBocO
I
1. (COCl)2, DMSO, Et3N, CH2Cl2, —78 °C
2. CrCl2, CHI3, THF, 0 °C to rt
(85% over 2 steps)
MeCOCl, MeOH,0 °C to rt
(99%)
Scheme 2.16: Preparation of amino alcohol 122 from alcohol 150
150 151 122
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The whole north-western fragment 81 was synthesised in 33% yield over 12 steps, which compares 
well with the 17% yield reported by Li.38  
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Scheme 2.17: Completion of C14-C26 northwestern fragment 81
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2.2 Synthesis of the C27-C35 north-eastern fragment  
 
2.2.1 Modifications of the C27-C35 Fragment 
 
The synthetic strategy for the C27-C35 fragment is based on Gibson’s work63. Removal of the 
acetonide in the final steps of the synthesis was identified as a potentially difficult step due to the 
sensitivity of the natural product and so an alternative protecting group strategy was explored. 
 
Cyclopentylidene ketals are more labile than acetonides, as cyclic ketals experience bond-angle 
strain introduced by the 1,3-dioxoane ring that could facilitate activation for hydrolysis.64 Therefore, 
2,2-dimethoxypropane was replaced by 1,1-dimethoxycyclopentane for the regioselective ketal 
formation with triol 155. Triol 155 could be accessed from ketone 156 and aldehyde 157 via a boron 
aldol reaction (Scheme 2.19).  
 
  
 
Ketone 156 was available as a starting material from other projects in this laboratory. Preparation of 
the β -hydroxy aldehyde 157 started with an asymmetric Noyori reduction 65 , 66  of methyl 
acetoacetate 158. This was transformed into β-hydroxy ester 159 in 80% yield (Scheme 2.20) 
utilising the in situ formed (R)-BINAP-Ru(II) catalyst under a hydrogen atmosphere (6 bar).  
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Scheme 2.19: Retrosynthetic analysis of C27-C35 fragment 154
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The absolute configuration of the newly formed alcohol was confirmed by application of the 
advanced Mosher method.67,68 Alcohol 159 was converted to the corresponding Mosher esters 160 
and 161 (Scheme 2.21). 
 
 
 
The α-proton, the ester carbonyl and the trifluoromethyl group of the ester lie in the same plane in 
both MTPA ester derivatives (Figure 2.2). The diamagnetic effect of the phenyl group shields protons 
Ha, Hb, Hc in the (R)-MTPA ester causing an upfield shift of their signals in the 1H NMR when 
compared to the corresponding signals in the (S)-MTPA ester. Hence, when ∆&	(&S-&R) is calculated, ∆& values should be positive for protons Ha, Hb, Hc, and ∆& values should be negative for protons 
Hx, Hy, Hz, thus allowing the assignment of the configuration of the stereocentre in question. 
 
 
 
1H NMR chemical shift analysis of the Mosher ester derivatives 160 and 161 is shown in Table 2.2. 
The ∆& value for H35 is positive and the ∆& values for HOMe, H33a and H33b are negative, showing 
that the desired (S)-configuration was formed in alcohol 159.  
 
O
MeO
O
H2, Ru-BINAP
6 bar, MeOH
(80%, >99% ee) O
MeO
OH
Scheme 2.20: Preparation of β-hydroxy ester 159
159158
MeO
O OH
(R)- or (S)-MTPA, DCC
DMAP, CH2Cl2
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O
OMe
PhCF3*
Scheme 2.21: Preparation of (R)- and (S)-Mosher ester derivatives
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161  (S)-Mosher ester
33 35
O
O
CF3
Ph OMe
(OMe) (Ph) (R)-MTPA
(S)-MTPA
H
β’
βγ
γ’
α
δ’
δ
HaHbHc
Hy HzHx
Figure 2.2: Configurational model for Mosher ester analysis
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Table 2.2: Mosher ester 1H NMR analysis of 159 
Position &H (S)-MTPA / ppm &H (R)-MTPA / ppm ∆&	(&S-&R) / ppm 
OMe 3.58 3.65 –0.07 
33a 2.69 2.71 –0.02 
33b 2.54 2.56 –0.02 
34 5.55 5.53 +0.02 
35 1.43 1.32 +0.11 
 
Completion of the β-hydroxy aldehyde 157 was achieved by TBS protection of the newly formed 
hydroxyl group and DIBAL-H reduction of the ester to the aldehyde (Scheme 2.22).  
 
 
 
Ethyl ketone 156 was treated with c-Hex2BCl and Et3N to form the (E)-boron enolate 164 via 
transition state TS 163 (Scheme 2.23). As TS 163 shows, chloride as a relatively poor leaving group 
adds bulk to the B centre, which sits on the opposite side of the carbonyl to R1 in order to minimise 
steric interactions. This forces the methyl group away from the boron centre. Additionally, the 
chloride can activate the C-H bond further, favouring deprotonation through this conformation. The 
(E)-boron enolate 164 is thus formed through an E2 mechanism.69 Addition of aldehyde 157 to the 
enolate 164 afforded the 1,2-anti, 1,4-syn adduct in 98% yield and high diastereoselectivity (>95:5). 
Computational studies have shown that the aldol reaction proceeds via a boat-like transition state53 
(TS 166), which minimises the 1,3-allylic strain within the enolate while a formyl hydrogen bond 
helps stabilise the transition state,54 leading to the 1,4-syn product 165. 
 
MeO
O OH
TBSCl, imid.
CH2Cl2 MeO
O OTBS
DIBAL-H, CH2Cl2
!78 ºC H
O OTBS(80%) (95%)
Scheme 2.22: Elaboration to β-hydroxy aldehyde 157
159 162 157
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An Evans-Tishchenko reduction56 was then effected to introduce the 1,3-anti relationship between 
C30 and C32 (For mechanism, see Chapter 2.1). The newly formed ester was cleaved to give diol 
167.  
 
 
 
Acetonide protection of diol 167 followed by DDQ-mediated oxidative cleavage of the PMB ether 
provided alcohol 168 (Scheme 2.25). The released primary alcohol was transformed into the 
(Z)-vinyl iodide over 2 steps: Dess-Martin oxidation70 and Stork-Zhao olefination71. The transition 
state and the intermediate for the Stork-Zhao olefination are shown. The ylid generated from 
(Ph3PCH2I)+I– and NaHMDS is non-stabilised, which leads to the early transition state TS 169. TS 
169 is puckered to avoid steric clashes, yielding cis-oxaphosphetane 170, which collapses to give the 
(Z)-vinyl iodide product 171. 
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Scheme 2.23: Diastereoselective 1,4-syn aldol reaction
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The acetonide and TBS groups were removed with catalytic PPTS in methanol (Scheme 2.26). 
Conditions were then screened for protection of the terminal diol with 1,1-dimethoxycyclopentane 
172. 
 
 
 
Cyclopentanone was chosen as the starting material for the preparation of 
1,1-dimethoxycyclopentane 172. Several sets of conditions to effect this transformation were 
investigated as shown in Table 2.3: 
 
 
 
 
 
 
PMBO OH OTBS
28 35
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OH O OTBS
28 35
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O
I
27
1. DMP, NaHCO3
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2. (Ph3PCH2I)+I-, NaHMDS
THF, !78 ºC to rt (93%)
Scheme 2.25: Formation of (Z)-vinyl iodide 171 from diol 167
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Entry Conditions (equiv.) Result 
1 (CH3O)3CH (3.0), TsOH (0.5%), MeOH, 16 h Full conversion 
2 (CH3O)3CH (2.0), TsOH (0.5%), MeOH, 16 h 50% conversion 
3 TiCl4 (0.01), Et3N (0.12), MeOH, 1 h 15% yield 
4 TiCl4 (0.01), Et3N (0.12), MeOH, 16 h 32% yield 
 
Trimethyl orthoformate and p-toluenesulfonic acid in methanol72 were initially selected (Entry 1), 
which resulted in full conversion of cyclopentanone indicated by the NMR data of the crude product. 
However, the 1,1-dimethoxycyclopentane 172 yielded could not be separated from the unreacted 
trimethyl orthoformate via distillation. It was assumed that by adding less trimethyl orthoformate, the 
product could be purified more easily. Hence the number of equivalents of trimethyl orthoformate 
was reduced from 3 to 2 (Entry 2). However, under the modified conditions, only 50% of the 
cyclopentanone was transformed into 1,1-dimethoxycyclopentane 172, and the product and the 
unreacted trimethyl orthoformate were still inseparable. It appeared that the yield was highly 
dependent on the equivalents of trimethyl orthoformate, thus using one equivalent of trimethyl 
orthoformate was expected to result in an even lower yield with some unreacted trimethyl 
orthoformate mixed with the product. At this point, alternative conditions utilising titanium 
tetrachloride and triethylamine73 were investigated. After a reaction time of one hour, the product 
was purified by distillation in 15% yield (Entry 3). Keeping the reaction for a longer time (16 h) gave 
a better yield (32%) of the product. 
 
With 1,1-dimethoxycyclopentane 172 in hand, terminal acetonide formation from triol 155 was 
tested.  
 
O
conditions OMe
OMe
Table 2.3: Attempted acetal formation of cyclopentanone
174 172
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The reaction proceeded significantly more slowly (full conversion in 3 h) than with 
2,2-dimethoxypropane (full conversion in 5 min), presumably due to the bulkier cyclopentyl group. 
Unfortunately, the thermodynamic ketal 176 was formed as the major product (50%) rather than the 
desired kinetic ketal 175 (15%) (Scheme 2.27).  
 
Following this disappointing result, we considered other protecting groups that might allow selective 
protection of the C32 and C34 alcohols and also facilitate straightforward deprotection in the 
endgame. A silylene acetal would match the silyl groups present in the other fragments and would 
hopefully fulfill this objective. Di-tert-butylsilyl bis(trifluoromethanesulfonate) was thus tried as an 
alternative reagent for the terminal diol protection. Considering the steric bulk of the reagent, it was 
expected to react with the terminal C34 alcohol first to form silyl ether 177 (Scheme 2.28), followed 
by a second reaction with the adjacent C32 alcohol, giving the protected product 178. To our delight, 
the reaction went smoothly and afforded product 178 in 96% yield. No migration to the internal 
position was observed.  
 
 
 
Alcohol 178 was oxidised70 to ketone 179 to confirm the structure of the product (Scheme 2.29). The 
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Scheme 2.27: Acetonide formation of triol 155
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proton signals for H30, H32 and H34 were identified by COSY correlations. After the oxidation, the 
H32 and H34 signals were identified but the H30 signal had disappeared, suggesting that the desired 
alcohol 178 was the product from the last step. 
 
 
 
Another concern was whether the silyl group could be removed during the final deprotection. This 
was tested by applying the anticipated global deprotection conditions to 178 (Scheme 2.30), which 
afforded the desired product 155 in excellent yield. 
 
 
 
To couple this fragment with the northwestern fragment 81 via a Stille-coupling reaction, vinyl 
iodide 178 needed to be transformed into vinyl stannane 180. This was accomplished by a 
Wulff-Stille reaction37 via a Pd-mediated catalytic cycle (Scheme 2.31).  
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Scheme 2.29: Oxidation of alcohol 178
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Scheme 2.30: Deprotection of the silyl group
HF∙pyridine, pyridine
THF
(99%)
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2.2.2 Installation of the dienyl stannane motif 
 
The dienyl stannane motif at C30 needed to be incorporated into the fragment either at this point or 
at a later stage, to be used as a coupling handle for the macrocyclisation. Two approaches were 
considered and tested (Scheme 2.32). The first approach was to explore the coupling of alcohol 180 
with carboxylic acid 96. Based on Kan’s unsuccessful trial59 a further investigation of coupling 
conditions was proposed. In the second approach, esterification would be employed first to install a 
β-phosphono ester, which would be transformed to the (2Z,4E)-diene via a stereoselective olefination 
after the fragment coupling stage. 
 
O O
35
OH
I
27
Si
tBu tBu
PdCl2(PPh3)2, Li2CO3
(Me3Sn)2, THF, 40 ºC
O O
35
OH
Me3Sn
27
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(65%)
Scheme 2.31: Wulff-Stille reaction of vinyl iodide 178 and mechanism
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As vinyl stannane 180 was valuable and vulnerable, the alcohol 185 was prepared from intermediate 
184 as a model substrate for the test reactions (Scheme 2.33). 
 
 
 
Acid 96 for approach I (Scheme 2.32) was prepared by the hydrolysis of ester 92 (from Jennifer Kan) 
with LiOH in 96% yield (Scheme 2.34).  
 
 
 
A detailed screen of esterification conditions for approach I was previously carried out by Kan.59 
Unfortunately, none of the conditions tested could deliver the desired product 186, either resulting in 
no reaction, or affording the undesired ester 187 with (E,E)-diene geometry. A new screen was 
undertaken as a further exploration of alternative conditions. The results are shown in Table 2.4: 
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Scheme 2.32: Installation of (2Z,4E)-dienyl stannane onto alcohol 180
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182
PMBO OHOH OH
tBu2Si(OTf)2, 2,6-lutidine
CH2Cl2, !78 ºC
(95%) PMBO OOH OSi
tBu tBu
Scheme 2.33: Preparation of the model alcohol 185
184 185
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Scheme 2.34: Preparation of acid 96
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Entry Reagent E,Z : E,E 
1 EDC + DMAP 0 : 1 
2 EDC  No product 
3 DCC + DMAP 0 : 1 
4 DCC  No product 
5 DCC + DIPEA No product 
6 DCC + DIPEA + HOBt No product 
7 DCC + LiHMDS 1 : 0 (15% yield) 
 
Steglich esterification74 (Entry 1) with EDC was tried first, yielding only the undesired (E,E)-diene 
ester 187. Isomerisation was likely caused by reversible Michael addition of DMAP to the activated 
dienoic acid prior to ester bond formation. Removing DMAP from the conditions (Entry 2) resulted 
in no reaction. Steglich esterification with DCC (Entry 3) also gave the undesired (E,E)-diene ester 
187 as the only product. Again, the reaction with only DCC (Entry 4) gave no product. DIPEA was 
used as a substitute for DMAP (Entry 5) to no avail. Addition of another activating agent, HOBt 
(Entry 6), still failed to deliver any product. Pleasingly, when alcohol 185 was premixed with 
LiHMDS for one hour at 78 ˚C before the mixture of DCC and acid 96 was added, the desired 
product 186 was formed as a single isomer. However, the yield (15%) was insufficient for practical 
purposes. 
 
After the unsuccessful trial of approach I, approach II (Scheme 2.32) was investigated. Phosphonate 
PMBO OOH OSi
tBu tBu CO2H
Bu3Sn
Reagent, CH2Cl2, 16 h
O O
35
O Si
tBu tBu
O
Bu3Sn
Z
E
5
PMBO
O OO Si
tBu tBu
PMBO
35
5
O
Bu3Sn
E
E
+
Table 2.4: Screen of esterification conditions
185 96
186
187
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acids 42, 188 and 189 were made in order to prepare phosphonate esters 190-192 from alcohol 185 
by esterification (Scheme 2.35).  
 
 
 
Phosphonate acids 42 and 188 were prepared by the addition of lithiated diphenyl 
methylphosphonate 193 or bis(2,2,2-trifluoroethyl) methylphosphonate 196 to benzyl chloroformate 
194, followed by the cleavage of the benzyl group using hydrogen and activated palladium (Scheme 
2.36).75 The synthesis of phosphonate acid 189 started with the reaction of methyl dichlorophosphite 
198 and 2-tert-butylphenol 199. An Arbuzov reaction with either methyl bromoacetate 201 or benzyl 
bromoacetate 202 afforded the corresponding phosphonates 203 and 204.76 Hydrolysis of methyl 
ester 203 did not yield the desired phosphonate acid 189. Pleasingly, cleavage of the benzyl group 
from phosphonoester 204 under hydrogen atmosphere gave the target phosphonate acid 189 in 99% 
yield.  
 
O OOH Si
tBu tBu
(RO)2P OH
OO
esterification
O OO Si
tBu tBu
(RO)2P
O O
PMBO
PMBO
R =  Ph                         42
       CH2CF3                188
       2-tert-butylphenyl 189
R =  Ph                        190
       CH2CF3                191
       2-tert-butylphenyl 192
Scheme 2.35: Esterification of alcohol 185
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With the phosphonate acids in hand, alcohol 185 was transformed into phosphonate esters 190-192 
via esterification under Steglich conditions74 in good yields (Scheme 2.37). 
 
 
 
Preparation of stannylenal 106 started with syn-stannylcupration of diethoxypropyne 205 using 
Lipshutz reagent (Bu3Sn(Bu)Cu(CN)Li2),77 followed by quenching the resulting organocuprate with 
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Scheme 2.36: Preparation of phosphonate acids 42, 188 and 189
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methanol.78 The crude vinyl stannane was then submitted to acid-catalysed acetal hydrolysis to give 
stannylenal 106 in 75% yield and excellent stereoselectivity over 2 steps (Scheme 2.38).  
 
 
 
With the phosphonate esters 190-192 and the stannylenal 106 in hand, the stereoselective olefination 
was attempted, as shown in Table 2.5. The mechanisms for all the three types of olefination are 
similar (Scheme 2.39). The first step is deprotonation of the β-phosphonoester, which would then 
attack the aldehyde that co-ordinates with the sodium cation to give intermediates 211 and 212. The 
anti-intermediate 211 would cyclise to form the cis-oxaphosphetane 213 which collapses to yield the 
cis-product 215. In contrast, the syn-intermediate 212 would generate the trans-product 216 via the 
trans-oxaphosphetane 214. The electron withdrawing R1 groups endow the electron-deficient 
phosphorous with high electrophilicity, leading to fast formation of oxaphosphetanes 213 and 214 
from intermediates 211 and 212. The slower generation of the intermediates 211 and 212 hence 
becomes the rate determining step (kcis/ktrans > ksyn/kanti). The anti-intermediate 211 is generated 
faster due to the favoured transition state TS 209 with less steric hindrance (kanti > ksyn), resulting in 
the cis-product 215 as the major product. However, due to the low chelation ability of potassium 
cation, the aldehyde is not co-ordinated with the potassium ion while being attacked by the enolate 
208, leading to the two transition states with similar energy. Therefore, the cis-product 215 and the 
trans-product 216 are generated in nearly 1:1 ratio when using potassium bases. 
 
OEt
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1. Bu3Sn(Bu)Cu(CN)Li2,
    THF, !78 ºC, 2h; MeOH
2. TsOH, acetone, H2O
    reflux, 36 h
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H
Scheme 2.38: Preparation of stannylenal 106
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Scheme 2.39: Mechanism of the olefinations
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Entry R Base Temperature Time E,Z : E,E 
1 Ph NaH –78 to –10˚C 6 h 1.4 : 1 
2 Ph KOtBu –78 to –20˚C 16 h 1.4 : 1 
3 Ph KOtBu –78 to –40˚C 16 h 1.4 : 1 
4 Ph KOtBu –78˚C 40 h 1.3 : 1 
5 2-tert-butylphenyl KOtBu –78˚C to rt 72 h No product 
6 2-tert-butylphenyl NaH –78 to 0˚C 48 h 1.3 : 1 
7 CF3CH2 KHMDS, 18-crown-6 –78˚C 40 h No product 
8 CF3CH2 KOtBu –78 to –30˚C 20 h 1.8 : 1 
9 CF3CH2 KOtBu –78˚C 72 h 2.0 : 1 
10 CF3CH2 NaH –78 to –30˚C 20 h 2.0 : 1 
 
All the test reactions gave full conversion of the phosphonate esters except Entries 5 and 7, the 
starting materials of which were recovered. Ando-type olefinations (R = Ph) were first tried. With 
NaH as the base (Entry 1), the reaction was complete in 6 hours with a moderate selectivity for the 
desired E,Z-product (186:187 = 1.4:1). Changing the base from NaH to KOtBu and maintaining a 
colder temperature of –20˚C instead of –10˚C (Entry 2) resulted in a longer reaction time, but the 
same selectivity was observed. Keeping the reaction below –40˚C (Entry 3) did not increase the 
reaction time, but the selectivity was not improved either. Keeping the reaction at –78˚C (Entry 4) 
resulted in a longer reaction time, and the selectivity was slightly worse than before (186:187 = 
O O
35
O Si
tBu tBu
(RO)2P
O O
Conditions, THF
Bu3Sn
O
H
O O
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O Si
tBu tBu
O
Bu3Sn
5
Z
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O O
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E
+
O
Bu3SnR = Ph or CF3CH2 or 2-tert-butylphenyl
E
Table 2.5: Tests of stereoselective olefination
PMBO
PMBO
PMBO
186
187
106
  
 
57 
1.3:1). Replacing the phenyl group with 2-tert-butylphenyl (Entry 5 and 6) was proposed to improve 
the selectivity as a bulkier R1 group might disfavour TS 210 (Scheme 2.39), resulting in a better ratio 
of the E,Z-product 186. KOtBu was first used as the base (Entry 5) but the reaction yielded no 
product. NaH was then trialled at –78 to 0˚C (Entry 6) and provided the product with a selectivity 
186:187 = 1.3:1. Still-Gennari-type olefinations (R = CF3CH2) were last attempted. The most 
common conditions for Still-Gennari reactions (KHMDS, 18-crown-6, Entry 7) were tested first, but 
no product was detected. KOtBu was then used as an alternative base (Entry 8). Pleasingly, after 20 
hours, the products were isolated with improved selectivity (186:187 = 1.8:1). With the assumption 
that keeping the reaction at a lower temperature would provide a better selectivity, the reaction was 
left at –78˚C for 72 hours (Entry 9), and the selectivity did improve further (186:187 = 2.0:1). Lastly, 
NaH was tested as the base (Entry 10). This condition required shorter reaction time (20 h) and the 
selectivity stayed the same.  
 
The best result from optimisation of the olefination conditions was using the Still-Gennari-type 
phosphonate and NaH at –78˚C. The corresponding phosphonate acid 188 was thus installed onto 
alcohol 180 by esterification in 76% yield, finalising the synthesis of the north-eastern fragment 217 
in an overall 23% yield over 14 steps LLS.  
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Scheme 2.40: Synthesis of the north-eastern fragment 217
180
188
O
PO
O O
CF3
CF3
  
 
58 
2.3 Synthesis of the C7-C13 Southern fragment  
 
The C7-C13 southern fragment 102 was synthesised based on Kan’s work 79 . The C8-C9 
trisubstituted olefin and the C10 and C11 stereogenic centres would be set up in a single operation 
using a chiral auxiliary-based vinylogous Mukaiyama aldol reaction80 between dibromoacrolein 218 
and silyl ketene aminal 219 (Scheme 2.41).  
 
 
 
For the preparation of vinylogous silyl ketene aminal 219, D-phenylalanine-derived oxazolidinone 
221 was acylated with 2-methyl-2-pentenoic acid 220, giving imide 222 in 98% yield. Imide 222 was 
then enolised using NaHMDS and the resulting dienolate was trapped with TBSCl to provide silyl 
ketene aminal 219 (Scheme 2.42). The (E,E)-geometry formation is presumed to be controlled by 
dicarbonyl chelation81 and minimisation of A1,3-strain during deprotonation. 
 
 
 
Dibromoacrolein 218 was synthesised in 3 steps from crotonaldehyde 223 (Scheme 2.43). 
Corey-Fuchs reaction of crotonaldehyde 223 provided dibromodiene 224, which was submitted to 
Sharpless asymmetric dihydroxylation followed by oxidative cleavage to give dibromoacrolein 218. 
Sharpless asymmetric dihydroxylation was applied due to its improved regioselectivity over other 
achiral methods rather than to provide good enantioselectivity. 
Bu3Sn
OTES
OH Vinylogous
Mukaiyama aldol
Br
Br
O
H
+ NO
O OTBS
Bn
Scheme 2.41: Retrosynthetic analysis of C7-C13 southern fragment 102
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Scheme 2.42: Preparation of vinylogous silyl ketene aminal 219
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Aminal 219 and dibromoacrolein 218 were submitted to the vinylogous aldol reaction using freshly 
distilled TiCl4 to generate the aldol adduct in 90% yield and 10:1 diastereoselectivity. The product 
was recrystallised to give the anti–adduct 226 as a single diastereomer. The high degree of 
diastereoselectivity can be attributed to the favoured conformation of silyl ketene aminal 219. 
Opposing dipole moments place the benzyl group above the top face (as drawn in Scheme 2.44), 
providing a less hindered lower π–face, on which side the dibromoacrolein 218 approaches to 
minimise steric strain.  
 
 
 
The C11 hydroxyl group of aldol adduct 226 was then protected as a TES ether 227. Stereoselective 
hydrogenolysis82 of the product 227 afforded (Z)-vinyl bromide 228 in 99% yield (Scheme 2.45). 
The mechanism is shown in Scheme 2.46. The high selectivity of this reaction is due to faster 
oxidative addition of Pd(0) to the less hindered trans C-Br bond, followed by transmetalation with 
Bu3SnH and reductive elimination. The chiral auxiliary of 228 was cleaved with NaBH4 and the 
O
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Scheme 2.43: Synthesis of dibromoacrolein 218
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vinyl bromide was transformed into a vinyl stannane by a halogen-lithium-tin exchange to yield 
C7-C13 fragment 102. Overall, this C7-C13 southern fragment 102 was synthesised in 52% yield 
over 7 steps LLS. 
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Scheme 2.45: Synthesis of C7-C13 fragment 102
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Scheme 2.46: Mechanism of stereoselective hydrogenolysis
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2.4 Fragment coupling and endgame strategy 
 
2.4.1 One-pot Stille cross-coupling 
 
With all the three fragments in hand, the next step was to couple them via the previously established 
one-pot Stille cross-coupling method.  
 
 
 
To gain a better understanding of how well the Stille coupling would work on our system, the 
coupling of the north-western fragment 81 and the southern fragment 102 was tried first. Pleasingly, 
the reaction was straightforward under Fürstner-type conditions,83 yielding the product 115 in 83% 
yield after 1.5 hours (Scheme 2.48). No double bond isomerisation or reaction with the vinyl 
bromide was observed. 
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Scheme 2.47: One-pot Stille cross-coupling reaction of the three fragments
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The second Stille coupling between fragment 115 and the north-eastern fragment 217 was carried out 
under the same conditions. The north-eastern fragment 217 was fully consumed in one hour, yielding 
the product 229 in 70% yield, and 22% of fragment 115 was recovered (Scheme 2.49). Although the 
north-eastern fragment 217 was used in excess (1.1 eq.), fragment 115 did not completely react. This 
was attributed to the slow destannylation of 217 during the reaction, which was supported by NMR 
data analysis.  
 
 
 
To improve the yield, the stoichiometry of the north-eastern fragment 217 was increased to 2.0 eq. In 
this trial, the fragment 115 was fully consumed after one hour, giving 88% yield of the desired 
product 229 (Scheme 2.50). 
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Scheme 2.48: Stille coupling of fragment 81 and fragment 102
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With the conditions for two sequential Stille cross-couplings established, conducting them in a 
one-pot manner was next pursued. The reaction was carefully monitored to ensure the fragments 
were fully consumed before the addition of the next building block. The desired product 229 was 
formed in 80% yield with no observed side products (Scheme 2.51).  
 
 
 
The same Fürstner-type conditions83 for the two sequential Stille coupling reactions made the 
efficient multi-component assembly in a single synthetic operation possible. This one-pot method 
reduced loss of the valuable intermediate 115 and minimised waste generation by avoiding work up 
and purification for the intermediate 115.  
 
 
(2.0 eq.)
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Scheme 2.50: Improved Stille coupling of fragment 115 and fragment 217
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2.4.2 Construction of the macrocycle 
 
Following the successful assembly of the three fragments, construction of the (2Z,4E)-diene and the 
(6Z,8E)-diene from the advanced intermediate 229 was next pursued. Intermediate 230 bearing a 
vinyl stannane at C5 and a vinyl iodide at C6 was targeted for the final macro-Stille coupling which 
would provide the tetraene motif and close the ring.  
 
 
 
The (2Z,4E)-diene was generated via the optimised Still-Gennari conditions 84  as previously 
discussed in Chapter 2.2.2. Phosphoryl ester 229 was deprotonated with NaH at 0 ºC for one hour 
before the mixture was cooled down to 78 ºC, at which point aldehyde 106 was added. After 20 
hours, (Z,E)-isomer 232 and (E,E)-isomer 233 were isolated as a 2.5 : 1 mixture in 80% yield.  
 
 
OTBS
MeO
O
N O OO Si
tBu tBuO
OTES I
Bu3Sn
OTBS
MeO
O
N O OO Si
tBu tBu
OTES
O
Macro-Stille 
coupling
Scheme 2.52: The proposed approach for constructing the macrocycle 231
8 2
2
8
OTBS
MeO
O
N O OO Si
tBu tBuO
OTES
OH PO O
O
CF3
CF3229 230 231
5
6
Bu3Sn
O
H
EOTBS
MeO
O
N O OO
Si
tBu tBuO
OTES
OH P
O
NaH, THF, 0 ºC;
!78 ºC
(80%)
OTBS
MeO
O
N O OO
Si
tBu tBuO
OTES
OH
Bu3Sn
OTBS
MeO
O
N O OO
Si
tBu tBuO
OTES
OH
Bu3Sn
+
E
E
Z
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Construction of the (6Z,8E)-iodo-diene 230 was designed as a two-step sequence: (1) MnO2 
mediated double oxidation of the C7 alcohol and the oxazoline;85 (2) Stork-Zhao olefination of the 
newly formed C7 aldehyde to give (Z)-vinyl iodide (Scheme 2.54). 
 
 
 
For the double oxidation step, excess MnO2 was added in one portion and the reaction was kept at 
room temperature for 16 hours. Although the desired product 234 was isolated cleanly, the yield was 
a disappointing 11% (Scheme 2.55).  
 
 
 
The southern fragment 102 was used to investigate the oxidation conditions. Submitting the fragment 
102 into the same oxidation conditions gave the desired aldehyde 235 in 80% yield after two hours 
(Scheme 2.56). This result possibly implies that although the oxidation conditions provided the 
product 234, the sensitive polyene motifs made the product prone to decomposition under the 
reaction conditions if kept for too long. 
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With this assumption, the oxidation conditions were modified: MnO2 was added into the reaction in 
several small portions instead of in one portion. The reaction was carefully monitored and quenched 
immediately once the starting material 232 was consumed. With the new method, the yield increased 
to 33% (Scheme 2.57). Many efforts were made to further improve the yield but nothing helped. The 
problem was deduced to be with the oxazoline-oxazole oxidation, as oxidation of an unactivated 
oxazoline to an oxazole is quite challenging.  
 
 
 
Stork-Zhao olefination was then applied to aldehyde 234 aiming to provide (Z)-vinyl iodide 230 
(Scheme 2.58). NaHMDS and (Ph3PCH2I)+I were mixed to generate the corresponding ylid, into 
which 5 mg of aldehyde 234 was added at 78 ˚C. However, the NMR data of the crude showed only 
the starting material 234 with no desired product 230 found.  
 
 
 
Aldehyde 235 generated from the southern fragment 102 (Scheme 2.56) was used to test the 
olefination conditions. Pleasingly, submitting 20 mg of aldehyde 235 into the same conditions gave 
(Z)-vinyl iodide 104 in 85% yield with full conversion (Scheme 2.59). The difference between the 
results of the two olefinations might arise from the difficulty in protecting the ylid from being 
quenched by adventitious moisture on small scales. This hypothesis was supported by repeating the 
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same reaction with 1 mg of aldehyde 235, which yielded no desired product 104. 
 
 
 
Following on from that discovery, it was proposed that a solution would be to prepare a stock 
solution of the ylid from NaHMDS and (Ph3PCH2I)+Ion a large scale, and add the desired amount 
of the pre-formed ylid to the reaction. This method proved effective on aldehyde 234, giving the 
desired (Z)-vinyl iodide 230 (Scheme 2.60).  
 
 
 
Due to the risk of isomerisation of the intermediate 230, this compound was submitted into the 
macrocyclisation step as the crude material without further purification. Fürstner-type conditions 
were chosen for the macro-Stille reaction. Although the desired macrocycle 231 was obtained, the 
yield was only 12% over these two steps (Scheme 2.61). The low yield was attributed to the faster 
intermolecular Stille coupling reactions, which resulted in the side products from polymerisation. To 
minimise this problem, Simon Williams86 proposed a way of adding the starting material 230 via 
syringe pump to ensure slow addition of 230 and high dilution of the reaction system, which 
improved the yield of the macrocyclisation.  
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Scheme 2.59: Stork-Zhao olefination of aldehyde 235
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The final deprotection step was completed by Williams86. HF·pyridine-mediated removal of all the 
silicon-based protecting groups (including the silylene at C32/C34) afforded chivosazole F over 3 
steps in 41% yield (Scheme 2.62). Gratifyingly, all 1H and 13C NMR spectroscopic data for this 
synthetic material correlated precisely with those reported for natural chivosazole F.25 
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2.5 Conclusions 
 
The structurally complex macrocycle 231 was synthesised over 19 steps in an overall 0.73% yield. 
Synthesis of the three fragments 81, 102 and 217 of similar size and complexity was first achieved. 
The macrocycle 231 was then assembled efficiently through the orchestration of the three Stille 
cross-coupling reactions, making the synthetic route highly convergent. Ten stereocentres and nine 
double bond geometries were installed with precise control. With improvement of the 
macrocyclisation step and completion of the global deprotection step (Williams), the total synthesis 
of chivosazole F has been achieved over 20 steps in an overall 2.5% yield. 
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Chapter 3 Results and discussion on glycosylation 
 
Chivosazole F and chivosazole A differ by a 6-deoxyglucopyranoside sugar side chain 236 at C11 of 
chivosazole A. The plan for the synthesis of the chivosazoles allowed for the synthesis of 
chivosazole A by selective removal of the TES group after the macrocyclisation step (Chapter 2.4.2) 
and glycosylation with the glycosyl donor 238, followed by a global deprotection (Scheme 3.1).  
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This strategy was based on the hypothesis that as the least bulky silyl protecting group on 
intermediate 230, TES would be the easiest to remove. However, finding the optimal selective 
deprotection conditions by relying only on the minor difference among the three silyl protecting 
groups was eventually considered too risky and not enough material was available to test it. An 
alternative and more reliable plan was devised, to install the sugar side chain onto the southern 
fragment before the fragment coupling stage, which requires a new southern fragment 242 (Scheme 
3.2). According to this strategy, having obtained the intermediate alcohol 226, instead of the TES 
protection in Scheme 2.45, a glycosylation would be effected with the prepared glycosyl donor 238 
to provide the glycoside 240. Stereoselective reduction82 of the vinyl dibromide moiety of glycoside 
240 would afford the (Z)-vinyl bromide 241. Removal of the chiral auxiliary and the 
tin-lithium-halogen exchange would generate the new southern fragment 242.  
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3.1 Glycosyl fluoride synthesis 
  
Synthesis of the glycosyl donor 238 started with 1,2,3-trimethoxy sugar 245, which was prepared by 
Rachel Elliott from methyl-α-D-glucopyranoside 243 over two steps: benzylidene acetal formation 
and methylation (Scheme 3.3).87 
 
 
 
The regioselective bromination of the sugar 245 via a radical mechanism gave the 
4-benzoyl-6-bromo sugar 246 as the single product.88 The benzoate on 246 was then removed with 
NaOMe in methanol89 to yield 6-bromo-4-hydroxy sugar 247, which was submitted into the 
reductive debromination with NaBH4 to afford the 4-hydroxy-5-methyl sugar 248.90 
 
 
 
With the sugar 248 in hand, the next goal was to transform the C1-methoxy motif to a suitable 
leaving group for the planned β-glycosylation. According to studies conducted by Elliott,87 the 
glycosyl fluorides 252 and 253 gave the best results. For this reason, the glycosyl fluorides 252 and 
253 were prepared first. Installation of the thiophenyl moiety91 on the sugar 248 generated the 
thioglycoside 249 as an inseparable mixture of two anomers (α:β = 3:1) in 80% yield (Scheme 3.5). 
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The secondary alcohol on the thioglycoside 249 was then protected with TBSCl to give the 
thioglycosides 250 and 251. TBS instead of TES was used as the protecting group here as Rachel 
Elliott87 reported that TES tended to be labile during the glycosylation process. The two anomers 
could be separated via careful column chromatography at this stage. The thiophenyl motif on the 
anomers 250 and 251 was then converted into the fluoride using DAST and NBS. 92  The 
α-thioglycoside 250 gave the β-glycosyl fluoride 252 as the single anomer, the β-thioglycoside 251 
gave the α-glycosyl fluoride 253 and the β-glycosyl fluoride 252. 
 
 
 
The mechanism for the leaving group conversion is shown below (Scheme 3.6). DAST releases a 
fluoride anion first, and the remaining cation 254 coordinatively binds to the thiophenyl motif on the 
thioglycoside 250 or 251 to form the activated intermediates 255 and 256. These intermediates can 
either react through an SN2 mechanism with stereochemical inversion, or form an oxonium ion 
intermediate 257 facilitated by the lone pair electrons on the adjacent oxygen. For the 
α-thioglycoside 250, the activated intermediate 255 is stable enough due to the anomeric effect, and 
can easily go through the SN2 pathway, forming the β-glycosyl fluoride 252. The activated 
intermediate 256 formed from the β-thioglycoside 251, however, is relatively less stable and tends to 
form the oxonium ion intermediate 257, which then goes through the SN1 pathway, yielding both the 
α-glycosyl fluoride 253 and the β-glycosyl fluoride 252. 
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3.2 Glycosylation  
 
3.2.1 Glycosylation with glycosyl fluoride  
 
The optimal conditions for the glycosylation developed by Elliott87 were applied to the reaction 
between intermediate 226 and glycosyl fluoride 252 (Scheme 3.7). The glycosylation adduct was 
provided as an inseparable 1:1.1 α:β  mixture in 60% yield without the previously reported 
concomitant silyl group deprotection.87 However, reproducing this result proved troublesome. Either 
no reaction was observed or a lower yield (35%) was obtained. At this point, we set out to explore a 
more reliable glycosylation procedure.  
 
 
 
The proposed mechanism of the glycosylation is shown in Scheme 3.8. 
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3.2.2 Glycosylation with thioglycoside  
 
Due to the poor yield (31%) of the	β-glycoside product 240, a new method of glycosylation93 was 
tried using thioglycoside 250 (Table 3.1).  
 
 
 
Entry Reagent Solvent Temperature Time Yield α:β 
1 NBS CH2Cl2 –20˚C to rt 16 h 99% 5:1 
2 NBS CH3CN rt 16 h 25%, 75% brsm 1.4:1 
3 NBS CH3CN –20˚C 1 h 99% 1:1.3 
4 NIS CH3CN –20˚C to rt 72 h 60% 1.4:1 
 
Entry 1 shows that the major product was the undesired α-glycoside product 258, suggesting that 
oxonium ion intermediate formation followed by direct nucleophile attack was the dominant pathway. 
Replacing the solvent with CH3CN and keeping the reaction at room temperature (Entry 2) improved 
the selectivity. Keeping the reaction at –20˚C (Entry 3) further improved the selectivity. Replacing 
NBS with NIS resulted in longer reaction time, lower yield and worse selectivity.  
 
According to the mechanism (Scheme 3.9), the reaction could either go via SN1 or SN2 mechanism. 
The SN1 pathway affords either the α-glycoside product 258 or the β-glycoside product 240. The 
SN2 pathway could only generate the β-glycoside product 240. Considering 258 was yielded under 
all the conditions discussed before, the reaction must not have proceeded via a SN2 pathway purely. 
When CH2Cl2 was the solvent, the ratio of 258 in the product mixture was 83%, meaning the SN1 
pathway was absolutely dominant, or even possibly the only pathway. Changing the solvent to 
O
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Table 3.1: Test of the conditions of glycosylation with thioglycoside 250
250 226
  
 
77 
CH3CN increased the ratio of 240 in the product. The better selectivity is attributed to the 
co-ordination of CH3CN to the oxonium ion from the axial position, leading to a larger proportion of 
the β-glycoside product 240. The lower temperature would make the kinetic SN2 pathway the 
dominant pathway, yielding the β-glycoside product 240 as the major product. 
 
 
 
With a stereoselective hydrogenolysis82 transforming the dibromoolefins of 258 and 240 to the 
(Z)-vinyl bromides, the two diastereomers 261 and 241 could be separated and characterised 
respectively. 
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Chapter 4 Conclusions and future work 
 
Synthesis of the macrocycle 231 of chivosazole F has been achieved over 19 steps with an overall 
0.73% yield. Ten stereocentres and nine double bond geometries were installed with precise control. 
Construction of the backbone relied on an orchestrated sequence of Stille cross-couplings of the three 
advanced fragments 81, 217 and 102 via an efficient one-pot process. The oxazole in chivosazole F 
was masked as an oxazoline in fragment 81, which was installed by amide coupling of 123 and 122, 
followed by DAST mediated cyclisation. The 1,4-syn and 1,3-anti stereochemical relationships 
within fragment 123 and fragment 155 were constructed via boron aldol reactions followed by 
Evans-Tishchenko reduction. The C32/C34 diol of 155 was selectively protected as a silylene, which 
could be successfully deprotected later. The key stereochemistry of fragment 226 was defined with a 
vinylogous Mukaiyama aldol reaction between 218 and 219 (Scheme 4.1). 
 
Williams86 managed to improve the yield of the macrocyclisation step and complete the global 
deprotection step, affording chivosazole F over 20 steps with an overall 2.5% yield (Kalesse’s total 
synthesis of chivosazole F: 25 steps with an overall 0.48% yield). 
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The highly convergent and versatile route was also utilised to explore the total synthesis of 
chivosazole A by introducing the 6-deoxyglucopyranoside sugar side chain during the synthesis of 
the southern fragment 242 (Scheme 4.2). Thioglycoside 250 was synthesised from 245 over 5 steps 
and used in the glycosylation reaction. It was shown that thioglycoside 250 performed better than 
glycosyl fluoride 252 in the glycosylation reaction, providing 258 and 240 as a 1:1.3 mixture. The 
desired diastereomer 241 could be isolated after the stereoselective reduction. The two-step sequence 
of chiral auxiliary cleavage and bromide-lithium-stannane exchange will afford the southern 
fragment 242. This will be submitted to the fragment coupling step and the subsequent steps that 
were applied in the total synthesis of chivosazole F to generate chivosazole A. It is expected that the 
sugar should not interfere with the fragment coupling step and the subsequent steps, and the TBS 
group on the sugar can be removed under the global deprotection conditions. Thus, applying the 
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same synthetic route from the total synthesis of chivosazole F to the total synthesis of chivosazole A 
is promising, highlighting the flexibility of our synthetic route. 
 
 
 
The yields and selectivity of some reactions can still be optimised further (Scheme 4.3). The 
selectivity of the HWE olefination of 229 might be improved by exploring other types of HWE 
olefinations considering many conditions have been tested for the Ando-type and Still-Gennari-type 
HWE olefinations of 229. Better oxidation conditions for unactivated oxazolines will hopefully 
increase the yield of the double oxidation reaction of 233. Changing the conditions (solvent, 
temperature) of the glycosylation could be a way of improving the selectivity. Glycosyl donors 
besides thioglycosides and glycosyl fluorides are also worth trying. 
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Overall, the total synthesis of the structurally complex, biologically active chivosazole F has been 
completed by our group in an expedient way. This synthetic route is adventurous and highly 
convergent, and could potentially be applicable to the synthesis of useful quantities of chivosazole F. 
This established route was also modified and utilised for studies towards the total synthesis of 
chivosazole A, which has provided promising results already.   
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Chapter 5 Experimental 
 
5.1 General and analytical procedures 
 
Reactions were carried out under an atmosphere of argon using oven dried glassware and standard 
techniques for handling air sensitive chemicals, unless the reaction contained aqueous reagents or 
unless otherwise stated.  
 
Reagents were purified using standard laboratory procedures. Benzene, toluene, dichloromethane, 
and acetonitrile were distilled from CaH2 and stored under an atmosphere of argon. Tetrahydrofuran 
and diethyl ether were distilled from potassium or sodium wire/benzophenone and stored under 
argon. Methanol was distilled from magnesium methoxide and stored under argon. 2,6-lutidine, 
triethylamine and HMPA were distilled from CaH2 and stored over CaH2 under an atmosphere of 
argon. DMF and DMSO were distilled from and stored over 4Å molecular sieves. Propionaldehyde 
was distilled from CaCl2 and used immediately. TiCl4 was distilled under argon and reduced pressure. 
DDQ was recrystallised from CHCl3. Proton Sponge® was recrystallised from ethanol. All other 
chemicals were used as received from the manufacturer unless otherwise stated. 
 
Aqueous solutions of ammonium chloride (NH4Cl), sodium bicarbonate (NaHCO3), sodium 
thiosulfate (Na2S2O3), brine (NaCl) and sodium/potassium (Na/K) tartrate were saturated. Buffer 
solutions were prepared as directed from stock tablets. 
 
Purification by flash column chromatography was carried out using Kieselgel 60 (230-400 mesh), 
Merck aluminium oxide 90 or Sigma-Aldrich Florisil® (<200 mesh) under a positive pressure. 
Preparative thin layer chromatography used Merck Kieselgel 60 F254 plates. 
 
TLC was carried out using Merck Kieselgel 60 F254 plates which were visualised using UV light (254 
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nm) and stained using potassium permanganate or phosphomolybdic acid/cerium(III) sulfate dips. 
Petroleum ether, boiling point 40-60 °C is abbreviated to PE. 
 
NMR spectra were recorded using the following machines: Bruker Avance TXO cryoprobe (700 
MHz), Avance DCH cryoprobe (500 MHz), Avance 500 BB (500 MHz), Avance TCI cryoprobe (500 
MHz) and Avance 400 DRX (400 MHz). 1H NMR spectra were recorded at 298 K using an internal 
deuterium lock for CDCl3 (δH = 7.26) or MeOD (δH = 3.31 ppm). 1H NMR data are presented as: 
chemical shift δ (in ppm, relative to TMS (δTMS = 0), integration, multiplicity (s = singlet, d = doublet, 
t = triplet, q = quartet, qn = quintet, m = multiplet, br = broad, app = apparent), coupling constants (J 
in Hz) and interpretation. Substituents are denoted by the backbone carbon they are attached to. 
Assignments have been made based on the 1D data presented along with a range of 2D spectra, and 
comparison with fully assigned spectra for similar compounds. Data is regarded in agreement with 
literature values or that reported by other people if the difference of δ is within 0.01 ppm and the 
difference of J is within 0.5 Hz. 13C NMR spectra were recorded at 298 K with proton decoupling 
and an internal deuterium lock for CDCl3 (δC = 77.0 ppm) or MeOD (δC = 49.0 ppm). Data are listed 
by chemical shift (δ/ppm) relative to TMS (δTMS = 0). Multiplicity and coupling constants are listed 
where coupling to a heteroatom is observed. 
 
Fourier transform IR spectroscopy (FT-IR) was carried out using a Perkin-Elmer Spectrum-One 
spectrometer, and spectra were recorded as a thin film. Wavelengths of maximum absorption ((max) 
are reported in wavenumbers (cm-1).  
 
Optical rotations were measured using a Perkin-Elmer 241 polarimeter at the sodium D line (589 nm) 
and are reported as [α]D20, concentration (c in g/100 mL) and solvent. 
 
High resolution mass spectroscopy (HRMS) was carried out by the EPSRC National Mass 
Spectrometry facility (Swansea, UK). The parent ion [M+NH4]+, [M+Na]+ or [M+H]+ is quoted. 
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5.2 Preparation of Reagents 
 
Samarium (II) diiodide (0.1 M in THF) 
 
To samarium metal (643 mg, 4.28 mmol) and 1,2-diiodoethane (603 mg, 2.14 mmol) under argon 
was added THF (20 mL). The mixture was sonicated for 30 min and the resulting dark blue solution 
(approx. 0.1 M) was used immediately. 
 
3,4-dimethoxybenzyl 2,2,2-trichloroacetimidate (DMBTCA) 
 
 
 
To a solution of potassium hydroxide (50% aqueous, 75 mL) and tetrabutylammonium hydrogen 
sulphate (211 mg, 0.620 mmol) in CH2Cl2 (75 mL) at –10 ˚C was added 3,4-dimethoxybenzyl 
alcohol (9.00 mL, 61.9 mmol) and trichloroacetonitrile (7.14 mL, 71.2 mmol) dropwise. The 
resulting solution was stirred for 3 h before being extracted with Et2O (3 × 40 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography over alumina (EtOAc/PE 1:9) yielded the acetimidate (16.1 g, 51.5 mmol, 83%) as a 
colourless oil. 
 
1H NMR (500 MHz, CDCl3) δH 8.35 (1H, s, NH), 6.99-6.95 (2H, m, ArH), 6.86-6.84 (1H, m, ArH), 
5.26 (2H, s, OCH2Ar), 3.86 (6H, s, ArOMe). 
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5.3 Detailed experimental procedures 
 
a. North-western fragment  
 
(S)-methyl 3-(3,4-dimethoxybenzyloxy)-2-methylpropanoate (127) 
 
 
 
PPTS (2.35 g, 9.40 mmol) was added to a solution of DMBTCA (30.6 g, 97.6 mmol) and 
methyl-(S)-3-hydroxy-2-methylpropanoate (126) (9.72 mL, 87.1 mmol) in CH2Cl2 (200 mL) and the 
mixture was stirred at rt for 2 h. The reaction mixture was quenched with saturated NaHCO3 solution 
(70 mL) and the phases were separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 mL) 
and the combined organic extracts were dried (MgSO4) and concentrated in vacuo. The residue was 
triturated with cold hexanes (ca. 1 L), filtered through a plug of Celite® and concentrated in vacuo. 
The residue was purified by flash column chromatography (EtOAc/PE 1:9) to give the ester 127 
(21.2 g, 79.3 mmol, 91%) as a colourless oil.  
 
Rf 0.45 (EtOAc/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 6.87-6.81 (3H, m, ArH), 4.46 (2H, s, 
OCH2Ar), 3.89 (3H, s, ArOMe), 3.87 (3H, s, ArOMe), 3.68 (3H, s, OMe), 3.63 (1H, dd, J = 9.2, 7.4 
Hz, H18a), 3.45 (1H, dd, J = 9.2, 5.9 Hz, H18b), 2.80-2.73 (1H, m, H19), 1.16 (3H, d, J = 7.1 Hz, Me19). 
Data in agreement with literature values.58 
 
 (S)-3-(3,4-dimethoxybenzyloxy)-N-methoxy-N,2-dimethylpropanamide (128) 
 
 
 
N,O-Dimethylhydroxylamine hydrochloride (5.34 g, 82.5 mmol) was dried by stirring in vacuo for 4 
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h. A solution of ester 127 (14.8 g, 55.0 mmol) in THF (100 mL) was added and the reaction mixture 
was cooled to -20 °C. Isopropylmagnesium chloride (181 mL, 0.913 M in Et2O, 164 mmol) was 
added dropwise. After stirring for 2 h, the reaction mixture was quenched with NH4Cl solution (100 
mL) and the phases were separated. The aqueous phase was extracted with Et2O (2 × 100 mL) and 
the combined organic phases were dried (MgSO4) and concentrated in vacuo. The crude product was 
purified by flash column chromatography (EtOAc/PE 1:4) to yield the amide 128 (16.2 g, 60.9 mmol, 
95%) as a colourless oil.     
 
Rf 0.19 (EtOAc/PE 1:1); 1H NMR (400 MHz, CDCl3) δH 6.88-6.81 (3H, m, ArH), 4.45 (2H, ABq, J 
= 12.0 Hz, OCH2Ar), 3.87 (3H, s, ArOMe), 3.86 (3H, s, ArOMe), 3.70-3.66 (1H, m, H18a), 3.68 (3H, 
s, NOMe), 3.40 (1H, dd, J= 8.7, 5.8 Hz, H18b), 3.30-3.23 (1H, m, H19), 3.20 (3H, s, NMe), 1.11 (3H, 
d, J = 7.1 Hz, Me19). Data in agreement with literature values.57  
 
 (S)-4-(3,4-dimethoxybenzyloxy)-3-methylbutan-2-one (124) 
 
 
 
Methylmagnesium bromide (60.8 mL, 3.0 M in Et2O, 182 mmol) was added dropwise to a solution 
of Weinreb amide 128 (16.2 g, 60.8 mmol) in THF (300 mL) at 0 oC. The reaction mixture was 
stirred for 2.5 h, quenched with NH4Cl solution (150 mL) and warmed to rt.  The layers were 
separated and the aqueous phase was extracted with Et2O (3 × 100 mL). The combined organic 
layers were dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash 
column chromatography (EtOAc/PE 1:4) to yield methyl ketone 124 (11.6 g, 52.9 mmol, 87%) as a 
colourless oil.  
 
Rf 0.38 (EtOAc/PE 3:7); 1H NMR (400 MHz, CDCl3) δH 6.86-6.80 (3H, m, ArH), 4.43 (2H, ABq, J 
= 12.0 Hz, OCH2Ar), 3.88 (3H, s, ArOMe), 3.87 (3H, s, ArOMe), 3.60 (1H, dd, J = 9.2, 7.6 Hz, H18a), 
3.46 (1H, dd, J = 9.2, 5.5 Hz, H18b), 2.90-2.81 (1H, m, H19), 2.18 (3H, s, H21), 1.09 (3H, d, J = 7.1 Hz, 
Me19). Data in agreement with that reported by Findlay.94  
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Potassium (1E,3E)-5-oxopenta-1,3-dien-1-olate (132) 
 
 
 
Pyridinium-1-sulfonate 130 (100 g, 628 mmol) was added portionwise to a stirred solution of 
potassium hydroxide (146 g, 2.60 mol) in H2O at -20 °C. The resulting solution was stirred for 1 h, 
warmed to rt over 4 h and heated at 40 °C for 30 min. After cooling to -20 °C, the precipitate was 
filtered through a pad of Celite®, washed with cold acetone (2 × 100 mL) and air-dried overnight. 
Activated charcoal (5 g) was added to a solution of the residue in MeOH (1 L) and heated at reflux 
for 20 min before filtering immediately. The solution was concentrated in vacuo to a volume of ca. 
50 mL. The precipitated product was filtered and washed with cold acetone (2 × 50 mL) to yield 
potassium glutaconaldehyde 132 (40.0 g, 294 mmol, 47%) as a yellow crystalline salt. 
 
1H NMR (500 MHz, DMSO) δH 8.65 (2H, d, J = 9.2 Hz, H22+H26), 7.04 (1H, t, J = 13.1 Hz, H24), 
5.09 (2H, dd, J = 13.1, 9.2 Hz, H23+H25). Data in agreement with literature values.47 
 
 (2E, 4E)-5-Bromo-2,4-pentadienal (125) 
 
 
 
A solution of N-bromosuccinimide (14.4 g, 80.7 mmol) in CH2Cl2 (300 mL) was added via cannula 
to a stirred solution of triphenylphosphine (21.2 g, 80.7 mmol) in CH2Cl2 (200 mL) at 0 °C. The 
mixture was warmed to rt and stirred for 45 min before potassium glutaconaldehyde salt 132 (5.00 g, 
36.7 mmol) was added in one portion. After stirring for 40 h, the reaction mixture was quenched with 
pH 7 buffer solution (200 mL). The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 200 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. 
The resultant crude was triturated with cold 30-40 petroleum ether and filtered through a pad of 
Celite®. The resulting solution was concentrated in vacuo. The crude product was purified by flash 
column chromatography (Et2O/PE 30-40 1:19) to yield the product 125 (1.70 g, 11.0 mmol, 30%) as 
O—K+H
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a yellow crystalline solid.  
 
Rf 0.20 (EtOAc/PE 1:9); 1H NMR (500MHz, CDCl3) δH 9.58 (1H, d, J = 7.8 Hz, CHO), 7.04-6.92 
(3H, m, H24+H25+H26), 6.22-6.14 (1H, m, H23). Data in agreement with that reported by Findlay.94 
 
(2S,5R,6E,8E)-9-bromo-1-((3,4-dimethylbenzyl)oxy)-5-hydroxy-2-methylnona-6,8-dien-3-one 
(136) 
 
 
 
Et3N (3.00 mL, 21.5 mmol) was added to a 1 M solution of (–)-Ipc2BCl in Et2O (17.5 mL, 17.5 
mmol) at 0 °C. A solution of ketone 124 (3.20 g, 12.7 mmol) in Et2O (15 mL) was added and the 
reaction mixture was stirred for 30 min. The mixture was cooled to –78 °C and aldehyde 125 (1.40 g, 
8.50 mmol) in Et2O/CH2Cl2 (1:1, 10 mL) was added dropwise. The reaction mixture was stirred for 
30 min and warmed to –20 °C for 16 h. The reaction was quenched with pH 7 buffer solution (30 mL) 
at 0 °C and stirred for 1 h. The layers were separated and the aqueous phase was extracted with Et2O 
(3 × 30 mL). The combined organic extracts were washed with brine (50 mL) and stirred over silica 
(30 g) for 1 hour. The resulting slurry was filtered and the filtrate was concentrated in vacuo and 
purified by flash column chromatography (EtOAc/PE 1:4) to afford product 136 (3.05 g, 7.21 mmol, 
85%, >95:5 dr) as a yellow oil.  
 
Rf 0.20 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 6.81 (3H, s, ArH), 6.65 (1H, dd, J = 13.5, 
11.0 Hz, H25), 6.29 (1H, d, J = 13.5 Hz, H26), 6.16 (1H, dd, J = 15.3, 10.8 Hz, H24), 5.67 (1H, dd, J = 
15.4, 5.5 Hz, H23), 4.63-4.56 (1H, m, H22), 4.40 (2H, s, OCH2Ar), 3.87 (6H, s, ArOMe), 3.57 (1H, t, 
J = 8.5 Hz, H18a), 3.47 (1H, dd, J = 9.2, 5.0 Hz, H18b), 3.24 (1H, d, J = 3.8 Hz, OH), 2.91-2.83 (1H, 
m, H19), 2.72 (1H, dd, J = 17.5, 3.3 Hz, H21a), 2.64 (1H, dd, J = 17.4, 8.8 Hz, H21b), 1.05 (3H, d, J = 
7.2 Hz, Me19). Data in agreement with that reported by Li.38 
 
 
Br
ODMB
OH
O
26
18
  
 
89 
(1E,3E,5R,7R,8S)-1-bromo-9-((3,4-dimethylbenzyl)oxy)-7-hydroxy-8-methylnona-1,3-dien-5-yl 
propionate (142)  
 
 
 
A 0.1 M solution of samarium diiodide in THF (3.20 mL, 0.320 mmol) was added to a solution of 
propionaldehyde (1.45 mL, 20.1 mmol) in THF (20 mL) at –20 °C. To the resultant yellow mixture 
was added a solution of aldol product 136 (1.34 g, 3.24 mmol) in THF (50 mL). The reaction mixture 
was stirred for 3 h before being quenched with NaHCO3 solution (50 mL). The layers were separated 
and the aqueous phase was extracted with Et2O (3 × 50 mL). The combined organic extracts were 
dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash chromatography 
(EtOAc/PE 1:4) to afford alcohol 142 (1.45 g, 3.08 mmol, 95%, >95:5 dr) as a colourless oil. 
 
Rf 0.20 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 6.86-6.79 (3H, m, ArH), 6.64 (1H, dd, J = 
13.5, 10.9 Hz, H25), 6.32 (1H, d, J = 13.5 Hz, H26), 6.15 (1H, dd, J = 15.4, 10.9 Hz, H24), 5.68 (1H, 
dd, J = 15.3, 6.7 Hz, H23), 5.56-5.50 (1H, m, H22), 4.45-4.39 (2H, m, OCH2Ar), 3.87 (3H, s, ArOMe), 
3.86 (3H, s, ArOMe), 3.52 (1H, dd, J = 9.3, 4.8 Hz, H18a), 3.51-3.46 (1H, m, H20), 3.43 (1H, dd, J = 
9.3, 6.7 Hz, H18b), 3.37 (1H, d, J = 4.0 Hz, OH), 2.32 (2H, q, J = 7.6 Hz, CO2CH2CH3), 1.85-1.75 
(2H, m, H19+H21a), 1.60 (1H, ddd, J = 13.8. 10.5, 3.0 Hz, H21b), 1.12 (3H, t, J = 7.6 Hz, CO2CH2CH3), 
0.90 (3H, d, J = 7.0 Hz, Me19). Data in agreement with that reported by Li.38 
 
(1E,3E,5R,7R,8S)-1-bromo-9-((3,4-dimethylbenzyl)oxy)-7-methoxy-8-methylnona-1,3-dien-5-yl 
propionate (143) 
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Proton Sponge® (7.60 g, 35.5 mmol) and trimethyloxonium tetrafluoroborate (7.02 g, 47.3 mmol) 
were added to a solution of alcohol 142 (1.41 g, 2.97 mmol) in CH2Cl2 (30 mL) at 0 °C. The reaction 
mixture was stirred for 2 h, quenched with NaHCO3 solution (50 mL) and filtered through a pad of 
Celite®. The layers were separated and the aqueous phase was extracted with CH2Cl2 (2 × 50 mL). 
The combined organic extracts were washed with aqueous citric acid solution (100 mL, 1.0 M), dried 
(MgSO4) and concentrated in vacuo. After purification by flash chromatography (EtOAc/PE 1:4), 
alcohol 143 was recovered and resubmitted to the reaction conditions. Methyl ether 107 (1.15 g, 2.38 
mmol, 80%) was obtained as a colourless oil. 
 
Rf 0.41 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 6.88-6.81 (3H, m, ArH), 6.65 (1H, dd, J = 
13.6, 10.9 Hz, H25), 6.32 (1H, d, J = 13.5 Hz, H26), 6.14 (1H, dd, J = 15.4, 11.0 Hz, H24), 5.65 (1H, 
dd, J = 15.3, 6.9 Hz, H23), 5.48-5.43 (1H, m, H22), 4.43 (2H, s, OCH2Ar), 3.88 (3H, s, ArOMe), 3.87 
(3H, s, ArOMe), 3.33 (1H, d, J = 6.5 Hz, H18), 3.29 (3H, s, OMe), 3.29-3.25 (1H, m, H20) 2.31 (2H, q, 
J = 7.6 Hz, CO2CH2CH3), 2.18-2.11 (1H, m, H19), 1.70 (1H, ddd, J = 14.1, 9.9, 2.2 Hz, H21a), 1.59 
(1H, ddd, J = 14.1, 9.9, 3.1 Hz, H21b), 1.12 (3H, t, J = 7.5 Hz, CO2CH2CH3), 0.88 (3H, d, J = 7.0 Hz, 
Me19). Data in agreement with that reported by Li.38 
 
(1E,3E,5R,7R,8S)-1-bromo-9-((3,4-dimethylbenzyl)oxy)-7-methoxy-8-methylnona-1,3-dien-5-ol 
(144) 
 
 
 
K2CO3 (421 mg, 3.05 mmol) was added to a solution of ester 143 (740 mg, 1.53 mmol) in MeOH (20 
mL). The reaction mixture was stirred for 16 h and subsequently diluted with water (20 mL). The 
mixture was extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated in vacuo. The crude residue was purified by flash chromatography (EtOAc/PE 3:7) 
to yield alcohol 144 (644 mg, 1.50 mmol, 98%) as a colourless oil. 
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Rf 0.30 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δ 6.86-6.79 (3H, m, ArH), 6.68 (1H, dd, J = 
13.4, 10.9 Hz, H25), 6.27 (1H, d, J = 13.4 Hz, H26), 6.18 (1H, ddd, J = 15.2, 10.9, 1.5 Hz, H24), 5.72 
(1H, dd, J = 15.3, 5.2 Hz, H23), 4.40 (2H, s, OCH2Ar), 4.39-4.32 (1H, m, H22), 3.86 (3H, s, ArOMe), 
3.85 (3H, s, ArOMe), 3.57-3.51 (1H, m, H20), 3.36-3.32 (2H, m, H18), 3.32 (3H, s, OMe), 3.21 (1H, d, 
J = 5.2 Hz, OH), 2.24-2.15 (1H, m, H19), 1.68 (1H, ddd, J = 14.7, 8.9, 3.2 Hz, H21a), 1.55 (1H, ddd, J 
= 14.7, 8.0, 3.1 Hz, H21b), 0.87 (3H, d, J = 7.0 Hz, Me19). Data in agreement with that reported by 
Li.38 
 
(((1E,3E,5R,7R,8S)-1-bromo-9-((3,4-dimethylbenzyl)oxy)-7-methoxy-8-methylnona-1,3-dien-5-
yl)oxy)(tert-butyl)dimethylsilane (145) 
 
 
 
Imidazole (146 mg, 2.15 mmol) was added to a solution of alcohol 144 (836 mg, 1.95 mmol) in 
CH2Cl2 (40 mL) at 0 °C. After stirring for 10 min, TBSCl (324 mg, 2.15 mmol) was added. The 
reaction mixture was warmed to rt and stirred for 16 h and, when complete by TLC, was quenched 
with NaHCO3 solution (10 mL). The layers were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. 
The crude product was purified by flash chromatography (EtOAc/PE 1:4) to yield TBS ether 145 
(965 mg, 1.77 mmol, 91%) as a colourless oil.     
 
Rf 0.70 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 6.89-6.80 (3H, m, ArH), 6.66 (1H, dd, J = 
13.6, 11.0 Hz, H25), 6.25 (1H, d, J = 13.6 Hz, H26), 6.06 (1H, dd, J = 15.4, 11.0 Hz, H24), 5.69 (1H, 
dd, J = 15.3, 6.8 Hz, H23), 4.42 (2H, ABq, J = 11.8 Hz, OCH2Ar), 4.34-4.28 (1H, m, H22), 3.88 (3H, s, 
ArOMe), 3.87 (3H, s, ArOMe), 3.53-3.47 (1H, m, H20), 3.31 (3H, s, OMe), 3.31 (1H, dd, J = 9.5, 6.7 
Hz, H18a), 3.24 (1H, dd, J = 9.0, 6.7 Hz, H18b), 2.29-2.21 (1H, m, H19), 1.45-1.39 (2H, m, H21), 0.89 
(9H, s, SiC(CH3)3), 0.86 (3H, d, J = 6.9 Hz, Me19), 0.05 (3H, s, SiCH3), 0.01 (3H, s, SiCH3). Data in 
agreement with that reported by Li.38 
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(2S,3R,5R,6E,8E)-9-bromo-5-((tert-butyldimethylsilyl)oxy)-3-methoxy-2-methylnona-6,8-dien-1
-ol (146) 
 
 
 
A solution of DDQ (250 mg, 1.10 mmol) and pH 7 buffer solution (8 mL) in CH2Cl2 (10 mL) were 
added to a solution of DMB ether 145 (400 mg, 0.920 mmol) in CH2Cl2 (30 mL) at 0 °C. The 
reaction mixture was stirred for 3 h before being quenched with NaHCO3 solution (30 mL). The 
layers were separated and the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash 
chromatography (EtOAc/PE 1:9) to yield alcohol 146 (348 mg, 0.880 mmol, 95%) as a yellow oil. 
 
Rf 0.50 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 6.69 (1H, dd, J = 13.5, 11.0 Hz, H25), 6.29 
(1H, d, J = 13.5 Hz, H26), 6.09 (1H, dd, J = 15.2, 10.8 Hz, H24), 5.71 (1H, dd, J = 15.2, 7.0 Hz, H23), 
4.31 (1H, app q, J = 6.5 Hz, H22), 3.62 (1H, dd, J = 10.7, 5.0 Hz, H18a), 3.54 (1H, dd, J = 10.9, 6.4 
Hz, H18b), 3.47-3.42 (1H, m, H20), 3.38 (3H, s, OMe), 2.24 (1H, br s, OH), 2.00-1.95 (1H, m, H19), 
1.58 (2H, app t, J = 6.1 Hz, H21), 0.90 (3H, d, J = 7.0 Hz, Me19), 0.89 (9H, s, SiC(CH3)3), 0.08 (3H, s, 
SiCH3), 0.02 (3H, s, SiCH3). Data in agreement with that reported by Li.38 
 
(2R,3R,5R,6E,8E)-9-bromo-5-((tert-butyldimethylsilyl)oxy)-3-methoxy-2-methylnona-6,8-dienoi
c acid (123) 
 
 
 
TEMPO (128 mg, 0.820 mmol) and PhI(OAc)2 (708 mg, 2.20 mmol) were added to a solution of 
alcohol 146 (247 mg, 0.632 mmol) in MeCN/H2O (1:1, 10 mL). The reaction mixture was stirred for 
2 h and subsequently diluted with EtOAc/H2O (1:1, 20 mL). The layers were separated, and the 
aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organic extracts were dried 
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(Na2SO4) and concentrated in vacuo. The residue was purified by flash chromatography (EtOAc/PE 
1:4) to give acid 123 (231 mg, 0.570 mmol, 90%) as a yellow oil.  
 
Rf 0.30 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 6.67 (1H, dd, J = 13.4, 10.8 Hz, H25), 6.27 
(1H, d, J = 13.4 Hz, H26), 6.08 (1H, dd, J = 15.2, 10.8 Hz, H24), 5.69 (1H, dd, J = 15.2, 6.8 Hz, H23), 
4.34-4.27 (1H, m, H22), 3.80-3.74 (1H, m, H20), 3.37 (3H, s, OMe), 2.95-2.86 (1H, m, H19), 1.63-1.48 
(2H, m, H21), 1.09 (3H, d, J = 7.0 Hz, Me19), 0.89 (9H, s, SiC(CH3)3), 0.07 (3H, s, SiCH3), 0.01 (3H, 
s, SiCH3). Data in agreement with that reported by Li.38 
 
(S)-3-Tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (148) 
 
 
 
Thionyl chloride (8.32 mL, 114 mmol) was added dropwise to a solution of L-serine (2.00 g, 19.0 
mmol) in MeOH (40 mL) at −10 °C. The reaction mixture was warmed to rt, stirred for 20 h and then 
concentrated in vacuo. Et3N (6.64 mL, 47.6 mmol) and Boc2O (4.60 g, 21.1 mmol) were added to a 
solution of the crude residue in CH2Cl2 (40 mL) at 0 °C. The layers were separated upon complete 
consumption of the starting material by TLC. The aqueous phase was extracted with CH2Cl2 (3 × 5 
mL), and the combined organic extracts were washed with brine (20 mL), dried (MgSO4), and 
concentrated in vacuo. 2,2-dimethoxypropane (17.4 mL, 142 mmol) and BF3•OEt2 (0.240 mL, 1.90 
mmol) were added to a solution of the crude material in acetone (24 mL) at rt. The reaction mixture 
was stirred for 2.5 h and subsequently Et3N (0.240 mL, 1.72 mmol) was added. The mixture was 
concentrated in vacuo and partitioned between Et2O (10 mL) and NaHCO3 solution (10 mL). The 
aqueous phase was extracted with Et2O (3 × 5 mL). The combined organic extracts were washed 
with brine (20 mL), dried (MgSO4), and concentrated in vacuo to provide methyl ester 148 (4.90 g, 
18.9 mmol, 99%) as a colourless oil as a 1.5:1 mixture of rotamers. 
 
Rf 0.35 (EtOAc/PE 3:7); 1H NMR (400 MHz, CDCl3) δH 4.44 (1H, dd, J = 6.8, 2.5 Hz, H16), 4.34 
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(1H, dd, J = 7.0, 3.0 Hz, H16), 4.14-4.06 (2H, m, H17), 4.03-3.96 (2H, m, H17), 3.73 (3H, s, OMe), 
3.71 (3H, s, OMe), 1.66-1.64 (6H, m, CMe2), 1.54-1.52 (6H, m, CMe2), 1.49 (9H, br s, tBu), 1.41 
(9H, br s, tBu). Data in agreement with literature values.60 
 Minor rotamer 
 
(R)-Tert-butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (150) 
 
 
 
A solution of methyl ester 148 (2.00 g, 7.72 mmol) in THF (8 mL) was added dropwise to a stirred 
solution of LiBH4 (336 mg, 15.4 mmol) in EtOH (10 mL) at −20 °C. The reaction mixture was 
warmed to rt and stirred for 16 h before being quenched with NH4Cl solution (2 mL). The layers 
were separated and the aqueous phase was extracted with EtOAc (3 × 2 mL). The combined organic 
extracts were washed with brine, dried (MgSO4), and concentrated in vacuo. The residue was 
purified by flash chromatography (EtOAc/PE 3:7) to yield primary alcohol 150 (1.07 g, 4.63 mmol, 
60%) as a colourless oil.  
 
Rf 0.50 (Et2O/PE 3:7); 1H NMR (400 MHz, CDCl3) δ 4.92-4.83 (1H, m, OH), 3.93-3.83 (2H, m, 
H17), 3.81-3.68 (1H, m, H16), 3.54-3.47 (1H, m, H15a), 3.21-3.13 (1H, m, H15b), 1.45 (3H, s, CMe2), 
1.41 (9H, s, tBu), 1.39 (3H, s, CMe2). Data in agreement with literature values.60  
 
 (R,E)-tert-butyl 4-(2-iodovinyl)-2,2-dimethyloxazolidine-3-carboxylate (151) 
 
 
 
A solution of oxalyl chloride (280 µL, 3.24 mmol) in CH2Cl2 (5 mL) was added to a solution of 
DMSO (460 µL, 6.48 mmol) in CH2Cl2 (3 mL) at −78 °C. After stirring for 15 min, alcohol 150 (500 
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mg, 2.16 mmol) in CH2Cl2 (5 mL) was added and the reaction mixture was stirred for a further 1 h at 
−78 °C. Et3N (1.80 mL, 13.0 mmol) was added and the reaction mixture was stirred at 0 °C for 30 
min. The reaction was quenched with NH4Cl solution (10 mL) and the layers were separated. The 
aqueous phase was extracted with CH2Cl2 (3 × 5 mL). The combined organic extracts were dried 
(MgSO4), concentrated in vacuo and the crude aldehyde was used immediately in the subsequent 
reaction. The crude aldehyde was dissolved in THF (15 mL) and added to a vigorously stirred 
solution of CrCl2 (4.29 g, 34.9 mmol) in THF (30 mL) at 0 °C. The mixture was stirred for 5 min 
before CHI3 (4.29 g, 10.9 mmol) was added. The reaction mixture was warmed to rt and stirred in the 
dark for 18 h. The reaction was diluted with H2O (30 mL) and the layers were separated. The 
aqueous phase was extracted with Et2O (3 × 20 mL). The organic extracts were washed with brine 
(20 mL), filtered through a pad of silica, dried (MgSO4) and concentrated in vacuo. The crude 
product was purified by flash chromatography (EtOAc/PE 1:9) to give vinyl iodide 151 (648 mg, 
1.84 mmol, 85%) as a yellow oil. 
 
Rf 0.40 (EtOAc/PE 1:9); 1H NMR (500 MHz, CDCl3, 323 K) δH 6.50 (1H, dd, J = 14.3, 7.6 Hz, H15), 
6.33 (1H, br d, J = 14.3 Hz, H14), 4.29 (1H, br s, H16), 3.99 (1H, dd, J = 9.0, 6.3 Hz, H17a), 3.76 (1H, 
dd, J = 9.0, 2.0 Hz, H17b), 1.59 (3H, s, CMe2), 1.50 (3H, s, CMe2), 1.46 (9H, s, tBu). Data in 
agreement with that reported by Kan.59 
 
 (R,E)-2-amino-4-iodobut-3-en-1-ol (122) 
 
 
 
Acetyl chloride (3.03 mL, 42.5 mmol) was added dropwise to MeOH (30 mL) at 0 °C. A solution of 
protected amino alcohol 151 (200 mg, 0.566 mmol) in MeOH (10 mL) was added dropwise to the 
solution. The reaction mixture was warmed to rt and stirred for 1 h. Removal of all volatiles in vacuo 
gave amino alcohol 122 (141 mg, 0.560 mmol, 99%) as a yellow hydrochloride salt. 
 
1H NMR (500 MHz, MeOD) δH 6.91 (1H, d, J = 15.0 Hz, H14), 6.62 (1H, dd, J = 15.0, 8.1 Hz, H15), 
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3.89-3.80 (1H, m, H16), 3.73 (1H, dd, J = 11.6, 4.3 Hz, H17a), 3.61 (1H, dd, J = 11.6, 6.7 Hz, H17b). 
Data in agreement with that reported by Kan.59  
 
(2R,3R,5R,6E,8E)-9-bromo-5-((tert-butyldimethylsilyl)oxy)-N-((R,E)-1-hydroxy-4-iodobut-3-en-
2-yl)-3-methoxy-2-methylnona-6,8-dienamide (152) 
 
 
 
A solution of HOBt (33.1 mg, 0.245 mmol) in CH2Cl2 (3 mL), iPr2NEt (113 µL, 0.615 mmol) and 
EDC (26.0 µL, 0.148 mmol) were added successively to a solution of acid 123 (50.0 mg, 0.123 
mmol) at 0 °C. The resulting mixture was stirred for 10 min, and amino alcohol 122 (61.1 mg, 0.245 
mmol) was added. The reaction mixture was warmed to rt and stirred for 1h. The reaction was 
quenched with water (2 mL) and the layers were separated. The aqueous phase was extracted with 
CH2Cl2 (3 × 2 mL). The combined organic extracts were washed with NaHCO3 solution (5 mL) and 
brine (5 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash column 
chromatography (EtOAc/PE 4:6) to yield amide 152 (66.8 mg, 0.111 mmol, 90%) as a white solid. 
 
Rf 0.20 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 6.67 (1H, dd, J = 13.5, 11.0 Hz, H25), 6.56 
(1H, dd, J = 14.7, 6.2 Hz, H15), 6.41 (1H, d, J = 14.7 Hz, H14), 6.40 (1H, d, J = 8.2 Hz, NH), 6.30 
(1H, d, J = 13.5 Hz, H26), 6.08 (1H, dd, J = 15.2, 11.0 Hz, H24), 5.67 (1H, dd, J = 15.2, 7.0 Hz, H23), 
4.55-4.49 (1H, m, H16), 4.32-4.26 (1H, m, H22), 3.71-3.63 (2H, m, H17), 3.48-3.43 (1H, m, H20), 3.40 
(3H, s, OMe), 2.47 (1H, dt, J = 6.9, 6.6 Hz, H19), 1.69-1.55 (2H, m, H21), 1.16 (3H, d, J = 7.0 Hz, 
Me19), 0.89 (9H, s, SiC(CH3)3), 0.06 (3H, s, SiCH3), 0.02 (3H, s, SiCH3). Data in agreement with that 
reported by Li.38 
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(R)-2-((2R,3R,5R,6E,8E)-9-bromo-5-((tert-butyldimethylsilyl)oxy)-3-methoxynona-6,8-dien-2-yl
)-4-((E)-2-iodovinyl)-4,5-dihydrooxazole (81) 
 
 
 
DAST (109 µL, 0.831 mmol) was added dropwise to a solution of amide 152 (50.0 mg, 83.1 µmol) 
in CH2Cl2 (1 mL) at −78 °C. After stirring for 20 min, the reaction mixture was quenched with 
K2CO3 (171 mg, 1.24 mmol), warmed to rt and diluted with NaHCO3 solution (2 mL). The phases 
were separated and the aqueous phase was extracted with CH2Cl2 (3 × 2 mL). The combined organic 
extracts were washed with brine (2 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
residue was purified by flash column chromatography (EtOAc/PE 1:4) to afford oxazoline 81 (48.2 
mg, 82.3 µmol, 99%) as a pale yellow oil. 
 
Rf 0.70 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 6.66 (1H, dd, J = 13.5, 11.0 Hz, H25), 6.50 
(1H, dd, J = 14.5, 6.6 Hz, H15), 6.41 (1H, d, J = 14.5 Hz, H14), 6.27 (1H, d, J = 13.5 Hz, H26), 6.07 
(1H, dd, J = 15.4, 11.0 Hz, H24), 5.69 (1H, dd, J = 15.4, 6.8 Hz, H23), 4.60 (1H, dt, J = 8.3, 6.5 Hz, 
H16), 4.34-4.26 (2H, m, H17a+H22), 3.97 (1H, app t, J = 8.0 Hz, H17b), 3.74-3.68 (1H, m, H20), 3.36 
(3H, s, OMe), 3.00-2.93 (1H, m, H19), 1.55-1.43 (2H, m, H21), 1.12 (3H, d, J = 7.1 Hz, Me19), 0.89 
(9H, s, SiC(CH3)3), 0.06 (3H, s, SiCH3), 0.00 (3H, s, SiCH3). Data in agreement with that reported by 
Li.38 
 
b. North-eastern fragment  
 
Benzyl 2-(diphenoxyphosphoryl)acetate (195)  
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To a solution of diphenylmethylphosphonate (4.10 mL, 20.0 mmol) and benzyl chloroformate (2.55 
mL, 17.9 mmol) in THF (10 mL) at −78 °C was added LiHMDS (1 M in THF, 35.0 mL, 35.0 mmol) 
dropwise. The reaction mixture was stirred at −20 °C for 16 h before being quenched with NH4Cl (20 
mL) and extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (Et2O/PE 1:4) yielded ester 195 
(6.85 g, 17.9 mmol, 99%) as a colourless oil.  
 
Rf 0.22 (EtOAc/PE 3:7); 1H NMR (400 MHz, CDCl3) δH 7.39-7.28 (10H, m, OPh), 7.21-7.14 (5H, 
m, OCH2Ph), 5.22 (2H, s, OCH2Ph), 3.31 (2H, d, J = 21.6 Hz, PCH2). Data in agreement with 
literature values.95 
 
2-(diphenoxyphosphoryl)acetic acid (42)  
 
 
 
To a solution of phosphonate 195 (6.85 g, 17.9 mmol) in EtOAc (50 mL) was added Pd/C (5%, 623 
mg). The reaction was stirred under H2 for 16 h before being filtered through Celite® and 
concentrated in vacuo to yield acid 42 (4.71 g, 16.1 mmol, 90%) as a white solid.  
 
Rf 0.05 (EtOAc/PE 3:7); 1H NMR (400 MHz, CDCl3) δH 7.34-7.28 (4H, m, OPh), 7.23-7.15 (6H, m, 
OCH2Ph), 3.28 (2H, d, J = 21.6 Hz, PCH2). Data in agreement with literature values.95 
 
Benzyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (197)  
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To a solution of bis(2,2,2-trifluoroethyl) methylphosphonate (3.61 mL, 20.0 mmol) and benzyl 
chloroformate (2.70 mL, 17.9 mmol) in THF (10 mL) at −78 °C was added LiHMDS (1 M in THF, 
35.0 mL, 35.0 mmol) dropwise. The reaction mixture was stirred at −20 °C for 16 h before being 
quenched with NH4Cl (20 mL) and extracted with CH2Cl2 (3 × 20 mL). The combined organic 
extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography 
(Et2O/PE 1:4) yielded ester 197 (5.34 g, 13.5 mmol, 75%) as a colourless oil.  
 
Rf 0.18 (EtOAc/PE 3:7); 1H NMR (400 MHz, CDCl3) δH 7.33-7.28 (5H, OCH2Ph), 5.13 (2H, s, 
OCH2Ph), 4.39-4.20 (4H, m, OCH2CF3), 3.14 (2H, d, J = 21.4 Hz, PCH2). Data in agreement with 
literature values.95 
 
2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetic acid (188)  
 
 
 
To a solution of phosphonate 197 (5.34 g, 13.5 mmol) in EtOAc (50 mL) was added Pd/C (5%, 931 
mg). The reaction was stirred under H2 for 16 h before being filtered through Celite® and 
concentrated in vacuo to yield acid 188 (3.28 g, 10.8 mmol, 80%) as a white solid.  
 
Rf 0.04 (EtOAc/PE 3:7); 1H NMR (400 MHz, CDCl3) δH 4.55-4.35 (4H, m, OCH2CF3), 3.18 (2H, d, 
J = 21.4 Hz, PCH2). Data in agreement with literature values.95 
 
Bis(2-(tert-butyl)phenyl) methyl phosphite (200)  
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To a solution of 2-tert-butylphenol (1.00 mL, 6.50 mmol) in toluene (20 mL) at 0 °C was added 
trimethylamine (0.950 mL, 6.87 mmol) and a solution of methyl dichlorophosphite (0.320 mL, 3.33 
mmol) in Et2O (3 mL). The reaction mixture was stirred at rt for 3 h, before being filtered through a 
pad of alumina. The filtrate was concentrated in vacuo to yield phosphite 200 (1.15 g, 3.18 mmol, 
98%) as a colourless oil.  
 
1H NMR (400 MHz, CDCl3) δH 7.39-7.35 (2H, m, ArH), 7.23-7.19 (2H, m, ArH), 7.16-7.10 (2H, m, 
ArH), 7.06-7.00 (2H, m, ArH), 3.79 (3H, d, J = 8.4 Hz, OMe), 1.43 (18H, s, tBu).  
 
Benzyl 2-(bis(2-(tert-butyl)phenoxy)phosphoryl)acetate (204)  
 
 
 
To phosphite 200 (1.00 g, 2.78 mmol) was added benzyl bromoacetate (0.660 mL, 4.16 mmol). The 
reaction mixture was stirred at 130 °C for 16 h. The excess of benzyl bromoacetate was removed 
under reduced pressure to yield acetate 204 (1.13 g, 2.28 mmol, 82%) as a colourless oil.  
 
1H NMR (400 MHz, CDCl3) δH 7.68-7.65 (2H, m, ArH), 7.39-7.28 (5H, m, ArH), 7.24-7.21 (2H, m, 
ArH), 7.14-7.06 (4H, m, ArH), 5.08 (2H, s, OCH2Ph), 3.40 (3H, d, J = 21.8 Hz, PCH2), 1.34 (18H, s, 
tBu).  
 
2-(bis(2-(tert-butyl)phenoxy)phosphoryl)acetic acid (189)  
 
 
 
To a solution of phosphonate 204 (1.13 g, 1.14 mmol) in EtOAc (20 mL) was added Pd/C (5%, 157 
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mg). The reaction was stirred under H2 for 16 h before being filtered through Celite® and 
concentrated in vacuo to yield acid 189 (461 mg, 1.14 mmol, 99%) as a white solid. 
 
1H NMR (400 MHz, CDCl3) δH 7.65-7.61 (2H, m, ArH), 7.39-7.35 (2H, m, ArH), 7.17-7.08 (4H, m, 
ArH), 3.36 (3H, d, J = 21.7 Hz, PCH2), 1.36 (18H, s, tBu).  
 
(2Z,4E)-5-(tributylstannyl)penta-2,4-dienoic acid (96) 
 
 
 
To dienoate 92 (100 mg, 0.25 mmol) in THF (45 mL) was added LiOH (1M in H2O, 25 mL) and 
H2O (15 mL). The reaction mixture was stirred for 48 h before being acidified with NaHSO4, 
extracted with EtOAc (3 × 30 mL), dried (Na2SO4) and concentrated in vacuo to yield acid 96 (92.3 
mg, 0.239 mmol, 96%) as a yellow oil. 
 
Rf 0.41 (EtOAc/PE 1:2); 1H NMR (500 MHz, CDCl3) δH 7.82 (1H, app dd, J = 18.8, 10.7 Hz, H4), 
6.83 (1H, app d, J = 18.8 Hz, H5), 6.60 (1H, app t, J = 11.1 Hz, H3), 5.61 (1H, br d, J = 11.2 Hz, H2), 
1.57-1.48 (6H, m, SnBu3), 1.37-1.26 (6H, m, SnBu3), 1.00-0.87 (15H, m, SnBu3). Data in agreement 
with that reported by Kan.59 
 
(E)-3-(tributylstannyl)acrylaldehyde (106) 
 
 
 
To a slurry of CuCN (2.1 g, 23.6 mmol) in THF at −78 °C was added nBuLi (1.6 M in hexanes, 29.6 
mL, 47.3 mmol) dropwise. The reaction mixture was stirred at −40 °C until a clear, yellow solution 
was obtained. Bu3SnH (12.7 mL, 47.3 mmol) was then added dropwise at −78 °C. The mixture was 
stirred at −40 °C for 15 min, to which 3,3-diethoxy-1-propyne (2.8 mL, 19.7 mmol) was added at 
−78 °C. After stirring for 2 h, MeOH (3 mL) was added to give a deep red solution, which was 
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stirred for 30 min before being quenched with NH4Cl (100 mL) at 0 °C. The mixture was filtered and 
extracted with Et2O (3 × 50 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. The crude was redissolved in acetone (75 mL) and water (8 mL), to which 
p-toluenesulfonic acid (187 mg, 0.985 mmol) was added, and the solution was stirred at 60 °C for 36 
h. The acetone was evaporated and the residue was dissolved in Et2O (100 mL) and the layers were 
separated. The organic layer was washed with NaHCO3 (50 mL), dried (MgSO4) and concentrated in 
vacuo. Purification by flash chromatography (Et2O/PE/Et3N 1:19:0.2) afforded aldehyde 106 (5.11 g, 
14.8 mmol, 75%, E:Z > 95:5) as a yellow oil. 
 
Rf 0.42 (Et2O/PE 1:20); 1H NMR (500 MHz, CDCl3) δH 9.41 (1H, d, J = 7.6 Hz, CHO), 7.79 (1H, 
app d, J = 19.2 Hz, H5), 6.62 (1H, app dd, J = 19.2, 7.6 Hz, H4), 1.55-1.47 (6H, m, SnBu3), 1.35-1.27 
(6H, m, SnBu3), 1.04-0.98 (6H, m, SnBu3), 0.93-0.86 (9H, m, SnBu3). Data in agreement with 
literature values.96 
 
Methyl (R)-3-hydroxybutanoate (159) 
 
 
 
To [RuCl2(C6H5)]2 (86.8 mg, 0.172 mmol) and (R)-BINAP (227 mg, 0.364 mmol) in a Schlenk tube 
was added dry DMF (6.0 mL). The reaction mixture was stirred at 100 °C for 10 min, before being 
cooled and concentrated (50 °C, 1 mm/Hg). The mixture was further concentrated (50 °C, 0.1 
mm/Hg) for 1 h to afford Ru-BINAP as a reddish brown solid. Methylacetoacetate (20.0 mL, 185 
mmol) was lyophilised three times before dry methanol (40.0 mL) was added. The mixture was 
lyophilised 3 more times before Ru-BINAP was added. The mixture was lyophilised twice before 
being transferred to an autoclave and placed under 6 bar H2 and left for 48 h. The reaction mixture 
was then concentrated in vacuo and distilled (76-78 °C, 15 mm/Hg) to yield alcohol 159 (17.5 g, 148 
mmol, 80%, >99% ee) as a colourless oil. 
 
1H NMR (500 MHz, CDCl3) δH 4.24-4.17 (1H, m, H34), 3.72 (3H, s, OMe), 2.85 (1H, br s, OH), 
MeO
O OH
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2.51 (1H, dd, J = 16.4, 3.6 Hz, H33a), 2.44 (1H, dd, J = 16.7, 8.6 Hz, H33b), 1.24 (3H, d, J = 6.4 Hz, 
H35). Data in agreement with literature values.66 
 
Methyl (R)-3-((tert-butyldimethylsilyl)oxy)butanoate (162) 
 
 
 
To a solution of alcohol 159 (10.0 g, 84.6 mmol) in CH2Cl2 (250 mL) was added imidazole (17.3 g, 
254 mmol) and TBSCl (25.5 g, 169 mmol). The reaction mixture was stirred at rt for 16 h before 
being quenched with NaHCO3 (100 mL) and extracted with CH2Cl2 (3 × 100 mL). The combined 
organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:9) yielded ester 162 (15.7 g, 67.7 mmol, 80%) as a colourless oil. 
 
Rf 0.60 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 4.32-4.23 (1H, m, H34), 3.66 (3H, s, OMe), 
2.48 (1H, dd, J = 14.5, 7.7 Hz, H33a), 2.37 (1H, dd, J = 14.5, 5.3 Hz, H33b), 1.19 (3H, d, J = 6.1 Hz, 
H35), 0.86 (9H, s, SiC(CH3)3), 0.06 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). Data in agreement with 
literature values.97 
 
(R)-3-((tert-butyldimethylsilyl)oxy)butanal (157) 
 
 
 
To a solution of ester 162 (15.2 g, 65.4 mmol) in CH2Cl2 (200 mL) at −78 °C was added DIBAL-H 
(1M in hexane, 71.9 mL, 71.9 mmol) dropwise. The reaction mixture was stirred for 3 h, before 
being quenched with Na+/K+ tartrate (200 mL) at 0 °C. The mixture was stirred for 2 h before being 
extracted with CH2Cl2 (3 × 100 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (Et2O/PE 1:9) yielded ester 157 (12.6 g, 
62.1 mmol, 95%) as a colourless oil. 
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Rf 0.12 (Et2O/PE 1:19); 1H NMR (500 MHz, CDCl3) δH 9.80 (1H, t, J = 2.4 Hz, H32), 4.39-4.32 (1H, 
m, H34), 2.55 (1H, ddd, J = 15.6, 7.0, 2.9 Hz, H33a), 2.46 (1H, dd, J = 15.7, 5.0, 2.0 Hz, H33b), 1.24 
(3H, d, J = 6.2 Hz, H35), 0.87 (9H, s, SiC(CH3)3), 0.08 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). Data in 
agreement with literature values.97  
 
(2S,4S,5S,7R)-7-((tert-butyldimethylsilyl)oxy)-5-hydroxy-1-((4-methoxybenzyl)oxy)-2,4-dimethy
loctan-3-one (165) 
 
 
 
To a solution of dicyclohexylboron chloride (8.41 mL, 38.4 mmol) in Et2O (100 mL) at 0 °C was 
added Et3N (6.24 mL, 44.8 mmol), followed by a solution of ketone 156 (7.56 g, 32.0 mmol) in Et2O 
(100 mL). The reaction mixture was stirred at 0 °C for 1 h, before aldehyde 157 (9.71 g, 48.0 mmol) 
in Et2O was added at –78 °C. The reaction mixture was stirred at –78 °C for 1 h, then –20 °C for 16 h, 
before being quenched at 0 °C with MeOH (130 mL), pH 7 buffer (130 mL), and H2O2 (100 mL). 
The solution was stirred for 1 h, poured into H2O (200 mL) and extracted with Et2O (3 × 100 mL). 
The combined organic extracts were washed with NaHCO3 (200 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 1:9) yielded aldol adduct 
165 (13.8 g, 31.4 mmol, 98%, >95:5 dr) as a colourless oil. 
 
Rf 0.45 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 7.20 (2H, d, J = 8.6 Hz, ArH), 6.86 (2H, d, 
J = 8.6 Hz, ArH), 4.40 (2H, ABq, J = 11.7, OCH2Ar), 4.16-4.09 (1H, m, H32), 4.04-3.98 (1H, m, H34), 
3.79 (3H, s, ArOMe), 3.64 (1H, app t, J = 8.7 Hz, H28a), 3.49 (1H, d, J = 4.4 Hz, OH), 3.41 (1H, dd, 
J = 8.8, 4.9 Hz, H28b), 3.11-3.04 (1H, m, H29), 2.69 (1H, app qn, J = 7.2 Hz, H31), 1.54 (1H, ddd, J = 
14.1, 7.2, 2.2 Hz, H33a), 1.47 (1H, ddd, J = 14.1, 10.1, 3.1 Hz, H33b), 1.17 (3H, d, J = 6.3 Hz, H35), 
1.06 (3H, d, J = 7.2 Hz, Me31), 1.04 (3H, d, J = 7.0 Hz, Me29), 0.89 (9H, s, SiC(CH3)3), 0.07 (3H, s, 
SiCH3), 0.06 (3H, s, SiCH3). Data in agreement with that reported by Gibson.34  
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(2R,4S,5R,6S,7S)-2-((tert-butyldimethylsilyl)oxy)-6-hydroxy-8-((4-methoxybenzyl)oxy)-5,7-dim
ethyloctan-4-yl propionate (166) 
 
 
 
To a solution of propionaldehyde (9.0 mL, 126 mmol) in THF (100 mL) at –20 °C was added 
samarium diiodide (20.5 mL, 0.1 M in THF, 2.05 mmol), followed by a solution of aldol adduct 165 
(9.0 g, 20.5 mmol) in THF (200 mL) dropwise. The reaction mixture was warmed to –10 °C over 2 h, 
before being quenched with NaHCO3 (200 mL) and extracted with Et2O (3 × 100 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:9) yielded alcohol 166 (9.63 g, 19.5 mmol, 95%, >95:5 dr) as a 
colourless oil. 
 
Rf 0.62 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 7.23 (2H, d, J = 8.6 Hz, ArH), 6.86 (2H, d, 
J = 8.6 Hz, ArH), 4.98 (1H, ddd, J = 9.9, 6.5, 1.8 Hz, H32), 4.43 (2H, s, OCH2Ar), 3.85-3.80 (1H, m, 
H34), 3.79 (3H, s, ArOMe), 3.66 (1H, dd, J = 9.0, 5.0 Hz, H28a), 3.55 (1H, dd, J = 9.0, 4.5 Hz, H28b), 
3.37-3.31 (1H, m, H30), 3.26 (1H, s, OH), 2.33 (2H, q, J = 7.6 Hz, CO2CH2CH3), 1.92-1.85 (1H, m, 
H29), 1.85-1.78 (1H, m, H31), 1.73 (1H, ddd, J = 14.5, 9.4, 1.9 Hz, H33a), 1.58 (1H, ddd, J = 14.5, 9.8, 
2.6 Hz, H33b), 1.14 (3H, d, J = 6.1 Hz, H35), 1.14 (3H, t, J = 7.6 Hz, CO2CH2CH3), 0.93 (3H, d, J = 
7.0 Hz, Me29), 0.91 (3H, d, J = 7.0 Hz, Me31), 0.87 (9H, s, SiC(CH3)3), 0.03 (3H, s, SiCH3), 0.00 (3H, 
s, SiCH3). Data in agreement with that reported by Gibson.34 
 
(2S,3S,4S,5S,7R)-7-((tert-butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-2,4-dimethyloctane-
3,5-diol (167) 
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To a solution of alcohol 166 (6.26 g, 12.6 mmol) in MeOH/H2O (10:1, 330 mL) was added K2CO3 
(10.5 g, 75.6 mmol). The reaction mixture was stirred for 16 h, before being quenched with H2O 
(200 mL) and extracted with CH2Cl2 (3 × 100 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 1:9) yielded 
diol 167 (5.50 g, 12.5 mmol, 99%) as a colourless oil. 
 
Rf 0.49 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 7.23 (2H, d, J = 8.6 Hz, ArH), 6.86 (2H, d, 
J = 8.6 Hz, ArH), 4.45 (2H, ABq, J = 11.4 Hz, OCH2Ar), 4.26-4.18 (1H, m, H34), 3.95 (1H, ddd, J = 
10.3, 5.4, 1.7, H32), 3.89-3.85 (1H, m, H30), 3.79 (3H, s, ArOMe), 3.57-3.50 (2H, m, H28), 2.00-1.90 
(1H, m, H29), 1.77 (1H, ddd, J = 14.0, 10.3, 3.6 Hz, H33a), 1.56-1.48 (2H, m, H31+H33b), 1.23 (3H, d, 
J = 6.3 Hz, H35), 0.96 (3H, d, J = 7.0 Hz, Me31), 0.89 (9H, s, SiC(CH3)3), 0.78 (3H, d, J = 6.9 Hz, 
Me29), 0.09 (3H, s, SiCH3), 0.08 (3H, s, SiCH3). Data in agreement with that reported by Gibson.34 
 
tert-butyl(((R)-1-((4S,5S,6S)-6-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,2,5-trimethyl-1,3-di
oxan-4-yl)propan-2-yl)oxy)dimethylsilane (262) 
 
 
 
To a solution of diol 167 (6.20 g, 14.1 mmol) in CH2Cl2 (200 mL) was added 2,2-dimethoxypropane 
(85.5 mL, 697 mmol) and pyridinium p-toluenesulfonate (360 mg, 1.41 mmol). The reaction mixture 
was stirred for 16 h, quenched with NaHCO3 (200 mL), and extracted with CH2Cl2 (3 × 100 mL). 
The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:9) yielded acetonide 262 (6.30 g, 13.1 mmol, 93%) as a colourless oil. 
 
Rf 0.80 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 7.24 (2H, d, J = 8.6 Hz, ArH), 6.86 (2H, d, 
J = 8.6 Hz, ArH), 4.40 (2H, s, OCH2Ar), 3.95-3.87 (1H, m, H34), 3.79 (3H, s, ArOMe), 3.63 (1H, dd, 
J = 10.9, 4.5 Hz, H30), 3.54 (1H, dd, J = 8.8, 3.0 Hz, H28a), 3.42-3.34 (2H, m, H32+H28b), 1.88-1.78 
(1H, m, H29), 1.60-1.50 (3H, m, H31+H33), 1.32 (3H, s, OC(CH3)2), 1.27 (3H, s, OC(CH3)2), 1.13 (3H, 
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d, J = 6.1 Hz, H35), 0.92 (3H, d, J = 6.7 Hz, Me29), 0.88 (9H, s, SiC(CH3)3), 0.84 (3H, d, J = 6.7 Hz, 
Me31), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). Data in agreement with that reported by Gibson.34 
 
(S)-2-((4S,5S,6S)-6-((R)-2-((tert-butyldimethylsilyl)oxy)propyl)-2,2,5-trimethyl-1,3-dioxan-4-yl)
propan-1-ol (168) 
 
 
 
To a solution of acetonide 262 (6.20 g, 12.9 mmol) in CH2Cl2 (200 mL) and pH 7 buffer (40 mL) at 
0 °C was added DDQ (3.22 g, 14.2 mmol). The reaction mixture was stirred at 0 °C for 1 h, before 
being quenched by NaHCO3 (100 mL) and extracted with CH2Cl2 (3 × 100 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:9) yielded alcohol 168 (4.20 g, 11.7 mmol, 91%) as a colourless oil. 
 
Rf 0.30 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 3.96-3.87 (1H, m, H34), 3.67 (1H, dd, J = 
10.5, 4.5 Hz, H30), 3.62-3.55 (1H, m, H32), 3.55-3.48 (1H, m, H28a), 3.46-3.40 (1H, m, H28b), 3.21 
(1H, dd, J = 9.7, 1.8 Hz, OH), 1.97-1.83 (1H, m, H29), 1.63-1.52 (3H, m, H31+H33), 1.38 (3H, s, 
OC(CH3)2), 1.34 (3H, s, OC(CH3)2), 1.14 (3H, d, J = 6.1 Hz, H35), 0.89 (9H, s, SiC(CH3)3), 0.87 (3H, 
d, J = 6.7 Hz, Me29), 0.75 (3H, d, J = 6.8 Hz, Me31), 0.06 (3H, s, SiCH3), 0.05 (3H, s, SiCH3). Data 
in agreement with that reported by Gibson.34 
 
tert-butyl(((R)-1-((4S,5S,6S)-6-((S,Z)-4-iodobut-3-en-2-yl)-2,2,5-trimethyl-1,3-dioxan-4-yl)propa
n-2-yl)oxy)dimethylsilane (171) 
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To a solution of alcohol 168 (4.20 g, 11.7 mmol) in CH2Cl2 (300 mL) was added NaHCO3 (5.83 g, 
70.0 mmol) and Dess-Martin periodinane (14.8 g, 35.0 mmol). The reaction mixture was stirred for 1 
h, before being concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 1:19) 
yielded the aldehyde (3.64 g, 10.1 mmol, 86%) as a colourless oil, which was immediately used in 
the subsequent step.  
To a suspension of (Ph3PCH2I)+I– (13.4 g, 25.2 mmol) in THF (150 mL) was added NaHMDS (1.0 M 
in THF, 25.2 mL, 25.2 mmol). The solution was stirred until a deep orange solution was obtained. 
The reaction mixture was then cooled to −78 °C, before a solution of the aldehyde (3.64 g, 10.1 
mmol) in THF (100 mL) was added. The reaction mixture was warmed to rt over 2 h, before being 
diluted with hexane. The mixture was filtered through a short pad of Celite® and concentrated in 
vacuo. Purification by flash chromatography (EtOAc/PE 1:19) afforded vinyl iodide 171 (4.53 g, 
9.39 mmol, 93%) as a colourless oil.  
 
Rf 0.90 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 6.15 (1H, d, J = 7.5 Hz, H27), 6.12 (1H, 
app t, J = 7.4 Hz, H28), 3.96-3.87 (1H, m, H34), 3.70 (1H, dd, J = 9.1, 4.7 Hz, H30), 3.43-3.36 (1H, m 
H32), 2.64-2.53 (1H, m, H29), 1.65-1.57 (1H, m, H31), 1.57-1.51 (2H, m, H33), 1.31 (3H, s, OC(CH3)2), 
1.29 (3H, s, OC(CH3)2), 1.14 (3H, d, J = 6.2 Hz, H35), 0.93 (3H, d, J = 6.8 Hz, Me29), 0.89 (9H, s, 
SiC(CH3)3), 0.87 (3H, d, J = 6.8 Hz, Me31), 0.06 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). Data in 
agreement with that reported by Gibson.34 
 
(2R,4S,5S,6S,7S,Z)-9-iodo-5,7-dimethylnon-8-ene-2,4,6-triol (155) 
 
 
 
To a solution of TBS ether 171 (3.55 g, 7.36 mmol) in MeOH (50 mL) was added PPTS (555 mg, 
2.21 mmol). The mixture was stirred for 16 h, the volatiles were removed in vacuo and the crude 
product purified by flash column chromatography (EtOAc/PE 1:4) to yield triol 155 (2.17 g, 6.62 
mmol, 90%) as an off-white solid. 
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Rf 0.29 (EtOAc/PE 1:4); = +30.0 (c 0.20, CHCl3); IR νmax = 3347, 2966, 2930, 2348, 2326, 
1456, 1376, 1260, 1066, 972, 804, 699; 1H NMR (500 MHz, CDCl3) δH 6.33 (1H, d, J = 7.4 Hz, H27), 
6.18 (1H, dd, J = 8.8, 7.4 Hz, H28), 4.24-4.15 (1H, m, H34), 4.05-3.97 (1H, m, H32), 3.92-3.87 (1H, m, 
H30), 3.12 (3H, d, J = 5.2 Hz, OH), 2.78-2.69 (1H, m, H29), 1.82 (1H, ddd, J = 14.5, 9.6, 3.1 Hz, 
H33a), 1.77-1.70 (1H, m, H31), 1.56 (1H, ddd, J = 14.5, 7.4, 2.4 Hz, H33b), 1.28 (3H, d, J = 6.3 Hz, 
H35), 1.03 (3H, d, J = 7.1 Hz, Me31), 0.96 (3H, d, J = 6.8 Hz, Me29); 13C NMR (125 MHz, CDCl3) δC 
144.0, 83.3, 75.0, 72.6, 65.9, 43.1, 42.2, 39.3, 23.4, 16.0, 10.7; HRMS (ES+) calc for C11H22IO3 
[M+H]+ 329.0608, found 329.0611. 
 
(2R,3S,4S,Z)-2-((4S,6R)-2,2-di-tert-butyl-6-methyl-1,3,2-dioxasilinan-4-yl)-6-iodo-4-methylhex-
5-en-3-ol (178) 
 
 
 
To a solution of triol 155 (500 mg, 1.52 mmol) in CH2Cl2 (20 mL) at –78 °C was added 2,6-lutidine 
(0.88 mL, 7.60 mmol) and tBu2Si(OTf)2 (0.59 mL, 1.82 mmol) dropwise. The mixture was stirred at 
–78 °C for 1h, before being quenched with MeOH (5 mL) followed by NaHCO3 solution (20 mL). 
The residue was extracted with CH2Cl2 (3 × 20 mL), and the combined organic extracts were dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 1:20) 
afforded alcohol 178 (684 mg, 1.46 mmol, 96%) as a colourless oil. 
 
Rf 0.25 (Et2O/PE 9:1); = +59.5 (c 1.0, CHCl3); IR νmax = 3481, 2964, 2932, 2892, 2858, 1474, 
1385, 1259, 1134, 978, 896, 865, 825, 797, 730, 648; 1H NMR (500 MHz, CDCl3) δH 6.29-6.23 (2H, 
m, H27+H28), 4.47-4.40 (1H, m, H34), 4.24 (1H, ddd, J = 10.1, 5.4, 1.9 Hz, H32), 3.96 (1H, dd, J = 8.0, 
1.7 Hz, H30), 3.00 (1H, br s, OH), 2.74-2.64 (1H, m, H29), 2.19 (1H, ddd, J = 14.3, 10.1, 5.9 Hz, H33a), 
1.72-1.65 (1H, m, H31), 1.52-1.47 (1H, m, H33b), 1.30 (3H, d, J = 6.6 Hz, H35), 1.03 (3H, d, J = 7.0 
Hz, Me31), 1.00 (18H, s, SitBu2), 0.95 (3H, d, J = 6.9 Hz, Me29); 13C NMR (125 MHz, CDCl3) δC 
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144.8, 82.2, 74.6, 73.2, 67.8, 43.0, 40.7, 38.8, 27.5, 27.4, 23.8, 21.5, 20.8, 16.5, 10.9; HRMS (ES+) 
calc for C19H38IO3Si [M+H]+ 469.1629, found 469.1619. 
 
(2R,3S,4S,Z)-2-((4S,6R)-2,2-di-tert-butyl-6-methyl-1,3,2-dioxasilinan-4-yl)-4-methyl-6-(trimethy
lstannyl)hex-5-en-3-ol (180) 
 
 
 
To a stirred solution of vinyl iodide 178 (916 mg, 1.96 mmol) in THF (20 mL) was added 
PdCl2(PPh3)2 (138 mg, 0.20 mmol), Li2CO3 (723 mg, 9.78 mmol) and (Me3Sn)2 (2.03 mL, 9.78 
mmol). The reaction was stirred at 40 °C for 3h, cooled to rt and concentrated in vacuo. Purification 
by flash chromatography (EtOAc/PE 1:20) afforded stannane 180 (644 mg, 1.27 mmol, 65%) as a 
colourless oil. 
 
Rf 0.58 (Et2O/PE 1:9); = +65.0 (c 0.1, CHCl3); IR νmax = 2962, 2930, 2857, 2360, 1726, 1598, 
1474, 1376, 1258, 1133, 1101, 981, 899, 864, 825, 799, 769, 730; 1H NMR (500 MHz, CDCl3) δH 
6.38 (1H, dd, J = 12.3, 9.5 Hz, H28), 5.94 (1H, d, J = 12.4 Hz, H27), 4.39 (1H, ddq, J = 12.5, 6.1, 2.6 
Hz, H34), 4.24 (1H, ddd, J = 9.4, 6.4, 2.4 Hz, H32), 3.96 (1H, br d, J = 8.0 Hz, H30), 2.51 (1H, d, J = 
1.8 Hz, OH), 2.15 (1H, ddq, J = 9.5, 6.5, 3.1 Hz, H29), 2.11 (1H, ddd, J = 14.3, 9.8, 5.7 Hz, H33a), 
1.64 (1H, ddq, J = 7.1, 7.1, 1.5 Hz, H31), 1.56 (1H, ddd, J = 14.2, 2.4, 2.4 Hz, H33b), 1.29 (3H, d, J = 
6.7 Hz, H35), 1.01 (9H, s, SitBu2), 0.99 (9H, s, SitBu2), 0.92 (3H, d, J = 7.1 Hz, Me31), 0.91 (3H, d, J 
= 6.7 Hz, Me29), 0.18 (9H, s, SnMe3); 13C NMR (125 MHz, CDCl3) δC 152.5, 130.4, 73.0, 72.4, 67.6, 
44.6, 39.9, 38.7, 27.3, 27.3, 23.7, 21.4, 20.7, 17.4, 9.7, −8.3; HRMS (ES+) calc for C22H47O3Si112Sn 
[M+H]+ 499.2337, found 499.2337. 
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(2R,3S,4S,Z)-2-((4S,6R)-2,2-di-tert-butyl-6-methyl-1,3,2-dioxasilinan-4-yl)-4-methyl-6-(trimethy
lstannyl)hex-5-en-3-yl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (217) 
 
 
 
To a solution of alcohol 180 (410 mg, 811 µmol) and acid 188 (370 mg, 1.22 mmol) in CH2Cl2 (20 
mL) was added DCC (1 M, 0.89 mL, 890 µmol) and the mixture was stirred for 10 min before being 
concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 1:20) afforded phosphonate 
217 (488 mg, 616 µmol, 76%) as a yellow oil. 
 
Rf 0.21 (Et2O/PE 1:9); = +62.4 (c 1.0, CHCl3); IR νmax = 2971, 2860, 1736, 1474, 1386, 1298, 
1267, 1174, 1143, 1097, 1071, 963, 900, 826, 769, 648; 1H NMR (500 MHz, CDCl3) δH 6.30 (1H, dd, 
J = 12.3, 9.8 Hz, H28), 5.81 (1H, d, J = 12.2 Hz, H27), 5.54 (1H, dd, J = 9.6, 1.3 Hz, H30), 4.51-4.38 
(4H, m, OCH2CF3), 4.39-4.32 (1H, m, H34), 3.82 (1H, ddd, J = 9.8, 8.9, 3.1 Hz, H32), 3.13-2.96 (2H, 
m, H2), 2.36-2.26 (1H, m, H29), 1.87-1.76 (2H, m, H31+H33a), 1.67 (1H, ddd, J = 14.4, 4.2, 3.6 Hz, 
H33b), 1.28 (3H, d, J = 6.4 Hz, Me35), 1.00 (9H, s, SitBu), 0.99 (3H, d, J = 6.5 Hz, Me29), 0.98 (9H, s, 
SitBu), 0.84 (3H, d, J = 7.0 Hz, Me31), 0.18 (9H, s, SnMe3); 13C NMR (125 MHz, CDCl3) δC 164.1 
(d, J = 2.8 Hz), 151.0, 129.9, 122.3 (qd, J = 278, 6.5 Hz), 122.2 (qd, J = 278, 6.0 Hz), 76.9, 69.9, 
67.3, 63.0-62.2 (2C, m), 44.3, 40.9, 38.2, 34.1, 27.5, 27.2, 23.8, 20.6 (d, J = 33.5 Hz), 17.7, 9.5, −8.3; 
HRMS (ES+) calc for C28H55F6O7PSi112SnN [M+NH4]+ 802.2434, found 802.2439. 
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c. Southern Fragment  
 
(E)-1,1-dibromopenta-1,3-diene (224) 
 
 
 
To a solution of triphenylphosphine (25.2 g, 96.4 mmol) in CH2Cl2 (150 mL) at 0 °C was added CBr4 
(32.0 g, 96.4 mmol). After stirring for 10 minutes, zinc (6.30 g, 96.4 mmol) was added. The reaction 
mixture was warmed to rt and stirred for 24 h. Crotonaldehyde 223 (4.0 mL, 48.2 mmol) was added 
at 0 °C. After stirring for 2 h at rt, the reaction mixture was poured into ice-cold pentane. The 
suspension was filtered, and the residue was washed with ice-cold pentane. The filtrate was 
concentrated in vacuo. Purification by flash chromatography (PE) afforded diene 224 (7.62 g, 33.7 
mmol, 70%) as a yellow oil.  
 
Rf 0.81 (Et2O/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 6.89 (1H, d, J = 10.0 Hz, H12), 6.10 (1H, ddq, 
J = 15.4, 10.0, 1.6 Hz, H11), 5.92 (1H, ddq, J = 15.4, 6.8, 0.73 Hz, H10), 1.77 (3H, ddd, J = 6.8, 1.6, 
0.39 Hz, Me10). Data in agreement with literature values.98 
 
(2R,3R)-5,5-dibromopent-4-ene-2,3-diol (225) 
 
 
 
To a solution of potassium osmate dihydrate (42.4 mg, 115 µmol) and (DHQD)2PHAL (111 g, 142 
µmol) in tBuOH (150 mL) and water (150 mL) was added CH3SO2NH2 (2.81 g, 28.6 mmol). The 
reaction mixture was stirred for 30 min, before K2CO3 (11.8 g, 85.7 mmol), NaHCO3 (7.21 g, 85.7 
mmol) and K3[Fe(CN)6] (28.3 g, 85.7 mmol) were added. The mixture was stirred for a further 30 
min and cooled to 0 °C. Diene 224 (6.44 g, 28.6 mmol) was added dropwise and the slurry was 
warmed to rt and stirred for 16 h. Na2SO3 (350 mg) was added at 0 °C and the mixture was stirred at 
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rt for 1 h. The resulting mixture was extracted with EtOAc, and the combined organic extracts were 
washed with 1M NaOH (100 mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (Et2O/PE 1:1), followed by recrystallisation (EtOH) yielded diol 225 (5.20 g, 20.0 
mmol, 70%) as a white crystalline solid. 
 
Rf 0.25 (Et2O/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 6.48 (1H, d, J = 8.6 Hz, H12), 4.11 (1H, dd, J 
= 8.6, 6.6 Hz, H11), 3.74 (1H, dq, J = 6.6, 6.4 Hz, H10), 2.79-2.58 (2H, m, OH), 1.23 (3H, d, J = 6.4 
Hz, Me10). Data in agreement with literature values.99 
 
3,3-dibromoacrylaldehyde (218) 
 
 
 
To a stirred solution of silica gel (60 g) in CH2Cl2 (500 mL) was added a solution of NaIO4 (6.39 g, 
30.0 mmol) in H2O (50 mL) dropwise. After 15 min, a solution of diol 225 (6.0 g, 23.1 mmol) in 
CH2Cl2 (50 mL) was added. After a further 15 min, the mixture was dried (Na2SO4) and filtered. The 
filtrate was concentrated in vacuo to yield aldehyde 218 (4.93 g, 22.9 mmol, 99%) as a yellow oil. 
Rf 0.75 (Et2O/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 9.67 (1H, d, J = 6.4 Hz, CHO), 6.96 (1H, dd, 
J = 6.4 Hz, H12). Data in agreement with that reported by Kan.59  
 
(R,E)-4-benzyl-3-(2-methylpent-2-enoyl)oxazolidin-2-one (222) 
 
 
 
To a solution of trans-2-methyl-2-pentenoic acid 220 (1.19 g, 10.4 mmol) in CH2Cl2 (30 mL) at 
−78 °C was added Et3N (3.53 mL, 25.3 mmol), followed by trimethylacetyl chloride (1.25 mL, 10.1 
mmol) dropwise. The reaction mixture was warmed to rt and stirred for 1 h, before being cooled to 
−78 °C. Oxazolidinone 221 (1.80 g, 10.1 mmol) in CH2Cl2 (5 mL) was added dropwise, followed by 
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LiCl (648 mg, 15.3 mmol). The reaction mixture was warmed to rt and stirred for 18 h, before being 
quenched with water (20 mL), extracted with CH2Cl2 (3 × 10 mL), and the combined organic 
extracts were washed with brine (20 mL), dried (Na2SO4) and concentrated in vacuo. Purification by 
flash chromatography (Et2O/PE 1:4) yielded imide 222 (2.73 g, 10.0 mmol, 98%) as a yellow oil. 
 
Rf 0.24 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 7.35-7.30 (2H, m, ArH), 7.29-7.24 (1H, m, 
ArH), 7.22-7.17 (2H, m, ArH), 6.08 (1H, tq, J = 7.3, 1.4 Hz, H9), 4.74-4.68 (1H, m, NCH), 4.23 (1H, 
app t, J = 8.6 Hz, CH2aAr), 4.14 (1H, dd, J = 9.0, 5.6 Hz, CH2bAr), 3.33 (1H, dd, J = 13.5, 3.5 Hz, 
OCH2aCH), 2.84 (1H, dd, J = 13.5, 9.2 Hz, OCH2bCH), 2.21 (2H, app qn, J = 7.5 Hz, H10), 1.91 (3H, 
s, Me8), 1.06 (3H, t, J = 7.5 Hz, Me10). Data in agreement with literature values.100 
 
(R)-4-benzyl-3-((1E,3E)-1-((tert-butyldimethylsilyl)oxy)-2-methylpenta-1,3-dien-1-yl)oxazolidin
-2-one (219) 
 
 
 
To a solution of imide 222 (4.0 g, 14.6 mmol) in THF (300 mL) at −78 °C was added NaHMDS (1 M 
in THF, 22.0 mL, 22.0 mmol) dropwise. After stirring for 1.5 h, TBSCl (4.4 g, 29.3 mmol) in THF 
(100 mL) was added dropwise. The reaction mixture was stirred for a further 1 h, before being 
quenched with NH4Cl (100 mL). The solvent was removed in vacuo and the residue was extracted 
with EtOAc (3 × 50 mL). The combined organic extracts were dried (Na2SO4) and concentrated in 
vacuo. Purification by flash chromatography (EtOAc/PE 1:9 to 1:4) yielded silyl ketene aminal 219 
(5.6 g, 14.5 mmol, 99%) as a colourless oil. 
 
Rf 0.15 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 7.34-7.27 (2H, m, ArH), 7.27-7.22 (1H, m, 
ArH), 7.17-7.10 (2H, m, ArH), 6.17 (1H, d, J = 15.6 Hz, H9), 5.68 (1H, dq, J = 15.6, 6.7 Hz, H10), 
4.31-4.21 (2H, m, NCH+CH2aAr), 4.17-4.09 (1H, m, CH2bAr), 3.12 (1H, br d, J = 13.0 Hz, 
OCH2aCH), 2.69-2.55 (1h, m, OCH2bCH), 1.82 (6H, s, Me8+Me10), 0.99 (9H, s, SitBuMe2), 0.21 (3H, 
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s, SitBuMe2), 0.14 (3H, s, SitBuMe2). Data in agreement with literature values.101 
 
(R)-4-benzyl-3-((4R,5R,E)-7,7-dibromo-5-hydroxy-2,4-dimethylhepta-2,6-dienoyl)oxazolidin-2-
one (226) 
 
 
 
To a solution of aldehyde 218 (4.9 g, 23.1 mmol) in CH2Cl2 (80 mL) at −78 °C was added TiCl4 
(1.64 mL, 15.0 mmol) dropwise, followed by a solution of silyl ketene aminal 219 (5.8 g, 15.0 mmol) 
in CH2Cl2 (80 mL). The reaction mixture was warmed to −20 °C and stirred for 18 h, before being 
quenched with pyridine (5 mL), Na+/K+ tartrate (50 mL) and NaHCO3 (50 mL). The mixture was 
stirred at rt until a homogeneous solution was formed. The solution was extracted with EtOAc (3 × 
50 mL), and the combined organic extracts were dried (Na2SO4) and concentrated in vacuo. 
Purification by flash chromatography (EtOAc/PE 1:4) yielded aldol adduct 226 (6.0 g, 12.3 mmol, 
82%) as a white solid. 
 
Rf 0.30 (EtOAc/PE 1:2); 1H NMR (500 MHz, CDCl3) δH 7.36-7.31 (2H, m, ArH), 7.31-7.27 (1H, m, 
ArH), 7.21-7.17 (2H, m, ArH), 6.51 (1H, d, J = 8.6 Hz, H12), 5.75 (1H, dq, J = 10.4, 1.5 Hz, H9), 
4.85-4.78 (1H, m, NCH), 4.31 (1H, app t, J = 8.8 Hz, OCH2aCH), 4.19 (1H, dd, J = 9.0, 6.4 Hz, 
OCH2bCH), 4.10 (1H, app t, J = 8.4 Hz, H11), 3.31 (1H, dd, J = 13.5, 3.4 Hz, CH2aAr), 3.26 (1H, br s, 
OH), 2.88 (1H, dd, J = 13.5, 9.0 Hz, CH2bAr), 2.75-2.66 (1H, m, H10), 1.97 (3H, d, J = 1.5 Hz, Me8), 
1.06 (3H, d, J = 6.8 Hz, Me10). Data in agreement with that reported by Kan.59 
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(R)-4-benzyl-3-((4R,5R,E)-7,7-dibromo-2,4-dimethyl-5-(triethylsilyl)hepta-2,6-dienoyl)oxazolidi
n-2-one (227) 
 
 
 
To a solution of alcohol 226 (1.95 g, 4.00 mmol) in CH2Cl2 (160 mL) at −78 °C was added 
2,6-lutidine (1.4 mL, 12.32 mmol), followed by TESOTf (2.2 mL, 9.84 mmol) dropwise. The 
reaction mixture was warmed to −65 °C over 30 min, before being quenched with NaHCO3 (50 mL) 
and extracted with CH2Cl2 (3 × 50 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (Et2O/PE 1:4) yielded TES ether 227 
(2.38 g, 3.96 mmol, 99%) as a white solid. 
 
Rf 0.60 (EtOAc/PE 1:2); 1H NMR (500 MHz, CDCl3) δH 7.35-7.29 (2H, m, ArH), 7.29-7.25 (1H, m, 
ArH), 7.22-7.18 (2H, m, ArH), 6.55 (1H, d, J = 8.4 Hz, H12), 5.95 (1H, dq, J = 10.1, 1.5 Hz, H9), 
4.73-4.65 (1H, m, NCH), 4.27 (1H, dd, J = 8.4, 4.1 Hz, H11), 4.24 (1H, app t, J = 8.4 Hz, OCH2aCH), 
4.15 (1H, dd, J = 9.0, 5.2 Hz, OCH2bCH), 3.34 (1H, dd, J = 13.5, 3.4 Hz, CH2aAr), 2.85 (1H, dd, J = 
13.5, 9.0 Hz, CH2bAr), 2.73-2.63 (1H, m, H10), 1.91 (3H, d, J = 1.5 Hz, Me8), 1.08 (3H, d, J = 6.8 
Hz, Me10), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.61 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). Data in 
agreement with that reported by Kan.59 
 
(R)-4-benzyl-3-((2E,4R,5R,6Z)-7-bromo-2,4-dimethyl-5-(triethylsilyl)hepta-2,6-dienoyl)oxazolid
in-2-one (228) 
 
 
 
To Pd(PPh3)4 (922 mg, 0.798 mmol) was added a solution of dibromoolefin 227 (2.40 g, 3.99 mmol) 
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in CH2Cl2 (120 mL) and Bu3SnH (1.61 mL, 5.99 mmol). The solution was stirred for 1 h and 
concentrated in vacuo. Purification by flash chromatography (Et2O/PE 1:4) yielded (Z)-vinyl 
bromide 228 (2.07 g, 3.96 mmol, 99%) as a colourless oil. 
 
Rf 0.60 (EtOAc/PE 1:2); 1H NMR (500 MHz, CDCl3) δH 7.35-7.29 (2H, m, ArH), 7.29-7.25 (1H, m, 
ArH), 7.22-7.18 (2H, m, ArH), 6.24 (1H, app t, J = 7.5 Hz, H12), 6.17 (1H, d, J = 7.3 Hz, H13), 6.06 
(1H, br d, J = 10.0 Hz, H9), 4.73-4.64 (1H, m, NCH), 4.55 (1H, dd, J = 8.2, 3.9 Hz, H11), 4.23 (1H, 
app t, J = 8.4 Hz, OCH2aCH), 4.14 (1H, dd, J = 9.0, 5.2 Hz, OCH2bCH), 3.34 (1H, dd, J = 13.5, 3.4 
Hz, CH2aAr), 2.85 (1H, dd, J = 13.5, 9.2 Hz, CH2bAr), 2.75-2.65 (1H, m, H10), 1.89 (3H, s, Me8), 
1.09 (3H, d, J = 6.8 Hz, Me10), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.61 (6H, q, J = 8.0 Hz, 
Si(CH2CH3)3). Data in agreement with that reported by Kan.59 
 
(2E,4R,5R,6Z)-7-bromo-5-(diethyl(methyl)silyl)-2,4-dimethylhepta-2,6-dien-1-ol (263) 
 
 
 
To a solution of imide 228 (2.00 g, 3.83 mmol) in THF/H2O (5:1, 90 mL) was added NaBH4 (725 mg, 
19.1 mmol). The reaction mixture was stirred in the dark for 3 h, before being quenched with NH4Cl 
(20 mL) at 0 °C. THF was evaporated in vacuo and the residue was extracted with Et2O (3 × 30 mL). 
The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:4) yielded alcohol 263 (1.20 g, 3.45 mmol, 90%) as a colourless oil. 
 
Rf 0.52 (EtOAc/PE 1:2); 1H NMR (500 MHz, CDCl3) δH 6.17 (1H, d, J = 7.3 Hz, H13), 6.09 (1H, 
app t, J = 7.7 Hz, H12), 5.32 (1H, d, J = 9.7 Hz, H9), 4.45 (1H, dd, J = 8.2, 5.2 Hz, H11), 4.00 (2H, d, 
J = 5.8 Hz, H7), 2.65-2.55 (1H, m, H10), 1.68 (3H, s, Me8),  0.99 (3H, d, J = 6.8 Hz, Me10), 0.94 (9H, 
t, J = 8.0 Hz, Si(CH2CH3)3), 0.59 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). Data in agreement with that 
reported by Kan.59 
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(2E,4R,5R,6Z)-5-(diethyl(methyl)silyl)-2,4-dimethyl-7-(tributylstannyl)hepta-2,6-dien-1-ol (102)  
 
 
 
To a solution of vinyl bromide 263 (200 mg, 0.572 mmol) in Et2O (10 mL) at −78 °C was added 
tBuLi (1.7 M in pentane, 1.35 mL, 2.29 mmol) dropwise. After stirring for 5 min, Bu3SnCl (0.93 mL, 
3.43 mmol) was added and the reaction mixture was warmed to rt, quenched with H2O (10 mL) and 
extracted with EtOAc (3 × 10 mL). The organic extracts were washed with H2O (10 mL), dried 
(Na2SO4) and concentrated in vacuo. Purification by flash chromatography (Et2O/PE/Et3N 1:9:0.02) 
afforded stannane 102 (218 mg, 0.389 mmol, 68%) as a colourless oil. 
 
Rf 0.50 (EtOAc/PE 1:5); 1H NMR (500 MHz, CDCl3) δH 6.42 (1H, dd, J = 13.1, 8.4 Hz, H12), 5.83 
(1H, d, J = 13.1 Hz, H13), 5.40 (1H, app d, J = 9.8 Hz, H9), 4.00 (2H, br s, H7), 3.77 (1H, dd, J = 8.4, 
4.1 Hz, H11), 2.46 (1H, ddq, J = 9.8, 6.9, 4.2 Hz, H10), 1.64 (3H, s, Me8), 1.53-1.45 (6H, m, SnBu3), 
1.36-1.28 (6H, m, SnBu3), 0.97 (3H, d, J = 6.9 Hz, Me10), 0.97-0.87 (15H, m, SnBu3), 0.93 (9H, t, J 
= 8.0 Hz, Si(CH2CH3)3), 0.56 (6H, q, J = 8.0 Hz, SiCH2CH3). Data in agreement with that reported 
by Kan.59 
 
d. Fragment coupling  
 
(2E,4R,5S,6Z,8E)-9-((R)-2-((2R,3R,5R,6E,8E)-9-bromo-5-((tert-butyldimethylsilyl)oxy)-3-metho
xynona-6,8-dien-2-yl)-4,5-dihydrooxazol-4-yl)-2,4-dimethyl-5-(triethylsilyl)nona-2,6,8-trien-1-o
l (115) 
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To a solution of Pd(PPh3)4 (25.8 mg, 22.4 µmol), CuTC (34.1 mg, 179 µmol) and [Ph2PO2][NBu4] 
(82.2 mg, 179 µmol) in DMF (3 mL) at 0 °C, was added a solution of bis-halide 81 (52.2 mg, 89.4 
µmol) and stannane 102 (50.0 mg, 89.4 µmol) in DMF (3 mL). After stirring at 0 °C in the dark for 3 
h, the reaction was quenched with water (5 mL) and extracted with Et2O (2 × 3 mL) and EtOAc (2 × 
3 mL). The organic extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:4) gave diene 115 (53.9 mg, 74.2 µmol, 83%) as a pale yellow oil. 
 
Rf 0.24 (EtOAc/PE 1:4); 1H NMR (500 MHz, CDCl3) δH 6.66 (1H, dd, J = 13.5, 10.9 Hz, H25), 6.36 
(1H, dd, J = 15.1, 11.4 Hz, H14), 6.26 (1H, d, J = 13.5 Hz, H26), 6.06 (1H, dd, J = 15.3, 10.8 Hz, H24), 
5.98 (1H, t, J = 11.2 Hz, H13), 5.69 (1H, dd, J = 15.3, 6.8 Hz, H23), 5.64 (1H, dd, J = 15.0, 5.7 Hz, 
H15), 5.39 (1H, dd, J = 11.2, 8.6 Hz, H12), 5.06 (1H, d, J =9.9 Hz, H9), 4.69-4.63 (1H, m, H16), 4.45 
(1H, dd, J = 8.2, 4.5 Hz, H11), 4.32 (1H, dd, J = 10.1, 8.2 Hz, H17a), 4.29-4.26 (1H, m, H22), 3.95 (2H, 
br d, J = 6.6 Hz, H7), 3.91 (1H, t, J = 7.9 Hz, H17b), 3.69 (1H, ddd, J = 9.3, 5.1, 2.5 Hz, H20), 3.35 
(3H, s, OMe), 2.95-2.88 (1H, m, H19), 2.67-2.59 (1H, m, H10), 1.72 (3H, d, J = 1.1 Hz, Me8), 
1.54-1.45 (2H, m, H21), 1.15 (3H, d, J = 7.1 Hz, Me19), 0.94 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.93 
(3H, d, J = 6.3 Hz, Me10), 0.89 (9H, s, SitBuMe2), 0.56 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.06 (3H, s, 
SitBuMe2), 0.00 (3H, s, SitBuMe2). Data in agreement with that reported by Li.38 
 
(2R,3S,4S,5Z,7E,9E,11R,13R,14R)-11-((tert-butyldimethylsilyl)oxy)-2-((4S,6R)-2,2-di-tert-butyl-
6-methyl-1,3,2-dioxasilinan-4-yl)-14-((R)-4-((1E,3Z,5S,6R,7E)-9-hydroxy-6,8-dimethyl-5-(trieth
ylsilyl)nona-1,3,7-trien-1-yl)-4,5-dihydrooxazol-2-yl)-13-methoxy-4-methylpentadeca-5,7,9-trie
n-3-yl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (229) 
 
 
 
To a solution of Pd(PPh3)4 (10.5 mg, 9.05 µmol), CuTC (17.2 mg, 90.5 µmol) and [Ph2PO2][NBu4] 
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(100 mg, 218 µmol) in DMF (3.0 mL) at 0 °C was added a solution of vinyl bromide 115 (31.0 mg, 
42.5 µmol) and stannane 217 (71.6 mg, 90.5 µmol) in DMF (3.0 mL). After stirring for 2 hours in the 
dark, the reaction was quenched with water (5 mL) and extracted with Et2O (2 × 5 mL) and EtOAc 
(2 × 5 mL). The extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:4) gave phosphonate 229 (47.5 mg, 37.3 µmol, 88%) as a yellow oil. 
One Pot Procedure 
To a solution of Pd(PPh3)4 (9.9 mg, 8.57 µmol), CuTC (13.7 mg, 71.8 µmol) and [Ph2PO2][NBu4] 
(33.0 mg, 71.8 µmol) in DMF (1.0 mL) at 0 °C as added a solution of bis-halide 81 (20.0 mg, 34.2 
µmol) and stannane 102 (19.1 mg, 34.2 µmol) in DMF (1.0 mL). After stirring at 0 °C in the dark for 
2 hours in the dark, a solution of stannane 217 (43.4 mg, 54.8 µmol) in DMF (1.0 mL) was added. 
The reaction was stirred for another 2 hours before being quenched with water (3 mL) and extracted 
with Et2O (2 × 2 mL) and EtOAc (2 × 2 mL). The extracts were dried (Na2SO4) and concentrated in 
vacuo. Purification by flash chromatography (EtOAc/PE 1:2) gave triene 229 (35.0 mg, 27.5 µmol, 
80%) as a yellow oil. 
 
Rf 0.4 (EtOAc/PE 4:6);  +4.50 (c 1.0, CHCl3); IR νmax 2930, 1738, 1664, 1462, 1262, 1173, 
1072, 964, 838, 805, 777, 744; 1H NMR (500 MHz, CDCl3) δH 6.41-6.31 (2H, m, H14+H26), 
6.23-6.13 (2H, m, H24+H25), 6.03 (1H, app t, J = 11.0 Hz, H27), 5.98 (1H, app t, J = 11.2 Hz, H13), 
5.67 (1H, dd, J = 14.0, 7.4 Hz, H23), 5.64 (1H, dd, J = 15.3, 5.4, H15), 5.42-5.36 (2H, m, H12+H30), 
5.31 (1H, app t, J = 10.3 Hz, H28), 5.06 (1H, d, J = 10.0, H9), 4.69-4.62 (1H, m, H16), 4.51-4.29 (8H, 
m, H11+H17a+H22+H34+(OCH2CF3)2), 3.95 (2H, s, H7), 3.91 (1H, app t, J = 7.9 Hz, H17b), 3.86 (1H, 
ddd, J = 8.8, 8.8, 2.8, H32), 3.76-3.68 (2H, m, H20+OH), 3.36 (3H, s, OMe), 3.05 (2H, d, J = 20.6 Hz, 
H2), 2.99-2.87 (2H, m, H19+H29), 2.67-2.59 (1H, m, H10), 1.90-1.80 (2H, m, H31+H33a), 1.72 (3H, s, 
Me8), 1.66-1.60 (1H, m, H33b), 1.54-1.49 (2H, m, H21), 1.29 (3H, d, J = 6.5 Hz, H35), 1.15 (3H, d, J = 
6.8 Hz, Me19), 1.02-0.85 (45H, m, Me10+Me29+Me31+Si(tBu)2+SitBuMe2+Si(CH2CH3)3), 0.56 (6H, 
q, J = 7.9 Hz, Si(CH2CH3)3), 0.06 (3H, s, SitBuMe2), 0.00 (3H, s, SitBuMe2); 13C NMR (125 MHz, 
CDCl3) 170.5, 164.1 (d, J = 3.8 Hz), 138.2, 135.7, 133.8, 133.7, 133.3, 132.8, 129.3, 129.3, 128.9, 
127.2, 27.2, 126.9, 122.5 (dq, J = 277, 8.6 Hz), 122.5 (dq, J = 278, 8.3 Hz), 78.1, 78.1, 72.7, 71.7, 
70.0, 69.6, 69.1, 67.3, 66.0, 62.5 (m), 57.1, 40.9, 40.1, 37.7, 35.7, 35.0, 33.8 (d, J = 145 Hz), 27.4, 
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121 
27.1, 25.9, 23.6, 21.1, 20.7, 18.1, 17.5, 14.3, 13.9, 11.2, 9.5, 6.9, 4.9, −3.8, −4.9; 19F NMR (470 
MHz, CDCl3) δF −75.42 (3F, t, J = 8.0 Hz), −75.48 (3F, t, J = 8.0 Hz); 31P NMR (202 MHz, CDCl3) 
δP 23.81; HRMS ESI calc. for C61H107F6NO12PSi3 [M+H]+ 1274.6737, found 1274.6739. 
 
e. Endgame  
 
(2R,3S,4S,5Z,7E,9E,11R,13R,14R)-11-((tert-butyldimethylsilyl)oxy)-2-((4S,6R)-2,2-di-tert-butyl-
6-methyl-1,3,2-dioxasilinan-4-yl)-14-((R)-4-((1E,3Z,5S,6R,7E)-9-hydroxy-6,8-dimethyl-5-(trieth
ylsilyl)nona-1,3,7-trien-1-yl)-4,5-dihydrooxazol-2-yl)-13-methoxy-4-methylpentadeca-5,7,9-trie
n-3-yl (2Z,4E)-5-(tributylstannyl)penta-2,4-dienoate (232) 
 
 
 
To a solution of phosphonate 229 (20.0 mg, 15.7 µmol) in THF (4.0 mL) at 0 °C was added sodium 
hydride (6.0 mg, 250 µmol). After 30 min, the reaction mixture was cooled to –78 °C and aldehyde 
106 (20.0 mg, 58.8 µmol) in THF (1 mL) was added. After stirring for 48 hours, the reaction mixture 
was quenched with water (5 mL) and extracted with EtOAc (3 × 10 mL). The organic layers were 
dried (Na2SO4) and concentrated in vacuo. Purification by flash chromatography (Et2O/PE 1:9) gave 
stannane 232 and 233 (17.1 mg, 12.6 µmol, 80%) as a colourless oil as a 2.5:1 mixture of Z/E 
isomers. 
 
Rf 0.8 (EtOAc/PE 4:6);  +9.97 (c 1.1, CHCl3); IR νmax 2929, 1716, 1663, 1619, 1461, 1376, 
1250, 1191, 1143, 1088, 1007, 837, 806, 776; 1H NMR (500 MHz, CDCl3) δH 7.79 (0.66H, ddd, J 
=18.8, 10.6, 1.0 Hz, H4), 7.14 (0.33H, dd, J = 15.3, 10.3 Hz, H3*), 6.79 (0.33H, d, J = 18.7 Hz, H5*), 
6.69 (0.66H, d, J = 18.7 Hz, H5), 6.63 (0.33H, dd, J = 18.5, 10.3 Hz, H4*), 6.45-6.33 (2.66H, m, 
H3+H14+H26), 6.20-6.08 (2H, m, H24+H25), 6.05-5.94 (2H, m, H13+H27), 5.79 (0.33H, d, J = 15.4 Hz, 
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H2*), 5.67-5.59 (2H, m, H15+H23), 5.51 (0.66H, d, J = 11.4 Hz, H2), 5.46 (0.33H, app t, J = 10.5 Hz, 
H28*), 5.42 (0.66H, dd, J = 10.5 Hz, H28), 5.39 (1H, dd, J = 11.1, 8.5 Hz, H12), 5.29-5.24 (1H, m, 
H30), 5.06 (1H, dd, J = 10.0, 1.1 Hz, H9), 4.66 (1H, m, H16), 4.45 (1H, ddd, J = 8.3, 4.4, 1.1 Hz, H11), 
4.39 (1H, ddq, J = 6.4, 6.4, 2.3 Hz, H34), 4.35-4.29 (1H, m, H22), 4.32 (1H, dd, J = 10.2, 8.4 Hz, H17a), 
4.00-3.90 (1H, m, H32), 3.95 (2H, s, H7), 3.91 (1H, app t, J = 7.8 Hz, H17b), 3.79-3.67 (2H, m, 
H20+OH), 3.36 (3H, s, OMe), 2.98-2.90 (1H, m, H29), 2.90 (1H, dq, J = 6.9, 5.5 Hz, H19), 2.63 (1H, 
ddq, J = 9.6, 6.8, 3.8 Hz, H10), 1.96-1.83 (2H, m, H31+H33a), 1.72 (3H, d, J = 1.1 Hz, Me8), 1.56-1.46 
(9H, m, H21+H33b+SnBu3), 1.36-1.23 (9H, m, H35+ SnBu3), 1.15 (3H, d, J = 7.1 Hz, Me19), 1.02-0.86 
(60H, m, Me10+Me29+Me31+ SnBu3+Si(tBu)2 +SitBuMe2+Si(CH2CH3)3), 0.56 (6H, q, J = 7.9 Hz, 
Si(CH2CH3)3), 0.07 (3H, s, SitBuMe2), 0.01 (3H, s, SitBuMe2); 13C NMR (125 MHz, CDCl3) 178.6, 
167.0*, 165.5, 147.3, 146.8*, 146.4, 146.2*, 144.4*, 142.8, 137.2*, 137.4, 135.7, 134.0, 133. 132.8, 
132.7, 129.8, 129.0, 128.9, 127.8, 127.6*, 127.2, 126.9, 120.2*, 116.2, 78.2, 76.0, 75.4, 72.7, 71.7, 
70.2, 69.6*, 69.4, 69.1, 67.6, 66.0, 57.2, 41.6*, 41.4, 40.1, 40.1, 37.3, 35.8, 35.5*, 35.2, 29.1, 29.0*, 
27.4, 27.3, 27.1, 25.9, 23.6, 21.3, 20.7, 18.1, 18.0*, 17.8, 14.3, 14.1, 13.9, 13.7, 11.4, 9.7, 9.6*, 6.9, 
4.9, –3.6, –4.8; HRMS ESI calc. for C72H132NO9Si3112Sn [M+H]+ 1350.8253, found 1350.8276. 
*Identifiable resonances for the minor 2E-isomer. 
 
(2R,3S,4S,5Z,7E,9E,11R,13R,14R)-11-((tert-butyldimethylsilyl)oxy)-2-((4S,6R)-2,2-di-tert-butyl-
6-methyl-1,3,2-dioxasilinan-4-yl)-14-(4-((1E,3Z,5S,6R,7E)-6,8-dimethyl-9-oxo-5-(triethylsilyl)no
na-1,3,7-trien-1-yl)oxazol-2-yl)-13-methoxy-4-methylpentadeca-5,7,9-trien-3-yl 
(2Z,4E)-5-(tributylstannyl)penta-2,4-dienoate (234) 
 
 
 
Oxazolines 232 and 233 (8.0 mg, 5.9 µmol) was dissolved in benzene (1.0 mL). Activated 
manganese dioxide (5 x 30 mg portions) was added every 30 min until the reaction was judged to be 
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complete by TLC analysis (2.5 h total). The reaction mixture was filtered through a short pad of 
Celite® and concentrated in vacuo. Purification by preparative thin layer chromatography 
(EtOAC/PE 1:10) afforded the pure Z-isomer 234 (1.6 mg, 1.2 µmol, 20%) along with a 1:1 mixture 
of E and Z isomers (1.0 mg, 0.75 µmol, 13%). 
 
Rf 0.70 (EtOAc/PE 1:4);  +5.90 (c 0.16, CHCl3); IR νmax 2927, 1716, 1691, 1457, 1377, 1246, 
1093, 1038, 1006, 826, 742; 1H NMR (500 MHz, CDCl3) δH 9.42 (1H, s, H7), 7.81 (1H, dd, J = 18.8, 
10.6 Hz, H4), 7.52 (1H, s, H17), 7.12 (1H, dd, J = 15.0, 11.8 Hz, H14), 6.71 (1H, d, J = 19.0 Hz, H5), 
6.51 (1H, d, J = 10.0 Hz, H9), 6.47-6.38 (2H, m, H3+H26), 6.38 (1H, d, J = 15.2 Hz, H15), 6.21-6.09 
(3H, m, H13+H24+H25), 6.01 (1H, app t, J = 11.1 Hz, H27), 5.61 (1H, dd, J = 14.3, 7.4 Hz, H23), 5.52 
(1H, d, J = 11.5 Hz, H2), 5.48-5.38 (2H, m, H12+H28), 5.29 (1H, dd, J = 7.1, 4.1 Hz, H30), 4.66 (1H, 
dd, J = 8.9, 4.5 Hz, H11), 4.41 (1H, ddq, J = 6.6, 6.6, 1.5 Hz, H34), 4.33 (1H, ddd, J = 9.5, 9.5, 2.5 Hz, 
H22), 3.97 (1H, ddd, J = 8.2, 8.2, 1.5 Hz, H32), 3.86-3.76 (1H, m, H20), 3.42-3.35 (1H, m, H19), 3.40 
(3H, s, OMe), 2.94 (1H, dd, J = 9.8, 6.8 Hz, H29), 2.89-2.80 (1H, m, H10), 1.97-1.84 (2H, m, 
H31+H33a), 1.76 (3H, s, Me8), 1.57-1.48 (9H, m, H21+H33b+SnBu3), 1.376-1.28 (12H, m, H35+Me10+ 
SnBu3), 1.10 (3H, d, J = 7.1 Hz, Me19), 1.04-0.86 (57H, m, Me29+Me31+ SnBu3+Si(tBu)2+SitBuMe2 
+Si(CH2CH3)3), 0.59 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.08 (3H, s, SitBuMe2), 0.02 (3H, s, 
SitBuMe2); 13C NMR (125 MHz, CDCl3) 195.6, 166.0, 165.5, 156.8, 147.4, 146.4, 142.8, 139.3, 
138.7, 137.3, 135.4, 134.1, 133.8, 132.6, 129.8, 129.1, 128.9, 127.9, 124.9, 122.5, 116.2, 79.1, 75.3, 
71.8, 70.3, 69.4, 67.6, 57.4, 41.4, 41.1, 40.2, 37.3, 36.0, 35.2, 29.1, 27.4, 27.3, 27.1, 25.9, 23.5, 21.3, 
20.7, 18.1, 17.8, 16.1, 13.7, 11.5, 9.8, 9.7, 9.5, 6.8, 5.0, −3.7, −4.8; HRMS ESI calc. for 
C72H128NO9Si122Sn [M+H]+ 1346.7940 found 1346.7935. 
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(12Z,2R,3R,5R,6E,8E,10Z,12S,13S,16Z,18E,20Z,22E,24R,25S,26Z,28E)-5-((tert-butyldimethylsil
yl)oxy)-13-((R)-1-((4S,6R)-2,2-di-tert-butyl-6-methyl-1,3,2-dioxasilinan-4-yl)ethyl)-3-methoxy-2,
12,22,24-tetramethyl-25-((triethylsilyl)oxy)-14-oxa-1(2,4)-oxazolacyclononacosaphane-6,8,10,16
,18,20,22,26,28-nonaen-15-one (231) 
 
 
 
To a suspension of (PPh3CH2I)+I− (100.0 mg, 189 µmol) in THF (3.0 mL) was added NaHMDS (0.63 
M in THF, 300 µL, 189 µmol) to form a clear, orange solution. 300 µL of the solution was 
transferred to a dry flask and cooled to −78 °C, to which a solution of aldehyde 234 (2.0 mg, 1.5 
µmol) in THF (300+100 µL) was added via cannula. The reaction was stirred at −78 °C for 1 h 
before being diluted with hexane (1 mL) and warmed to rt. The reaction mixture was filtered through 
a short plug of silica gel and concentrated in vacuo to yield vinyl iodide 230 which was used directly 
without further purification. 
To a solution of Pd(PPh3)4 (5.0 mg, 4.2 µmol), CuTC (7.0 mg, 36.7 µmol) and [Ph2PO2][NBu4] (40.0 
mg, 87.0 µmol) in DMF (0.5 mL) at 0 °C was added a solution of the crude vinyl iodide 230 in DMF 
(1.5 mL). The reaction mixture stirred for 30 min before being filtered through a plug of silica, 
concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 1:10) yielded macrocycle 
231 (0.19 mg, 0.18 µmol, 12%) as a colourless oil. 
 
Rf 0.46 (EtOAc/PE 1:9); 1H NMR (500 MHz, CDCl3) δ 7.72 (1H, dd, J = 13.5, 7.8 Hz, H17), 7.09 
(1H, dd, J = 15.0, 11.7 Hz, H14), 6.86 (1H, dd, J = 15.0, 11.3 Hz, H4), 6.76 (1H, dd, J = 15.0, 10.6 Hz, 
H5), 6.43-6.35 (1H, m, H26), 6.37 (1H, app t, J = 11.5 Hz, H3), 6.28-6.20 (2H, m, H15+H24), 6.13 (1H, 
dd, J = 14.5, 10.7 Hz, H25), 6.06 (1H, app t, J = 11.5 Hz, H13), 5.92 (1H, app t, J = 11.2 Hz, H27), 
5.82 (1H, app t, J = 11.0 Hz, H6), 5.77 (1H, d, J = 11.3 Hz, H7), 5.71 (1H, dd, J = 14.7, 3.8 Hz, H23), 
5.50-5.44 (3H, m, H12+H2+H30), 5.29 (1H, app t, J = 10.7 Hz, H28), 4.95 (1H, br d, J = 8.8 Hz, H9), 
4.80-4.75 (1H, m, H11), 4.42-4.37 (1H, m, H22), 4.37-4.34 (1H, m, H34), 3.90 (1H, dd, J = 10.3, 3.6 
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Hz, H20), 3.87-3.82 (1H, m, H32), 3.49-3.46 (1H, m, H19), 3.46 (3H, s, OMe), 3.06-3.00 (1H, m, H29), 
2.83-2.77 (1H, m, H10), 1.92 (3H, s, Me8), 1.87-1.81 (1H, m, H31), 1.65-1.57 (2H, m, H33a+H21a), 
1.35-1.18 (7H, m, Me19+H33b+H35), 1.04-0.81 (46H, Me10+Me29+Me31+H21b+Si(tBu)2+SitBuMe2 
+Si(CH2CH3)3), 0.59 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.09 (3H, s, SitBuMe2), 0.02 (3H, s, 
SitBuMe2). Data in agreement with that reported by Williams.86 
 
f. Sugar  
 
(2S,3S,4S,5R,6S)-2-(bromomethyl)-4,5,6-trimethoxytetrahydro-2H-pyran-3-yl benzoate (246) 
 
 
 
To a solution of 1,2,3-trimethoxy sugar 245 (2.0 g, 6.44 mmol) in benzene (60 mL) was added NBS 
(1.15 g, 6.44 mmol) and AIBN (105.8 mg, 0.644 mmol). The reaction mixture was stirred at 60 °C 
for 1 h, before being quenched by NaHCO3 (30 mL) and extracted with EtOAc (3 x 20 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:4) yielded 4-benzoyl-6-bromo sugar 246 (1.75 g, 4.51 mmol, 70%) as 
a yellow oil. 
 
Rf 0.40 (EtOAc/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 8.07 (2H, dd, J = 8.0, 1.3 Hz, ArH), 7.61 
(1H, app t, J = 7.4 Hz, ArH), 7.48 (2H, app t, J = 7.8 Hz, ArH), 5.07 (1H, app t, J = 9.6 Hz, H4), 4.93 
(1H, d, J = 3.6 Hz, H1), 4.02 (1H, ddd, J = 10.4, 8.3, 2.3 Hz, H5), 3.74 (1H, t, J = 9.4 Hz, H3), 3.56 
(3H, s, OMe), 3.54 (3H, s, OMe), 3.50-3.46 (1H, m, H6a), 3.48 (3H, s, OMe), 3.40 (1H, dd, J = 11.2, 
8.2 Hz, H6b), 3.38 (1H, dd, J = 9.6, 3.6 Hz, H2). Data in agreement with literature values.102 
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(2S,3S,4S,5R,6S)-2-(bromomethyl)-4,5,6-trimethoxytetrahydro-2H-pyran-3-ol (247) 
 
 
 
To a solution of 4-benzoyl-6-bromo sugar 246 (886 mg, 2.28 mmol) in methanol (50 mL) was added 
NaOMe (6.2 mg, 0.114 mmol). The reaction mixture was stirred at 65 °C for 16 h, before being 
quenched by NH4Cl (10 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts 
were dried (Na2SO4) and concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 
1:1) yielded 6-bromo-4-hydroxy sugar 247 (579 mg, 2.03 mmol, 89%) as a yellow oil. 
 
Rf 0.22 (EtOAc/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 4.89 (1H, d, J = 3.6 Hz, H1), 3.79-3.71 (2H, 
m, H5+H6a), 3.64 (3H, s, OMe), 3.57 (1H, dd, J = 11.1, 6.3 Hz, H6b), 3.50 (3H, s, OMe), 3.47 (3H, s, 
OMe), 3.47 (1H, app t, J = 8.9 Hz, H3), 3.42 (1H, dt, J = 8.9, 2.7 Hz, H4), 3.26 (1H, dd, J = 9.3, 3.6 
Hz, H2), 2.44 (1H, d, J = 2.6 Hz, OH). Data in agreement with literature values.89 
 
(2R,3R,4S,5R,6S)-4,5,6-trimethoxy-2-methyltetrahydro-2H-pyran-3-ol (248) 
 
 
 
To a solution of 6-bromo-4-hydroxy sugar 247 (486 mg, 1.71 mmol) in DMSO (5 mL) was added 
NaBH4 (323 mg, 8.55 mmol). The reaction mixture was stirred at 80 °C for 3 h, before being 
quenched by water (5 mL) and extracted with Et2O (3 x 5 mL). The combined organic extracts were 
washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:1) yielded 4-hydroxy-6-methyl sugar 248 (282 mg, 1.37 mmol, 80%) 
as a colourless oil. 
 
Rf 0.13 (EtOAc/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 4.78 (1H, d, J = 3.6 Hz, H1), 3.66 (1H, dq, 
J = 9.5, 6.2 Hz, H5), 3.62 (3H, s, OMe), 3.58 (3H, s, OMe), 3.41 (3H, s, OMe), 3.40 (1H, app t, J = 
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9.2 Hz, H3), 3.22 (1H, dd, J = 9.6, 3.6 Hz, H2), 3.12 (1H, dt, J = 9.2, 2.4 Hz, H4), 2.49 (1H, d, J =2.5 
Hz, OH), 1.27 (3H, d, J = 6.3 Hz, H6). Data in agreement with literature values.103 
 
(2R,3R,4S,5R)-4,5-dimethoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-ol (249) 
 
 
 
To a solution of 4-hydroxy-6-methyl sugar 248 (181 mg, 0.878 mmol) in DCE (8 mL) was added 
ZnI2 (841 mg, 2.63 mmol), Bu4NI (486 mg, 1.32 mmol) and TMSSPh (0.830 mL, 4.39 mmol). The 
reaction mixture was stirred at 65 °C for 2 h, before being cooled to rt and filtered through a pad of 
Celite®. The filtrate was dried (Na2SO4) and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/PE 1:4) yielded thioglycoside 249 (197 mg, 0.693 mmol, 80%, α:β = 3:1) 
as a colourless oil. 
 
α-anomer: Rf 0.50 (EtOAc/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 7.55-7.50 (2H, m, ArH), 
7.36-7.25 (3H, m, ArH), 5.69 (1H, d, J = 5.3 Hz, H1), 4.24 (1H, dq, J = 9.4, 6.2 Hz, H5), 3.68 (3H, s, 
OMe), 3.59 (1H, dd, J = 9.5, 5.3 Hz, H2), 3.52 (3H, s, OMe), 3.35 (1H, app t, J = 9.4 Hz, H3), 3.21 
(1H, app t, J = 9.3 Hz, H4), 2,43 (1H, d, J = 2.6 Hz, OH), 1.31 (3H, d, J = 6.3 Hz, H6). β: Rf 0.50 (EtOAc/PE 1:1); 1H NMR (500 MHz, CDCl3) δH 7.57-7.52 (2H, m, ArH), 7.36-7.25 (3H, 
m, ArH), 4.57 (1H, d, J = 9.3 Hz, H1), 3.68 (3H, s, OMe), 3.63 (3H, s, OMe), 3.41-3.33 (1H, m, H5), 
3.21 (1H, app t, J = 9.0 Hz, H4), 3.15 (1H, app t, J = 8.4 Hz, H3), 3.11 (1H, app t, J = 8.4 Hz, H2), 
2,35 (1H, d, J = 2.4 Hz, OH), 1.37 (3H, d, J = 6.1 Hz, H6). Data in agreement with that reported by 
Elliott.87 
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tert-butyl(((2R,3R,4R,5R)-4,5-dimethoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-yl)oxy
)dimethylsilane (250,251) 
 
 
 
To a solution of thioglycoside 249 (187 mg, 0.658 mmol, α:β = 3:1) in CH2Cl2 (10 mL) was added 
TBSCl (992 mg, 6.58 mmol), imidazole (896 mg, 13.2 mmol) and DMAP (161 mg, 1.32 mmol). The 
reaction mixture was stirred for 16 h, before being quenched with NH4Cl (10 mL) and extracted with 
Et2O (3 x 10 mL). The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. 
Purification by flash chromatography (Et2O/PE 1:19) yielded α-TBS ether 250 (167 mg, 0.419 
mmol, 64%) and β-TBS ether 251 (55.8 mg, 0.140 mmol, 21%) as colourless oil. 
 
α-anomer: Rf 0.29 (Et2O/PE 1:9);  +174.4 (c 1.0, CHCl3); IR νmax 3670, 2980, 2908, 1407, 
1395, 1379, 1250, 1240, 1230, 1101, 1076, 1068, 1054, 893; 1H NMR (500 MHz, CDCl3) δH 
7.52-7.48 (2H, m, ArH), 7.33-7.22 (3H, m, ArH), 5.65 (1H, d, J = 5.5 Hz, H1), 4.14 (1H, dq, J = 8.8, 
6.2 Hz, H5), 3.57 (3H, s, OMe), 3.53 (1H, dd, J = 9.3, 5.5 Hz, H2), 3.50 (3H, s, OMe), 3.22 (1H, app 
t, J = 8.8 Hz, H3), 3.17 (1H, app t, J = 8.6 Hz, H4), 1.22 (3H, d, J = 6.3 Hz, H6), 0.91 (9H, s, 
SiC(CH3)3), 0.13 (3H, s, SiCH3), 0.08 (3H, s, SiCH3); 13C NMR (125 MHz, CDCl3) 134.5, 131.1, 
128.6, 126.7, 86.0, 83.4, 82.4, 75.9, 68.7, 61.0, 57.4, 25.6, 17.8, 17.7, –4.2, –5.0; HRMS ESI calc. 
for C20H38NO4SSi [M+NH4]+ 416.2291, found 416.2290. β-anomer: Rf 0.29 (Et2O/PE 1:9);  –30.0 (c 1.0, CHCl3); IR νmax 3672, 2952, 2930, 2892, 2858, 
1473, 1382, 1250, 1169, 1145, 1097, 1072, 964, 860, 836, 777, 744, 691; 1H NMR (500 MHz, 
CDCl3) δH 7.53-7.48 (2H, m, ArH), 7.31-7.21 (3H, m, ArH), 4.52 (1H, d, J = 9.1 Hz, H1), 3.60 (3H, s, 
OMe), 3.56 (3H, s, OMe), 3.31-3.23 (1H, m, H5), 3.16 (1H, app t, J = 8.8 Hz, H4), 3.09-3.01 (2H, m, 
H3+H2), 1.26 (3H, d, J = 6.2 Hz, H6), 0.89 (9H, s, SiC(CH3)3), 0.11 (3H, s, SiCH3), 0.07 (3H, s, 
SiCH3); 13C NMR (125 MHz, CDCl3) 133.7, 131.2, 128.5, 126.9, 88.1, 86.9, 83.3, 76.4, 75.4, 60.9, 
60.2, 25.6, 18.2, 17.7, –4.3, –4.9; HRMS ESI calc. for C20H35O4SSi [M+H]+ 399.2020, found 
399.2022. 
1 5
O
OTBSMeO
OMe
PhS
][ 20α D
][ 20α
  
 
129 
tert-butyl(((2R,3R,4R,5R,6S)-6-fluoro-4,5-dimethoxy-2-methyltetrahydro-2H-pyran-3-yl)oxy)di
methylsilane (252) 
 
 
 
To a solution of α-thioglycoside 250 (45.0 mg, 0.113 mmol) in CH2Cl2 (2 mL) at –15 °C was added 
DAST (22.3 µL, 0.169 mmol). The reaction mixture was stirred for 2 min, before NBS (26.2 mg, 
0.147 mmol) was added. The solution was stirred at –15 °C for a further 30 min before being 
quenched with NaHCO3 (1 mL) and extracted with CH2Cl2 (3 x 1 mL). The combined organic 
extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash chromatography 
(Et2O/PE 1:19) yielded β-glycosyl fluoride 252 (31.2 mg, 0.101 mmol, 90%) as a colourless oil. 
 
Rf 0.52 (Et2O/PE 1:9);  +12.3 (c 1.0, CHCl3); IR νmax 3674, 2984, 2900, 2357, 1389, 1256, 
1161, 1105, 1048, 953, 858, 840, 780; 1H NMR (500 MHz, CDCl3) δH 5.10 (1H, dd, J = 53.4, 6.9 Hz, 
H1), 3.56 (3H, s, OMe), 3.54 (3H, s, OMe), 3.38 (1H, dq, J = 9.2, 6.2 Hz, H5), 3.23 (1H, app t, J = 
9.0 Hz, H4), 3.14 (1H, ddd, J = 12.7, 8.6, 7.0 Hz, H2), 3.02 (1H, app t, J = 8.6 Hz, H3), 1.29 (3H, d, J 
= 6.2 Hz, H6), 0.89 (9H, s, SiC(CH3)3), 0.11 (3H, s, SiCH3), 0.08 (3H, s, SiCH3); 13C NMR (125 
MHz, CDCl3) 109.7 (d, J = 214 Hz), 85.2 (d, J = 11.5 Hz), 84.2 (d, J = 21.0 Hz), 75.2, 72.5, 60.9, 
59.9, 25.9, 18.2, 18.1, –4.0, –4.6; HRMS ESI calc. for C14H30FO4Si [M+H]+ 309.1897, found 
309.1898. 
 
tert-butyl(((2R,3R,4R,5R)-6-fluoro-4,5-dimethoxy-2-methyltetrahydro-2H-pyran-3-yl)oxy)dime
thylsilane (252,253) 
 
 
 
To a solution of β-thioglycoside 251 (22.0 mg, 55.2 µmol) in CH2Cl2 (1 mL) at –15 °C was added 
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DAST (11.1 µL, 84.1 µmol). The reaction mixture was stirred for 2 min, before NBS (13.1 mg, 73.5 
µmol) was added. The solution was stirred at –15 °C for a further 30 min before being quenched with 
NaHCO3 (1 mL) and extracted with CH2Cl2 (3 x 1 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo. Purification by flash chromatography (Et2O/PE 1:19) yielded 
α-glycosyl fluoride 253 (2.3 mg, 7.37 µmol, 13%) and β-glycosyl fluoride 252 (11.3 mg, 36.8 µmol, 
67%) as colourless oil. 
 
α-anomer: Rf 0.50 (Et2O/PE 1:9);  +38.6 (c 1.0, CHCl3); IR νmax 2929, 1463, 1256, 1160, 1094, 
1024, 894, 861, 837, 777, 743; 1H NMR (500 MHz, CDCl3) δH 5.61 (1H, dd, J = 53.7, 2.8 Hz, H1), 
3.81 (1H, dq, J = 9.3, 6.2Hz, H5), 3.56 (3H, s, OMe), 3.54 (3H, s, OMe), 3.31 (1H, app t, J = 9.1 Hz, 
H4), 3.18 (1H, app t, J = 9.1 Hz, H3), 3.17 (1H, ddd, J = 25.7, 9.5, 2.7 Hz, H2), 1.24 (3H, d, J = 6.3 
Hz, H6), 0.90 (9H, s, SiC(CH3)3), 0.13 (3H, s, SiCH3), 0.08 (3H, s, SiCH3); 13C NMR (125 MHz, 
CDCl3) 104.5 (d, J = 226 Hz), 82.6 (d, J = 10.5 Hz), 82.5 (d, J = 14.5 Hz), 75.5, 70.6, 61.3, 58.8, 
25.9, 18.2, 18.1, –3.9, –4.6; HRMS ESI calc. for C14H3019FO4Si [M+H]+ 309.1897, found 309.1897. β-anomer: Rf 0.52 (Et2O/PE 1:9); 1H NMR (500 MHz, CDCl3) δH 5.11 (1H, dd, J = 53.1, 6.8 Hz, 
H1), 3.57 (3H, s, OMe), 3.55 (3H, s, OMe), 3.38 (1H, dq, J = 9.3, 6.2 Hz, H5), 3.23 (1H, app t, J = 
9.0 Hz, H4), 3.14 (1H, ddd, J = 12.7, 8.5, 7.0 Hz, H2), 3.01 (1H, app t, J = 8.6 Hz, H3), 1.29 (3H, d, J 
= 6.1 Hz, H6), 0.89 (9H, s, SiC(CH3)3), 0.11 (3H, s, SiCH3), 0.08 (3H, s, SiCH3). 
 
g. Glycosylation  
 
(4R)-4-benzyl-3-((4R,5R,E)-7,7-dibromo-5-(((3R,4R,5R,6R)-5-((tert-butyldimethylsilyl)oxy)-3,4-
dimethoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,4-dimethylhepta-2,6-dienoyl)oxazolidin-2
-one (240,258) 
 
 
][ 20α D
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With "-glycosyl fluoride 252 
To SnCl2 (21.5 mg, 114 µmol), AgClO4 (23.5 mg, 114 µmol) and 4Å molecular sieves (10 mg) in 
Et2O (0.5 mL) at –15 °C was added a solution of alcohol 226 (11.1 mg, 22.7 µmol) in Et2O (0.2 mL). 
The reaction mixture was stirred for 2 min, before a solution of	β-glycosyl fluoride 252 (14.0 mg, 
45.4 µmol) in Et2O (0.2 mL) was added. The solution was stirred at –15 °C for 2 h before being 
warmed to rt and stirred for a further 16 h. The reaction mixture was diluted with Et2O (2 mL) and 
filtered through a pad of Celite®. The filtrate was washed consecutively with NaHCO3 (1 mL) and 
brine (1 mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash chromatography 
(EtOAc/PE 1:4) yielded glycosylation adduct 258 and 240 (10.5 mg, 13.6 µmol, 60%, α:β = 1:1.1) 
as a colourless oil.	 
With α-thioglycoside 250 
To α-thioglycoside 250 (200 mg, 0.502 mmol), alcohol 226 (163 mg, 0.334 mmol) and 4Å 
molecular sieves (200 mg) in CH3CN (20 mL) at –20 °C was added N-bromosuccinimide (179 mg, 
1.00 mmol). The reaction mixture was stirred at –20 °C for 2 h before being quenched with NaHSO3 
(20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated in vacuo. Purification by flash chromatography (EtOAc/PE 1:4) yielded 
glycosylation adduct 258 and 240 (256 mg, 0.332 mmol, 99%, α:β = 1:1.3) as a colourless oil.	 
 
 α-diastereomer: Rf 0.70 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 7.36-7.31 (2H, m, ArH), 
7.30-7.27 (1H, m, ArH), 7.23-7.19 (2H, m, ArH), 6.55 (1H, d, J = 9.0 Hz, H12), 5.94-5.90 (1H, m, 
H9), 4.87 (1H, d, J = 3.4 Hz, H1’), 4.64-4.58 (1H, m, NCH), 4.30 (1H, dd, J = 9.0, 5.9 Hz, H11), 
4.26-4.21 (1H, OCH2aCH), 4.15 (1H, dd, J = 8.9, 4.6 Hz, OCH2bCH), 3.69 (1H, dd, J = 9.3, 6.3 Hz, 
H5’), 3.53 (3H, s, OMe), 3.42 (3H, s, OMe), 3.37 (1H, dd, J = 13.4, 3.2 Hz, PhCH2a), 3.20 (2H, m, 
H2’+H3’), 3.10 (1H, m, H4’), 2.85 (1H, m, H10), 2.81 (1H, dd, J = 13.4, 9.5, PhCH2b), 1.95 (3H, d, J = 
1.4 Hz, Me8), 1.21 (3H, d, J =7.0 Hz, H6’), 1.14 (3H, d, J = 7.0 Hz, Me10), 0.89 (9H, s, SiC(CH3)3), 
0.11 (3H, s, SiCH3), 0.07 (3H, s, SiCH3); 13C NMR (125 MHz, CDCl3) 172.0, 153.2, 138.5, 138.1, 
132.2, 130.1, 129.7, 128.9, 127.1, 93.9, 91.1, 86.7, 85.1, 80.2, 76.7, 68.9, 66.4, 61.1, 58.3, 55.7, 37.9, 
37.0, 26.2, 18.3, 18.1, 15.8, 14.1, –4.7, –3.8. β-diastereomer: Rf 0.70 (EtOAc/PE 3:7); 1H NMR (500 MHz, CDCl3) δH 7.36-7.31 (2H, m, ArH), 
7.30-7.27 (1H, m, ArH), 7.23-7.19 (2H, m, ArH), 6.59 (1H, d, J = 9.0 Hz, H12), 5.94-5.90 (1H, m, 
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H9), 4.70-4.63 (1H, m, NCH), 4.32 (1H, d, J = 7.3 Hz, H1’), 4.26-4.21 (2H, H11+OCH2aCH), 4.16 
(1H, dd, J = 8.8, 4.1 Hz, OCH2bCH), 3.56 (3H, s, OMe), 3.54 (3H, s, OMe), 3.37 (1H, dd, J = 13.4, 
3.2 Hz, PhCH2a), 3.20 (1H, m, H5’), 3.13 (1H, m, H4’), 2.98 (2H, m, H2’+H3’), 2.81 (1H, dd, J = 13.4, 
9.5, PhCH2b), 2.80 (1H, m, H10), 1.92 (3H, d, J = 1.4 Hz, Me8), 1.20 (3H, d, J =7.0 Hz, H6’), 1.12 
(3H, d, J = 6.9 Hz, Me10), 0.89 (9H, s, SiC(CH3)3), 0.11 (3H, s, SiCH3), 0.07 (3H, s, SiCH3); 13C 
NMR (125 MHz, CDCl3) 172.0, 153.2, 139.0, 138.1, 132.2, 130.1, 129.7, 128.9, 127.1, 104.7, 91.1, 
86.7, 85.1, 84.8, 76.2, 73.3, 66.4, 60.8, 60.3, 55.5, 37.9, 37.2, 25.9, 18.3, 18.1, 16.0, 14.1, –4.7, –3.8. 
IR νmax 2957, 2927, 2856, 1789, 1684, 1455, 1383, 1350, 1303, 1258, 1213, 1156, 1087, 1039, 969, 
861, 836, 796, 776, 703; HRMS ESI calc. for C33H5379Br2N2O8Si [M+NH4]+ 791.1937, found 
791.1938. 
 
(R)-4-benzyl-3-((2E,4R,5R,6Z)-7-bromo-5-(((2R,3R,4R,5R,6R)-5-((tert-butyldimethylsilyl)oxy)-3
,4-dimethoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,4-dimethylhepta-2,6-dienoyl)oxazolidi
n-2-one (241) 
 
 
 
To Pd(PPh3)4 (113 mg, 97.8 µmol) was added a solution of dibromoolefin (760 mg, 0.980 mmol) in 
CH2Cl2 (20 mL) and Bu3SnH (0.310 mL, 1.15 mmol). The solution was stirred for 2 h and 
concentrated in vacuo. Purification by flash chromatography (Et2O/PE 1:4) yielded (Z)-vinyl 
bromide 241 (307 mg, 0.441 mmol, 45%) and the 1’-diastereometer 261 (239 mg, 0.343 mmol, 35%) 
as colourless oils. 
 
Rf 0.70 (EtOAc/PE 3:7);  –19.9 (c 1.0, CHCl3); IR νmax 2930, 2857, 1788, 1682, 1455, 1385, 
1349, 1303, 1250, 1212, 1156, 1086, 1006, 966, 859, 836, 776, 741, 702, 674; 1H NMR (500 MHz, 
CDCl3) δH 7.36-7.31 (2H, m, ArH), 7.30-7.27 (1H, m, ArH), 7.23-7.19 (2H, m, ArH), 6.31 (1H, dd, J 
O N
O
Bn
O BrO O
TBSO OMe
OMe
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= 8.4, 7.3 Hz, H12), 6.26 (1H, d, J = 7.3 Hz, H13), 6.01 (1H, d, J = 10.0 Hz, H9), 4.66-4.60 (1H, m, 
NCH), 4.52 (1H, dd, J = 8.5, 4.5 Hz, H11), 4.32 (1H, d, J = 7.6 Hz, H1’), 4.23 (1H, t, J = 9.0 Hz, 
OCH2aCH), 4.15 (1H, dd, J = 9.0, 4.3 Hz, OCH2bCH), 3.58 (3H, s, OMe), 3.55 (3H, s, OMe), 3.38 
(1H, dd, J = 13.4, 3.2 Hz, PhCH2a), 3.23-3.19 (1H, m, H5’), 3.15-3.11 (1H, m, H4’), 3.00-2.96 (2H, m, 
H2’+H3’), 2.83-2.78 (2H, m, H10+PhCH2b), 1.90 (3H, d, J = 1.4 Hz, Me8), 1.20 (3H, d, J = 6.1 Hz, 
H6’), 1.16 (3H, d, J = 7.0 Hz, Me10), 0.89 (9H, s, SiC(CH3)3), 0.10 (3H, s, SiCH3), 0.05 (3H, s, 
SiCH3); 13C NMR (125 MHz, CDCl3) 171.6, 152.8, 138.1, 135.3, 135.2, 131.5, 129.5, 129.0, 127.4, 
108.4, 104.3, 86.6, 85.0, 82.4, 76.0, 72.5, 66.4, 61.1, 60.6, 55.7, 37.5, 37.4, 26.0, 18.2, 18.1, 15.9, 
13.9, –4.6, –3.9; HRMS ESI calc. for C33H5379BrN2O8Si [M+NH4]+ 713.2827, found 713.2828. 
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Selected NMR Spectra 
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